UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, ~~2016~~2017

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from [ ] to [ ]

Commission file number 333-199589

DNA TESTING CENTERS, CORP.

(Exact name of registrant as specified in its charter)

Florida		applied for
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
2378 Parkhaven Blvd., Oakville, Ontario		L6H 0E7
(Address of principal executive offices)		(Zip Code)

Florida

applied for

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

2378 Parkhaven Blvd., Oakville, Ontario		L6H 0E7
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +1 866 863 5139

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Name of Each Exchange On Which Registered
N/A		N/A

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.0001 par value

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes o [ ] No x [X]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o [ ] No x [X]

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days. Yes x [X] No o [ ]

1Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-K (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark ~~whether the registrant has submitted electronically and posted on its corporate Website,~~ if ~~any,~~disclosure ~~every~~of ~~Interactive~~delinquent ~~Data~~filers ~~File required to be submitted and posted~~ pursuant to ~~Rule~~Item 405 of Regulation S-K (§229.405 of this chapter) ~~during~~is not contained herein, and will not be contained, to the ~~preceding~~best 12of ~~months~~registrant’s (knowledge, in definitive proxy or ~~for~~information ~~such~~statements incorporated ~~shorter~~by ~~period~~reference ~~that~~in ~~the~~Part ~~registrant~~III ~~was~~of ~~required~~this toForm ~~submit~~10-K ~~and~~or ~~post~~any ~~such~~amendment ~~files)~~to this Form 10-K. ~~Yes x No o~~[ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o[ ] Accelerated filer o[ ] Non-accelerated filer o[ ] Smaller reporting company o[ ] (Do not check if a smaller reporting company) Emerging growth company þ[X]

If an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨ [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o [ ] No x [X]

The aggregate market value of Common Stock held by non-affiliates of the Registrant on June 30, ~~2016~~2017 was $Nil based on a $Nil average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date. 21,496,404 common shares as of ~~August~~June 154, ~~2017~~2019.

DOCUMENTS INCORPORATED BY REFERENCE

None.

TABLE OF CONTENTS

Item 1. Business	43
Item 1A. Risk Factors	1110
Item 1B. Unresolved Staff Comments	2019
Item 2. Properties	2019
Item 3. Legal Proceedings	2120
Item 4. Mine Safety Disclosures	2120
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	21
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	20
Item 6. Selected Financial Data	2221
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	22
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 7A. Quantitative and Qualitative Disclosures About Market Risk	2726
Item 8. Financial Statements and Supplementary Data	2827
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	4039
Item 9A. Controls and Procedures	4039
Item 9B. Other Information	4140
Item 10. Directors, Executive Officers and Corporate Governance	4241
Item 11. Executive Compensation	4544
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	4947
Item 13. Certain Relationships and Related Transactions, and Director Independence	5048
Item 14. Principal Accounting Fees and Services	5149
Item 15. Exhibits, Financial Statement Schedules	5250

Item 1. Business

FORWARD LOOKING STATEMENTS

This annual report (“Report”) contains certain forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues, or other financial items; any statements of the plans, strategies, and objectives of management for future operation; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements of belief; and any statement of assumptions underlying any of the foregoing. Such forward-looking statements are subject to inherent risks and uncertainties, and actual results could differ materially from those anticipated by the forward-looking statements.

These forward-looking statements involve significant risks and uncertainties, including, but not limited to, the following: competition, promotional costs and the risk of declining revenues. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of a number of factors. These forward-looking statements are made as of the date of this filing, and we assume no obligation to update such forward-looking statements. The following discusses our financial condition and results of operations based upon our audited financial statements which have been prepared in conformity with accounting principles generally accepted in the United States. It should be read in conjunction with our financial statements and the notes thereto included elsewhere herein.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our consolidated financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States generally accepted accounting principles.

In this annual report, unless otherwise specified, all dollar amounts are expressed in United States Dollars (US$) and all references to “common shares” refer to the common shares in our capital stock.

As used in this annual report, the terms “we”, “us”, “our” and the “company” mean DNA Testing Centers, Corp., and our wholly owned subsidiary, DNA Testing Centers of Canada, Ltd. an Alberta, Canada corporation, unless otherwise indicated.

Overview

Our principal executive offices are located at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada. Our telephone number is 1-866-863-5139 and our website is located at www.dnatestingcanada.com. The information contained on our website is not part of this Report.

We were incorporated in the State of Florida on July 3, 2014 for the purposes of acquiring our wholly owned subsidiary DNA Centers of Canada, Ltd., a Canadian corporation formed on April 6, 2009 and engaged in the distribution of DNA diagnostic testing products to medical practitioners and directly to consumers located in Canada.

~~Item~~On July 13, 2014, we issued an aggregate of 19,999,998 common shares to acquire 100% of the outstanding securities of DNA Centers of Canada, Ltd. ~~Business~~6,666,666 common shares were issued to each of the following selling shareholders of DNA Centers of Canada, Ltd:

~~FORWARD~~● ~~LOOKING~~7612176 ~~STATEMENTS~~Canada Inc., a Canadian corporation, controlled by Dr. Barjinder Sohal, our chief executive officer, president and director; ● 7322640 Canada Inc. a Canadian corporation controlled by Dr. Nitan Arora, our vice president and director; and ● 7322747 Canada Inc. a Canadian corporation controlled by Navjot Nanda our secretary, treasurer and director,

~~This~~At the ~~annual~~time ~~report (“Report”) contains certain forward-looking statements. All statements other than statements~~ of ~~historical~~the ~~fact are “forward-looking statements” for purposes of these provisions~~acquisition, ~~including~~7612176 ~~any~~Canada ~~projections of earnings~~Inc., ~~revenues,~~7322640 orCanada ~~other~~Inc. ~~financial items; any statements of the plans, strategies,~~ and ~~objectives~~7322747 ofCanada ~~management~~Inc. ~~for~~each ~~future~~held ~~operation;~~33.33% ~~any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements~~ of ~~belief;~~DNA ~~and any statement~~ Centers of ~~assumptions~~Canada, ~~underlying any of the foregoing~~Ltd. ~~Such~~representing ~~forward-looking~~100% ~~statements~~of ~~are~~its ~~subject~~outstanding ~~to inherent risks and uncertainties, and actual results could differ materially from those anticipated by the forward-looking statements~~securities.

~~These~~DNA Testing ~~forward-looking~~Centers ~~statements~~of ~~involve significant risks and uncertainties~~Canada, ~~including~~Ltd., ~~but~~our ~~not~~wholly ~~limited~~owned tosubsidiary, ~~the~~commenced ~~following:~~sales ~~competition, promotional costs and the risk~~ of ~~declining~~its ~~revenues.~~products ~~Our actual results could differ materially from those anticipated~~ in ~~such forward-looking statements as a result of a number of factors~~April 2010. ~~These~~To ~~forward-looking statements are made as of the~~ date ~~of this filing~~, ~~and~~product sales wewere ~~assume~~generated nofrom ~~obligation~~our towebsite ~~update~~and ~~such~~sold ~~forward-looking~~by ~~statements~~phone order. ~~The~~Sales ~~following~~generated ~~discusses~~from our ~~financial~~website ~~condition~~are ~~and~~placed ~~results~~by ofphone ~~operations~~order. ~~based~~We presently ~~upon~~offer our ~~audited~~paternity ~~financial~~testing ~~statements~~kits ~~which~~for ~~have~~purchase ~~been~~on ~~prepared~~our inwebsite. ~~conformity~~We ~~with~~offer ~~accounting~~our ~~principles~~remaining ~~generally~~test ~~accepted~~kits infor ~~the~~purchase ~~United~~on ~~States. It should be read in conjunction with~~ our ~~financial~~website using ~~statements~~an ~~and~~online ~~the~~shopping ~~notes thereto included elsewhere herein~~cart.

~~Although~~During wethe ~~believe~~years ~~that~~ended ~~the~~December 31, ~~expectations~~2017, ~~reflected~~and in2016, ~~the~~our ~~forward-looking~~revenues ~~statements~~were ~~are~~$49,816 ~~reasonable~~and $31,866, werespectively, ~~cannot~~from ~~guarantee~~the ~~future~~sale ~~results~~of our DNA test kits. During the years ended December 31, ~~levels~~2017, ofand ~~activity~~2016, ~~performance~~we orsold ~~achievements.~~198 ~~Except~~and as227 ~~required~~total byDNA ~~applicable~~test ~~law~~kits, ~~including~~respectively. We received $87,690 from the ~~securities~~sale ~~laws~~of 584,598 shares of ~~the~~our ~~United~~common ~~States~~stock during September and October 2014. In May 2015, we doreceived ~~not~~approximately $53,177 ~~intend~~from tothe ~~update~~sale ~~any~~of 363,233 shares of ~~the~~our ~~forward-looking~~common ~~statements~~stock. toWe ~~conform~~did ~~these~~not ~~statements~~issue toany ~~actual~~securities ~~results~~during fiscal 2016.

Our average ~~consolidated~~monthly ~~financial~~operating ~~statements~~expenses ~~are~~during ~~stated~~the in12-month ~~United~~period ~~States~~beginning ~~Dollars~~January ~~(US~~1, 2017 have been approximately $)6,130, and ~~are~~we anticipate ~~prepared~~that inwe ~~accordance~~will ~~with~~continue ~~United~~to ~~States~~incur ~~Generally~~expenses ~~Accepted~~at ~~Accounting~~a ~~Principles~~similar rate for the balance of fiscal 2018. As of February 28, 2019, we had cash on hand of approximately $● which will be insufficient to pay our operating expenses for 6 months. We plan to spend $97,000 to implement our plan of operations as described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operation” on page 23 of this Report. We do not presently have sufficient funds available to complete our plan of operations and there is no assurance we will have sufficient funds available to implement our plan of operations which could cause you to lose your investment.

AsWe provide ~~used~~DNA intesting ~~this~~kits ~~annual~~directly ~~report,~~to ~~the~~consumers ~~terms “we”, “us”, “our”~~ and ~~the~~to ~~“company”~~health ~~mean~~care ~~DNA~~practitioners. ~~Testing~~We ~~Centers,~~distribute ~~Corp.,~~ and ship our ~~wholly~~products ~~owned~~only ~~subsidiary,~~in ~~DNA Testing Centers of~~ Canada~~, Ltd~~. ~~an Alberta, Canada corporation, unless otherwise indicated.~~

~~Overview~~To date, our operations and those of our wholly owned subsidiary, DNA Testing Center of Canada, Ltd., include: (i) development of our business plan; (ii) research and development of DNA testing methods and technologies; (iii) locating suppliers for DNA testing kits; (iv) locating and reviewing potential labs to interpret our DNA testing kits; (v) creating our marketing strategy; (vi) developing content for our website that describes DNA technology, the DNA testing process and the DNA test kits we sell; and (v) selling our DNA testing kits to medical practitioners and directly to consumers.

WeDNA Testing ~~were~~Centers ~~incorporated~~of inCanada, ~~the~~Ltd., ~~State~~our ofwholly ~~Florida~~owned onsubsidiary, ~~July~~commenced 3,sales ~~2014~~of ~~for~~its ~~the~~products ~~purposes~~in April of ~~acquiring~~2010. ~~our~~To ~~wholly~~date, ~~owned~~product sales ~~subsidiary~~were ~~DNA~~generated ~~Centers~~from ofour ~~Canada,~~website ~~Ltd.,~~and asold ~~Canadian~~by ~~corporation~~phone ~~formed~~order. onOur ~~April~~customers 6,pick ~~2009~~up and ~~engaged~~pay infor ~~the~~their ~~distribution~~purchases ofat ~~DNA~~our ~~diagnostic~~office location ~~testing~~at ~~products~~2378 toParkhaven ~~medical~~Boulevard, ~~practitioners~~Oakville, ~~and~~Ontario, ~~directly~~L6H to0E7, ~~consumers~~Canada. ~~located~~We indo ~~Canada~~not use an outside sales force.

4We presently offer our paternity testing kits for purchase on our website. We offer our remaining test kits for purchase on our website using an online shopping cart.

OnCustomer Price ~~July~~and 3,Accuracy ~~2014, we issued an aggregate~~ of ~~19,999,998~~Our ~~common shares to acquire 100% of the outstanding securities of~~ DNA ~~Centers~~Test ~~of Canada, Ltd. 6,666,666 common shares were issued to each of the following selling shareholders of DNA Centers of Canada, Ltd:~~Kits

·As reflected in the chart below, all of our tests have an accuracy rate of 99.8% except for our prenatal gender test which is 98% effective. All of our tests are based upon a saliva sample. The most common reason for result errors in our tests is an insufficient saliva sample.

~~7612176~~The cost ~~Canada~~per ~~Inc.,~~test akit ~~Canadian~~for ~~corporation,~~our ~~controlled~~DNA bytesting ~~Dr.~~kits ~~Barjinder~~and ~~Sohal,~~accuracy ~~our~~of ~~chief~~each ~~executive~~kit ~~officer,~~is ~~president~~summarized ~~and director;~~below:

Type of Test	Price Per Kit		Accuracy of Test
Prenatal Gender Test	$	149.00		98	%
Paternity Tests - Informational	$	94.00		99.8	%
Paternity Tests - Legal	$	150.00		99.8	%
Kinship Test	$	155.00		99.8	%
Ancestry DNA Testing	$	250.00		99.8	%
Genetic Predisposition (Carrier, Drug, Health)	$	249.00		99.8	%
Genetic Pred + Diet & Fitness as Bundle Test	$	349.00		99.8	%
Carrier Testing	$	300.00		99.8	%
Drug Response Testing	$	300.00		99.8	%
Health Condition Testing	$	300.00		99.8	%
Diet & Fitness Testing	$	300.00		99.8	%

~~7322640~~DNA Testing ~~Canada Inc. a Canadian corporation controlled by Dr. Nitan Arora, our vice president and director; and~~Technologies

·DNA testing generates genetic profile information by analyzing an organism’s unique genetic identity. The process of identifying unique variations in a genome is referred to as DNA testing. DNA testing is the standard method used for forensic identification, ancestry tracing and to confirm paternity and other family relationships.

~~7322747~~We provide ~~Canada~~two ~~Inc.~~types aof ~~Canadian~~DNA ~~corporation controlled by Navjot Nanda our secretary, treasurer and director,~~testing.

AtThe first ~~the~~is ~~time~~composed of ~~the~~ancestral ~~acquisition,~~testing ~~7612176~~(both ~~Canada~~paternal ~~Inc.~~and maternal), ~~7322640~~paternity ~~Canada~~testing ~~Inc.~~(informational and ~~7322747~~legal), ~~Canada~~prenatal ~~Inc. each held 33.33% of DNA Centers of Canada~~gender testing, ~~Ltd.~~and ~~representing~~twin ~~100%~~diagnostic ~~of its outstanding securities~~testing.

~~DNA~~The second ~~Testing~~tests ~~Centers~~for ofdisease ~~Canada, Ltd~~predisposition., ~~our~~These ~~wholly~~tests ~~owned~~can ~~subsidiary,~~identify ~~commenced~~a ~~sales~~person’s ofgenetic ~~its~~risk ~~products~~for incancer, ~~April~~heart ofconditions, inherited ~~2010. To~~conditions, ~~date~~nutrition, ~~product~~fitness ~~sales~~response, ~~were generated from our website~~ and ~~sold~~drug byresponse ~~phone~~to ~~order~~medication. Sales generated from our website are placed by phone order. We presently offer our paternity testing kits for purchase on our website. We offer our remaining test kits for purchase on our website using an online shopping cart.

~~During~~A DNA ~~the~~profile ~~year~~can ~~ending~~be ~~December~~determined ~~31, 2016, and 2015, our revenues were $31,886 and $20,636, respectively~~ from ~~the~~any ~~sale~~type of ~~our~~biological ~~DNA~~specimen ~~test~~containing ~~kits. During~~nuclear ~~the year ending December 31, 2016, and 2015, we sold 227 and 129 total~~ DNA ~~test kits~~, ~~respectively.~~including Weblood ~~received~~or ~~$87,690~~a ~~from~~tissue ~~the sale of 584~~sample,~~598~~ such ~~shares~~as ofa ~~our~~cheek ~~common~~swab ~~stock~~or ~~during September and October 2014~~saliva. ~~In May 2015, we received approximately $53,177 from the sale of 363,233 shares of our common stock. We did not issue any securities during fiscal 2016.~~

Our average monthly operating expenses during the 12 month period beginning January 1, 2017 have been approximately $8,500, and we anticipate that we will continue to incur expenses at a similar rate for the balance of fiscal 2017. As of August 15, 2017, we had cash on hand of approximately $5,923.13 which will be insufficient to pay our operating expenses for 6 months. We plan to spend $97,000 to implement our plan of operations as described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operation” on page 23 of this Report. We do not presently have sufficient funds available to complete our plan of operations and there is no assurance we will have sufficient funds available to implement our plan of operations which could cause you to lose your investment.

DNA testing currently used for identity purposes examines specific sequences of DNA that exhibit variability between different individuals. Our ~~Business~~tests use SNP genotyping, DNA sequencing and STR markers.

~~We provide DNA testing kits directly to consumers and to health care practitioners. We distribute and ship our products only in Canada.~~SNP Genotyping

ToA SNP ~~date,~~is ~~our~~a ~~operations~~Single ~~and~~Nucleotide ~~those~~Polymorphism. ofThese ~~our~~are ~~wholly~~single ~~owned~~base ~~subsidiary,~~pairs ~~DNA~~in ~~Testing~~a ~~Center~~genome ofthat ~~Canada~~exhibit variation across the human population. There are two applications a SNP can be used for, ~~Ltd~~one is whole genome association studies and the other is point mutation. In whole genome association studies, ~~include:~~large ~~(i)~~amounts ~~development~~of data in the form of ~~our~~SNPs ~~business~~are ~~plan;~~gathered ~~(ii)~~from ~~research~~a ~~and~~sample ~~development~~of people. Depending on what the target of ~~DNA~~the ~~testing~~study ~~methods~~is, ~~and~~associations ~~technologies;~~can ~~(iii)~~be ~~locating~~made ~~suppliers~~based ~~for~~on ~~DNA~~a ~~testing~~person’s ~~kits;~~SNP ~~(iv)~~profile. ~~locating~~Here ~~and~~is ~~reviewing~~a ~~potential~~fictitious ~~labs~~example: a toperson ~~interpret~~with ~~our~~an ~~DNA~~“A” ~~testing~~base ~~kits;~~at ~~(v)~~position ~~creating~~765,659 ~~our~~on ~~marketing~~chromosome ~~strategy;~~11 ~~(vi)~~has ~~developing~~a ~~content~~100 ~~for~~times ~~our~~higher ~~website~~likelihood ~~that~~of ~~describes~~developing ~~DNA~~a ~~technology,~~rare form ~~the~~of ~~DNA~~cancer ~~testing~~than ~~process~~a ~~and~~person ~~the~~with ~~DNA~~a ~~test~~“T” ~~kits~~base. weThis ~~sell;~~is ~~and~~not ~~(v)~~a ~~selling~~definitive ~~our~~diagnosis ~~DNA~~but ~~testing~~can ~~kits~~definitely tobe ~~medical~~helpful ~~practitioners~~information for ~~and~~the ~~directly~~patient toin ~~consumers~~terms of preventative care.

5A SNP marker can also detect a genetic disease like cystic fibrosis. In this case the SNP (or 3 base pairs in the case of cystic fibrosis) will show definitively if a person has the disease or not. The association is 100%.

DNA Testing Centers of Canada, Ltd., our wholly owned subsidiary, commenced sales of its products in April of 2010. To date, product sales were generated from our website and sold by phone order. Our customers pick up and pay for their purchases at our office location at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada. We do not use an outside sales force. Sequencing

WeIn DNA ~~presently~~sequencing, ~~offer~~300-500 ~~our~~base ~~paternity~~pair ~~testing~~stretches ~~kits~~of ~~for~~DNA ~~purchase~~are onelucidated ~~our~~to ~~website~~show a more complete picture. WeDNA ~~offer~~sequencing ~~our~~is ~~remaining~~helpful ~~test~~in determining ~~kits~~genetic ~~for~~disorders ~~purchase~~that onSNP ~~our~~analysis ~~website~~alone ~~using~~cannot ando. ~~online~~DNA ~~shopping~~sequencing ~~cart~~is also critical in the development of SNP assays.

~~Customer Price and Accuracy of Our DNA Test Kits~~STR Markers

AsA short ~~reflected~~tandem repeat (“STR”) is a portion of DNA in ~~the~~which ~~chart~~small ~~below,~~sequences ~~all~~are repeated a variable number of times. ~~our~~Typically, ~~tests~~there ~~have~~are an10 ~~accuracy~~to ~~rate~~25 possible variations of ~~99.8%~~a ~~except~~given ~~for~~human ~~our~~STR ~~prenatal~~marker, ~~gender~~with ~~test~~each ~~which~~person ishaving ~~98%~~just ~~effective~~one or two variations. ~~All~~ ofBy ~~our~~looking ~~tests~~at ~~are~~a ~~based~~moderate ~~upon~~number of STRs, a ~~saliva~~DNA ~~sample~~profile is determined that is virtually unique for each individual. ~~The~~ STRs are the most common ~~reason~~genetic ~~for~~markers ~~result~~used ~~errors~~ in ~~our~~the ~~tests~~industry isto andetermine ~~insufficient~~identity ~~saliva~~in ~~sample~~forensic, paternity and security applications.

~~The cost per test kit for our DNA testing kits and accuracy of each kit is summarized below:~~Our Products

Type of Test	Price Per Kit	Accuracy of Test
Prenatal Gender Test	$149.00	98%
Paternity Tests - Informational	$94.00	99.8%
Paternity Tests - Legal	$150.00	99.8%
Kinship Test	$155.00	99.8%
Ancestry DNA Testing	$250.00	99.8%
Genetic Predisposition (Carrier, Drug, Health)	$249.00	99.8%
Genetic Pred + Diet & Fitness as Bundle Test	$349.00	99.8%
Carrier Testing	$300.00	99.8%
Drug Response Testing	$300.00	99.8%
Health Condition Testing	$300.00	99.8%
Diet & Fitness Testing	$300.00	99.8%

We sell the following types of DNA test kits to medical practitioners and directly to consumers located in Canada:

~~DNA~~Prenatal Gender ~~Testing Technologies~~Test

~~DNA~~The Prenatal ~~testing~~Gender ~~generates~~Test ~~genetic~~determines ~~profile~~gender ~~information~~after by7 ~~analyzing~~weeks anof ~~organism’s unique genetic identity~~gestation. ~~The~~ ~~process~~This oftest ~~identifying~~works ~~unique~~by ~~variations~~looking infor a ~~genome~~Y ischromosome ~~referred~~within ~~to as DNA testing. DNA testing is~~ the ~~standard method used for forensic identification, ancestry tracing and to confirm paternity and other family relationships~~mother’s blood.

WePaternity Test ~~provide~~– ~~two types of DNA testing.~~ Informational

The Paternity ~~first~~Test isuses ~~composed~~a ofcheek ~~ancestral~~swab ~~testing~~collected (from both ~~paternal~~the child and ~~maternal),~~the ~~paternity~~alleged ~~testing~~father ~~(informational~~to ~~and~~determine ~~legal),~~parentage. ~~prenatal~~DNA ~~gender~~Testing ~~testing,~~Centers uses ~~and~~a ~~twin~~15 ~~diagnostic~~genetic ~~testing~~marker analysis.

The second tests for disease predisposition. These tests can identify a person’s genetic risk for cancer, heart conditions, inherited conditions, nutrition, fitness response, and drug response to medication.6

APaternity Test ~~DNA~~- ~~profile can be determined from any type of biological specimen containing nuclear DNA, including blood or a tissue sample, such as a cheek swab or saliva.~~Legal

6The Paternity Test uses a cheek swab collected from both the child and the alleged father to determine parentage. DNA Testing Centers uses a 15 genetic marker analysis. This test must be performed at a medical clinic and is designed to be used in legal proceedings to establish paternity.

DNA testing currently used for identity purposes examines specific sequences of DNA that exhibit variability between different individuals. Our tests use SNP genotyping, DNA sequencing and STR markers.Kinship Testing

~~SNP~~A DNA ~~Genotyping~~kinship test determines the relationship between two or more individuals to assess an alleged relationship such as full or half siblings, grandparents and aunts or uncles

AAncestral Origins SNP is a Single Nucleotide Polymorphism. These are single base pairs in a genome that exhibit variation across the human population. There are two applications a SNP can be used for, one is whole genome association studies and the other is point mutation. In whole genome association studies, large amounts of data in the form of SNPs are gathered from a sample of people. Depending on what the target of the study is, associations can be made based on a person’s SNP profile. Here is a fictitious example: a person with an “A” base at position 765,659 on chromosome 11 has a 100 times higher likelihood of developing a rare form of cancer than a person with a “T” base. This is not a definitive diagnosis but can definitely be helpful information for the patient in terms of preventative care.Testing

AThe Ancestry ~~SNP~~test ~~marker~~provides ~~can~~an ~~also~~estimated ~~detect~~percentage ~~a genetic disease like cystic fibrosis. In this case the SNP (or 3 base pairs in the case~~ of ~~cystic~~ancestry ~~fibrosis)~~from ~~will~~four ~~show~~different ~~definitively~~population ifgroups: aIndigenous ~~person~~American, ~~has~~European, East ~~the~~Asian ~~disease~~and orSub-Saharan ~~not~~African. ~~The association is 100%.~~

~~DNA Sequencing~~Genetic Predisposition

InGenetic predisposition ~~DNA~~testing ~~sequencing,~~can ~~300-500~~identify ~~base pair stretches of DNA are elucidated to show~~ a ~~more~~person’s ~~complete~~predisposition ~~picture. DNA~~for ~~sequencing~~over is70 ~~helpful~~health inconditions ~~determining~~based ~~genetic~~upon ~~disorders~~their ~~that SNP analysis alone cannot do.~~ DNA ~~sequencing is also critical in the development of SNP assays~~.

~~STR~~Carrier Test ~~Markers~~Identification

ACarrier test ~~short~~identification ~~tandem~~can ~~repeat~~identify ~~(“STR”)~~individuals iswho acarry ~~portion of DNA in which small sequences are repeated~~ a variable number of times. Typically, there are 10 to 25 possible variations of a given human STR marker, with each person having just one or two variations. By looking at a moderate number of STRs, a DNA profile is determined that is virtually unique for each individual. STRs are the most common genetic ~~markers used in the industry to determine identity in forensic, paternity and security applications~~disorder.

~~Our~~Drug Response ~~Products~~Testing

WeDrug response ~~sell~~testing ~~the~~identifies ~~following~~uses ~~types~~a ofperson’s DNA ~~test kits~~ to ~~medical~~identify ~~practitioners~~metabolism enzymes and ~~directly~~transporters that have been linked to harmful ~~consumers~~reactions ~~located~~with incommon ~~Canada:~~medical prescriptions.

~~Prenatal~~The Testing ~~Gender Test~~Process

~~The~~Our DNA ~~Prenatal~~test ~~Gender~~kits ~~Test~~include ~~determines~~swabs ~~gender~~to ~~after~~collect 7a ~~weeks~~saliva sample, detailed instructions and pre-labeled packaging to send the sample to us. Upon receipt of ~~gestation~~the sample, it is registered in our database and sent to a third party laboratory to be interpreted. ~~This~~ All tests are interpreted by either US laboratories accredited by CLIA and CAP or Canadian laboratories accredited by the Standard Council of Canada and CAP. After interpretation, the laboratory delivers the test ~~works~~results to us by ~~looking~~email. ~~for~~Upon areceipt, Ywe ~~chromosome~~enter ~~within~~the results in our customer database and deliver the ~~mother’s~~results ~~blood~~to the consumer by email.

~~Paternity~~The results ~~Test~~for –paternity ~~Informational~~tests and Y-chromosome relationship tests and grandparent or uncle or aunt tests, are interpreted within 4 to 5 business days of the lab’s receipt of the test. Ancestry origin tests are interpreted within 21 to 28 days of receipt. Genetic predisposition test including diet and fitness testing are interpreted within 28-42 days of receipt. We typically deliver the test results to the customer by email within 1 to 4 days after our receipt.

~~The Paternity Test uses a cheek swab collected from both the child and the alleged father to determine parentage. DNA Testing Centers uses a 15 genetic marker analysis.~~7

7Suppliers

~~Paternity~~We purchase ~~Test~~our -DNA ~~Legal~~test components from Pro Printing and Mailing Services Inc. located at 1235 Trafalgar Road, Oakville, Ontario, L6H 3P1 and assemble the products at our facilities, or we purchase finished kits previously from Pathway Genomics Lab, 4045 Sorrento Valley Boulevard, San Diego, CA 92121.

The Paternity Test uses a cheek swab collected from both the child and the alleged father to determine parentage. DNA Testing Centers uses a 15 genetic marker analysis. This test must be performed at a medical clinic and is designed to be used in legal proceedings to establish paternity.Marketing Strategy

~~Kinship~~Our first ~~Testing~~product sale was in April 2010. All sales to date have been generated by our website or related parties. Sales generated from our website are placed by phone order. We presently offer our paternity testing kits for purchase on our website. We offer an online shopping cart featuring all of our products.

AOur core ~~DNA~~marketing ~~kinship~~strategy ~~test~~is ~~determines~~to ~~the~~brand ~~relationship~~our ~~between~~“DNA ~~two~~For orFamily” ~~more~~slogan ~~individuals~~for tothose ~~assess~~seeking aninformation ~~alleged~~that ~~relationship~~can be determined by DNA testing such as ~~full~~kinships orand ~~half~~ancestry ~~siblings~~and our “DNA For Health” slogan for those seeking to improve their health by DNA testing to determine disease predisposition, ~~grandparents~~nutrition and ~~aunts~~fitness ~~or uncles~~testing.

~~Ancestral~~We implemented ~~Origins~~our ~~Testing~~marketing plan in April 2015.

~~The~~● ~~Ancestry~~In ~~test~~April ~~provides an estimated percentage of ancestry from four different population groups~~2015: ~~Indigenous American, European, East Asian and Sub-Saharan African.~~

~~Genetic~~○ ~~Predisposition~~we began to create email materials for our marketing campaign for physicians, medical practitioners and fitness centers in Canada; ○ we began social media campaigns on Twitter, Facebook, and other websites to market our products;

~~Genetic~~● ~~predisposition~~In ~~testing~~July ~~can identify a person’s predisposition for over 70 health conditions based upon their DNA.~~2017:

~~Carrier~~○ ~~Test~~we ~~Identification~~continue to use Google AdWords and search engine optimization campaigns targeting consumers in Canada; ○ we started advertising our products in medical journals; ○ we are planning to implement a new search engine optimization (SEO) plan

Carrier test identification can identify individuals who carry a genetic disorder.

	●	In July 2017, we continue to offer incentives for medical practitioners, medical facilities and fitness centers that purchase our products on a repeat basis; and
	●	We are actively looking for opportunities to offer event promotions to medical offices, clinics and fitness centers in Canada to demonstrate our products.

~~Drug~~We also ~~Response~~seek ~~Testing~~to attract medical practitioners and their customers through the existing relationships of our chief executive officer, president and director, Dr. Barjinder Sohal, a licensed physician, and Dr. Nitan Arora, our vice president and director, a chiropractic physician.

~~Drug~~We believe ~~response~~that ~~testing~~a ~~identifies~~marketing ~~uses~~mix aof ~~person’s~~social ~~DNA~~media, toemail ~~identify~~advertising, ~~metabolism~~print ~~enzymes~~advertising in medical journals and ~~transporters~~health/ ~~that~~fitness ~~have~~publications, internet ~~been~~advertising, ~~linked~~and tomedical ~~harmful~~office ~~reactions~~and ~~with~~fitness ~~common~~center ~~medical~~event ~~prescriptions~~promotions providing information and sample test kits is an optimal strategy to increase sales.

~~The Testing Process~~Government Regulation

~~Our~~The components ~~DNA~~of ~~test~~our kits ~~include~~are ~~swabs~~regulated toaccording ~~collect a saliva sample, detailed instructions and pre-labeled packaging~~ to ~~send~~Canadian ~~the~~regulation ~~sample to us~~standards. ~~Upon~~ ~~receipt~~The oflaboratories ~~the~~that ~~sample,~~process itour istests ~~registered~~are in Canada ~~our database~~ and ~~sent~~the ~~to a third party laboratory to be interpreted~~US. ~~All~~ ~~tests~~Some results are ~~interpreted~~processed byin ~~either~~Canada ~~US laboratories accredited by CLIA~~ and ~~CAP~~the orUS ~~Canadian~~based ~~laboratories~~on ~~accredited by~~ the ~~Standard~~type ~~Council~~ of ~~Canada~~test ~~and~~being ~~CAP~~performed. ~~After~~ ~~interpretation,~~The ~~the~~labs ~~laboratory~~meet ~~delivers~~ the highest ~~test~~industry ~~results to us by email~~standards. ~~Upon~~ ~~receipt,~~They weare ~~enter~~compliant ~~the~~with ~~results~~ISO in17025, ~~our~~CAP ~~customer database~~ and ~~deliver~~CLIA ~~the~~lab ~~results to the consumer by email~~standards.

The results for paternity tests and Y-chromosome relationship tests and grandparent or uncle or aunt tests, are interpreted within 4 to 5 business days of the lab’s receipt of the test. Ancestry origin tests are interpreted within 21 to 28 days of receipt. Genetic predisposition test including diet and fitness testing are interpreted within 28-42 days of receipt. We typically deliver the test results to the customer by email within 1 to 4 days after our receipt. 8

~~Dependence on a Few Customers~~Employees

~~In 2016, revenues were from two different customers who accounted for 87%~~ As of the ~~revenues.~~date ~~In 2015, revenues were from three different customers who accounted for 88%~~ of ~~the~~this ~~revenues. Our~~Annual ~~remaining revenues were from several patients. As a result~~Report, awe ~~material~~have ~~portion~~5 ~~of our revenues are concentrated in a few customers. Should any of these key customers decrease or cease ordering products from us~~employees, ~~our~~as ~~revenues and results of operations will be negatively affected.~~follows:

8● 3 are our officers and/or directors, of which 2 are doctors ● 1 clerical employee who distributes tests, and handles calls, and emails ● 1 administrative employee who handles office management and oversees development of content for our website

~~Suppliers~~None of our employees are represented by a collective bargaining agreement, nor have we experienced any work stoppages. We believe that we maintain good relationships with our employees.

We purchase our DNA test components from Pro Printing and Mailing Services Inc. located at 1235 Trafalgar Road, Oakville, Ontario, L6H 3P1 and assemble the products at our facilities, or we purchase finished kits previously from Pathway Genomics Lab, 4045 Sorrento Valley Boulevard, San Diego, CA 92121.Competition

~~Marketing~~We compete ~~Strategy~~with other companies offering DNA testing products in Canada that are similar to or substantially the same as the products offered by us. This may put us at a competitive disadvantage since our tests are not unique. Our competitors include www.thednalab.com, www.dnacanada.com, and www.easyDNA.ca. Competitors for our over-the-counter ancestry testing kits include dna.ancestry.com, www.accu-metrics.com and www.medcan.com.

~~Our~~To compete, ~~first~~we ~~product~~plan ~~sale was in April of 2010. All sales~~ to date have been generated by our website or related parties. Sales generated from our website are placed by phone order. We presently offer our paternity testing kits for purchase on our website. We offer an online shopping cart featuring all of our products.:

~~Our~~● ~~core~~develop ~~marketing~~a ~~strategy~~user isfriendly appealing website to ~~brand~~sell our DNA testing kits directly to consumers and medical practitioners in Canada; ● develop our slogans “DNA For Family” ~~slogan~~and ~~for~~“DNA ~~those~~For ~~seeking~~Health”; ~~information~~● ~~that~~attract ~~can~~medical bepractitioners ~~determined~~and bytheir ~~DNA~~customers ~~testing~~through ~~such~~the asexisting ~~kinships~~relationships of our chief executive officer, president and ~~ancestry~~director, Dr. Barjinder Sohal, a licensed physician, and Dr. Nitan Arora, our ~~“DNA~~vice ~~For~~president ~~Health”~~and ~~slogan~~director, ~~for~~a ~~those~~chiropractic ~~seeking~~physician; toand ~~improve~~● ~~their~~implement ~~health~~our bymarketing ~~DNA~~plan ~~testing~~that toincludes ~~determine~~incentives ~~disease~~for ~~predisposition~~medical practitioners, ~~nutrition~~medical facilities and fitness ~~testing~~centers that purchase our products on a repeat basis.

WeThe DNA ~~implemented~~testing and product market is highly competitive and rapidly changing. Our ability to compete depends upon many factors within and outside our control, including the performance and reliability of our test kits, customer service, marketing ~~plan~~efforts and development of our logs and brand name. Due to the relatively low barriers to entry in ~~April~~the DNA testing products market in Canada we expect additional competition from other emerging companies. Many of ~~2015~~our existing and potential competitors are substantially larger than us and have significantly greater financial, technical and marketing resources. As a result, they may be able to respond more quickly to new or emerging technologies for DNA testing products. There can be no assurance that we will be able to compete successfully against current or future competitors or that competitive pressure will not have a material adverse effect on our business, operating results and financial condition.

·Seasonality

InOur business ~~April~~is ofnot ~~2015:~~affected by seasonal factors.

weItem 1A. ~~began~~Risk ~~to create email materials for our marketing campaign for physicians, medical practitioners and fitness centers in Canada;~~Factors

oThe statements contained in or incorporated into this annual report that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. If any of the following risks actually occur, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

weRisks Related ~~began social media campaigns on Twitter, Facebook, and other websites~~ to ~~market~~Our ~~our~~Financial ~~products;~~Condition

·There is substantial doubt about our ability to continue as a going concern as a result of our limited operating history and financial resources, and if we are unable to generate significant revenue or secure financing we may be required to cease or curtail our operations.

InWe incurred ~~July~~net losses of $52,551 and $161,287 for the years ended December 31, 2017 :and 2016, respectively. As a result, our independent registered public accounting firm has included an explanatory paragraph in its audit opinion that we may be unable to continue as a going concern. Our limited operating history and financial resources raise substantial doubt about our ability to continue as a going concern and our financial statements contain a going concern qualification. Our consolidated financial statements do not include adjustments that might result from the outcome of this uncertainty and if we are unable to generate significant revenue or secure financing we may be required to cease or curtail our operations.

oWe are an early stage company with little or no historical performance for you to base an investment decision upon, and we may never become profitable.

We are a recently formed company. For the years ended December 31, 2017 and 2016, we ~~continue~~had torevenues ~~use~~of ~~Google~~$49,816 ~~AdWords~~and $31,886, respectively. For the years ended December 31, 2017 and ~~search~~2016, ~~engine~~we ~~optimization~~have ~~campaigns~~a ~~targeting~~net ~~consumers~~loss of $52,551 and $161,287, respectively. Accordingly, we have limited historical performance upon which you may evaluate our prospects for achieving our business objectives and becoming profitable in ~~Canada;~~light of the risks, difficulties and uncertainties frequently encountered by early stage companies such as us. Accordingly, before investing in our common stock, you should consider the challenges, expenses and difficulties that we will face as an early stage company, and whether we will ever become profitable.

oWe are dependent on the sale of our securities to fund our operations.

We received proceeds from the sale of shares of our common stock which funds our current operations. As at the date of this Annual Report, we ~~started~~have ~~advertising~~cash on hand of approximately $● which is not sufficient to fund our ~~products~~operations for the next six months. We are dependent on the sale of our securities to fund our operations, and will remain so until we generate sufficient revenues to pay for our operating costs. Our officers and directors have made no written commitments with respect to providing a source of liquidity in ~~medical~~the ~~journals;~~form of cash advances, loans and/or financial guarantees.

o10

If we are ~~planning~~unable to ~~implement~~generate asufficient ~~new~~revenues ~~search~~for ~~engine~~our ~~optimization~~operating ~~(SEO)~~expenses ~~plan~~we will need financing, which we may be unable to obtain; should we fail to obtain sufficient financing, our revenues will be negatively impacted.

·For the years ended December 31, 2017 and 2016, we had revenues of $49,816 and $31,886 respectively from the sale of our DNA testing kits. For the years ended December 31, 2017, and 2016, we incurred a net loss of $52,551 and $161,287, respectively. Because we have limited revenues and lack historical financial data, including revenue data, our future revenues are unpredictable. We estimate that will require approximately $8,083 per month or $97,000 over the next 12 months to meet our current and anticipated operational costs, which consist of rent, advertising, salaries and other general, administrative expenses to comply with our public reporting obligations. As at February 28, 2019, we had cash on hand of approximately $● which is insufficient to pay our operating expenses for less than one month. We plan to spend $97,000 to implement our plan of operations as described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operation” on page 23 of this Report. There is no assurance we will have sufficient funds available to implement our plan of operations which could cause you to lose your investment.

InUntil we ~~July~~generate ofmaterial ~~2017~~operating revenues, we require additional debt or equity funding to continue our operations and implement our plan of operations. We intend to ~~offer~~raise ~~incentives~~additional ~~for~~funds ~~medical~~from ~~practitioners~~an offering of our stock in the future; however, ~~medical~~this ~~facilities~~offering may ~~and~~never ~~fitness~~occur, ~~centers~~or ~~that~~if ~~purchase~~it ~~our~~occurs, ~~products~~we onmay abe ~~repeat~~unable ~~basis;~~to raise the required funding. We do not have any plans or specific agreements for new sources of funding and we have no agreements for financing in place.

·Expenses required to operate as a public company will reduce funds available to develop our business and could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

Operating as a public company is more expensive than operating as a private company, including additional funds required to obtain outside assistance from legal, accounting, investor relations, or other professionals that could be more costly than planned. We ~~are~~may ~~actively~~also be ~~looking~~required ~~for~~to ~~opportunities~~hire additional staff to ~~offer~~comply ~~event~~with ~~promotions~~additional SEC reporting requirements. We anticipate that the cost of SEC reporting will be approximately $60,000 annually. Our failure to ~~medical~~comply ~~offices~~with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, ~~clinics~~cash flow and ~~fitness~~financial ~~centers~~condition. If we fail to meet these requirements, we will be unable to secure a qualification for quotation of our securities on the OTC Bulletin Board, or, if we have secured a qualification, we may lose the qualification and our securities would no longer trade on the OTC Bulletin Board. Further, if we fail to meet these obligations and consequently fail to satisfy our SEC reporting obligations, investors will then own stock in ~~Canada~~a company that does not provide the disclosure available in quarterly, annual reports and other required SEC reports that would be otherwise publicly available leading to ~~demonstrate~~increased difficulty in selling their stock due to our ~~products~~becoming a non-reporting issuer.

We also seek to attract medical practitioners and their customers through the existing relationships of our chief executive officer, president and director, Dr. Barjinder Sohal, a licensed physician, and Dr. Nitan Arora, our vice president and director, a chiropractic physician.11

WeRisks Related believe that a marketing mix of social media, email advertising, print advertising in medical journals and health/ fitness publications, internet advertising and medical office and fitness center event promotions providing information and sample test kits is an optimal strategy to ~~increase~~Our ~~sales.~~Business

~~Government~~We may ~~Regulation~~be subject to significant regulations in the future and may not be able to obtain necessary regulatory clearances to sell our products.

~~The~~We presently ~~components~~sell ofand ship our DNA testing kits ~~are~~only ~~regulated~~in ~~according~~Canada. toCanada ~~Canadian~~does ~~regulation~~not ~~standards~~presently regulate the sale of over the counter DNA testing kits. ~~The~~ ~~laboratories~~Countries such as the United States limit the types of DNA testing kits that ~~process~~can ~~our~~be ~~tests~~sold ~~are~~directly into ~~Canada~~consumers ~~and~~specifically related to the ~~US. Some~~diagnosis ~~results~~and ~~are~~treatment ~~processed~~of indiseases ~~Canada~~ and ~~the~~certain USmedical ~~based~~conditions. onShould Canada adopt future regulations limiting the ~~type~~sale of ~~test~~our ~~being~~DNA ~~performed~~testing kits directly to consumers our revenues will likely decrease. ~~The~~ ~~labs~~If ~~meet~~we ~~the~~expand ~~highest~~our ~~industry~~business ~~standards~~to the U. ~~They~~S. or ~~are~~other ~~compliant~~countries, ~~with~~we ~~ISO~~will ~~17025~~likely become subject to regulation by the FDA or other comparable agencies of other countries, ~~CAP~~which may ~~and~~require ~~CLIA~~us ~~lab~~to ~~standards~~obtain regulatory approval or clearance before we can market those products.

9These regulatory approval processes may be expensive, time-consuming and uncertain, and our failure to obtain or comply with these approvals or clearances could harm our business, financial condition and operating results.

~~Employees~~We must be able to adapt to rapidly changing technology trends and evolving industry standards or we risk our products becoming obsolete.

AsThe DNA testing market in which we compete is characterized by intensive development efforts and rapidly advancing technology. Our future success will depend, in large part, upon our ability to anticipate and keep pace with advancing technology and competing innovations. We may not be successful in identifying, developing and marketing new products or enhancing our existing products. We believe that a number of ~~the~~large ~~date~~companies, wewith ~~have~~significantly 5greater ~~employees~~financial, asmanufacturing, ~~follows:~~marketing, distribution and technical resources and experience than ours, are focusing on the development of visualization products for minimally invasive surgery.

·Adverse publicity of our DNA testing products and any similar products distributed by others could harm our reputation and adversely affect our revenues.

3We believe we are highly dependent upon positive consumer perceptions of the reliability of our ~~officers~~DNA testing kits as well as similar products distributed by other DNA product and/ testing companies. Consumer perception of the reliability of DNA testing can be substantially influenced by scientific research or ~~directors~~findings, national media attention and other publicity about the use of ~~which~~DNA technologies. 2Adverse publicity from these sources regarding the reliability, quality or efficacy of our products could harm our reputation and results of operations. The mere publication of news articles or reports asserting that over the counter DNA testing kits are ~~doctors~~not reliable for the purposes intended particularly where such kits are used to determine genetic predisposition to certain diseases or conditions could have a material adverse effect on our business, financial condition and results of operations, regardless of whether such news articles or reports are scientifically supported.

·We may be subject to intellectual property rights claims, which are costly to defend, could require us to pay damages and could limit our ability to sell some of our products.

1We have ~~clerical~~no ~~employee~~secured ~~who~~intellectual ~~distributes~~property ~~tests,~~protection of the DNA Testing Centers name. Our industry is characterized by vigorous pursuit and ~~handles~~protection ~~calls~~of intellectual property rights, which has resulted in protracted and ~~emails~~expensive litigation for several companies. Third parties may assert claims of misappropriation of trade secrets or infringement of intellectual property rights against us for which we may be liable.

·12

1If our ~~administrative~~business ~~employee~~expands, ~~who~~the ~~handles~~number ~~office~~of ~~management~~products and ~~oversees~~competitors ~~development~~in our markets increases and product overlaps occur, infringement claims may increase in number and significance. Intellectual property lawsuits are subject to inherent uncertainties due to the complexity of ~~content~~the ~~for~~technical ~~our~~issues ~~website~~involved, and we cannot be certain that we would be successful in defending ourselves against intellectual property claims. Further, many potential litigants have the capability to dedicate substantially greater resources than we can to enforce their intellectual property rights and to defend claims that may be brought against them. Furthermore, a successful claimant could secure a judgment that requires us to pay substantial damages or prevents us from distributing our products.

~~None~~Third parties ofcan ~~our~~purchase ~~employees~~the ~~are~~same ~~represented~~products ~~by a collective bargaining agreement, nor have~~ we ~~experienced~~sell ~~any~~which ~~work~~may ~~stoppages. We~~negatively ~~believe~~affect ~~that we maintain good relationships with~~ our ~~employees~~revenues.

~~Competition~~We purchase our test components from Pro Printing and Mailing Services Inc. and finished test kits previously from Pathway Genomics Lab, both of which sell products to other companies. As such, third parties can purchase the same products as us which puts us at a competitive disadvantage and may have a negative impact on our revenues.

WeIf we ~~compete~~fail ~~with other companies offering DNA testing products in Canada that are similar~~ to ordevelop ~~substantially~~ the ~~same~~DNA asTesting ~~the~~Centers ~~products~~brand ~~offered by us. This may put us at a competitive disadvantage since our tests are not unique. Our competitors include www.thednalab.com~~cost-effectively, ~~www.dnacanada.com, and www.easyDNA.ca. Competitors for~~ our ~~over-the-counter~~business ~~ancestry~~may ~~testing~~be ~~kits~~adversely ~~include dna~~affected.~~ancestry.com, www.accu-metrics.com and www.medcan.com.~~

ToThe success ~~compete~~of our products marketed under the DNA Testing Centers brand will depend upon the effectiveness of our marketing efforts. Brand promotion activities may not yield increased revenue, and even if they do, any increased revenue may not offset the expenses incurred in building the brands. If we ~~plan~~fail to: successfully promote and maintain our brands, or incur substantial expenses in an unsuccessful attempt to promote and maintain our brands, we may fail to attract enough new customers or retain our existing customers to the extent necessary to realize a sufficient return on our brand-building efforts, and our business and results of operations could suffer.

·The DNA testing industry is highly competitive, and our failure to compete effectively could adversely affect our market share, financial condition and future growth.

~~develop~~The DNA atesting ~~user~~industry ~~friendly~~is ~~appealing~~highly ~~website~~competitive with respect to ~~sell~~price, brand and product recognition and new product introductions. Many of our ~~DNA~~competitors ~~testing~~are ~~kits~~larger, ~~directly~~more toestablished ~~consumers~~and possess greater financial, personnel, distribution and ~~medical~~other ~~practitioners~~resources than inwe ~~Canada;~~have. As such, the growth of product sales is highly competitive and uncertain. If we cannot compete effectively, we may not be profitable.

·The purchase of many of our products is discretionary, and may be negatively impacted by adverse trends in the general economy and make it more difficult for us to generate revenues.

~~develop~~Our business is affected by general economic conditions since our ~~slogans “DNA~~products ~~For~~are ~~Family”~~ discretionary and “ we depend, to a significant extent, upon a number of factors relating to discretionary consumer spending. These factors include economic conditions and perceptions of such conditions by consumers, employment rates, the level of consumers’ disposable income, business conditions, interest rates, consumer debt levels and availability of credit. Consumer spending on our DNA ~~For~~testing ~~Health”;~~products may be adversely affected by changes in general economic conditions.

·13

~~attract~~The success ~~medical practitioners and their customers through the existing relationships~~ of our ~~chief~~business ~~executive~~depends ~~officer,~~on ~~president~~our ~~and~~ability ~~director,~~to ~~Dr.~~market ~~Barjinder Sohal, a licensed physician,~~ and ~~Dr.~~advertise ~~Nitan~~the ~~Arora,~~products ~~our~~we ~~vice~~sell ~~president and director, a chiropractic physician; and~~effectively.

·Our ability to establish effective marketing and advertising campaigns is the key to our success. Our advertisements promote our corporate image, our DNA testing products and the pricing of such products. If we are unable to increase awareness of our products, we may not be able to attract new customers. Our marketing activities may not be successful in promoting the DNA testing products we sell or pricing strategies or in retaining and increasing our customer base. We cannot assure you that our marketing programs will be adequate to support our future growth, which may result in a material adverse effect on our results of operations.

~~implement~~Our lack ~~our~~of ~~marketing~~registered ~~plan~~trademarks ~~that includes incentives for medical practitioners, medical facilities~~ and ~~fitness~~trade ~~centers~~names ~~that~~could ~~purchase~~potentially harm our ~~products on a repeat basis~~business.

~~The DNA testing~~ Trademarks and ~~product~~trade ~~market~~names isdistinguish ~~highly~~the ~~competitive~~various ~~and~~companies ~~rapidly~~from ~~changing~~each other. ~~Our~~ ~~ability~~If topotential ~~compete~~distributors ~~depends~~and ~~upon~~customers ~~many~~are ~~factors~~unable ~~within~~to ~~and outside~~ distinguish our ~~control,~~products ~~including~~from ~~the~~those ~~performance and reliability~~ of ~~our~~other ~~test kits~~companies, ~~customer~~we ~~service,~~could ~~marketing~~lose ~~efforts~~sales ~~and~~to ~~development of~~ our ~~logs and brand name~~competitors. ~~Due~~ toWe ~~the~~do ~~relatively~~not ~~low~~have ~~barriers~~any toregistered ~~entry~~trademarks inand trade ~~the~~names, ~~DNA~~so ~~testing products market in Canada~~ we ~~expect~~only ~~additional~~has ~~competition~~common ~~from~~law ~~other~~rights ~~emerging~~with ~~companies. Many~~respect ofto ~~our~~infractions ~~existing~~or ~~and~~infringements ~~potential~~on ~~competitors~~its ~~are~~products. ~~substantially~~Many ~~larger~~subtleties ~~than~~exist in usproduct ~~and have significantly greater financial~~descriptions, ~~technical~~offering and ~~marketing~~names ~~resources. As~~that acan ~~result,~~easily ~~they~~confuse ~~may~~distributors beand ~~able~~customers. toThe ~~respond~~name ~~more~~of ~~quickly~~our toprincipal ~~new or emerging technologies for DNA testing~~ products~~. There~~ may ~~can~~ be nofound ~~assurance~~in ~~that~~numerous wevariations ~~will~~of bethe ~~able~~name toand ~~compete~~descriptions ~~successfully~~in ~~against~~various ~~current~~media orand ~~future~~product ~~competitors~~labels. orThis ~~that~~presents ~~competitive~~a ~~pressure~~risk ~~will~~of losing ~~not~~potential ~~have~~customers alooking ~~material~~for ~~adverse~~our ~~effect~~products onand ~~our~~buying ~~business,~~someone ~~operating~~else’s ~~results~~because ~~and~~they ~~financial~~cannot ~~condition~~differentiate between them.

~~Seasonality~~We may be subject to product liability claims and we do not have insurance coverage for such claims which could negatively impact our financial condition.

~~Our~~By selling DNA test kits, we will face an inherent business risk of exposure to product liability claims in the event that the use of our products results in personal injury or death. Also, in the event that any of our testing kits is defective, we may be required to recall or replace such products. We do not ~~affected~~maintain byproduct ~~seasonal~~liability ~~factors~~insurance coverage to protect us from such claims. A successful product liability claim or series of claims brought against us would negatively impact our business.

10Risks Related To Our Management

~~Item~~Should we ~~1A.~~lose ~~Risk~~the ~~Factors~~services of our management, our financial condition and proposed expansion may be negatively impacted.

~~The~~Our future ~~statements~~depends ~~contained~~on inthe orcontinued ~~incorporated~~contributions ~~into~~of ~~this~~Dr. Barjinder ~~annual~~Sohal, ~~report~~our ~~that~~chief ~~are~~executive ~~not~~officer, ~~historic~~president ~~facts~~and ~~are~~director, ~~forward-looking~~Dr. ~~statements~~Nitan ~~that~~Arora, ~~are~~our CFO, ~~subject~~vice topresident ~~risks~~ and ~~uncertainties~~director ~~that~~and ~~could~~Navjot ~~cause~~Nanda, ~~actual~~our ~~results~~secretary, totreasurer ~~differ~~and ~~materially~~director, ~~from~~who ~~those~~would ~~set~~each ~~forth~~be indifficult orto ~~implied~~replace. Their byservices ~~forward-looking~~are ~~statements.~~critical Ifto ~~any~~the management of ~~the~~our ~~following~~business ~~risks~~and ~~actually~~operations. ~~occur,~~We do ~~our~~not ~~business,~~maintain ~~financial~~key ~~condition~~man orlife ~~results~~insurance on any of ~~operations~~our ~~could~~officers beor ~~harmed~~directors. InShould ~~that~~we ~~case,~~lose the ~~trading~~services ~~price~~of any of our ~~common~~officers and ~~stock~~directors, ~~could~~we ~~decline~~may be unable to replace their services with equally competent and experienced personnel, our operational goals and ~~you~~strategies may ~~lose~~be ~~all~~adversely oraffected, ~~part~~which ofwill ~~your~~negatively ~~investment~~affect our potential revenues.

~~Risks Related to Our Financial Condition~~14

~~There~~Our officers isand ~~substantial~~directors ~~doubt~~have ~~about~~other ~~our~~business ~~ability~~interests toand ~~continue~~conflict ~~as a going concern as a result~~ of ~~our~~interests ~~limited~~which ~~operating history and financial resources, and if we are unable to generate significant revenue or secure financing we~~ may not be ~~required~~resolved toin ~~cease or curtail~~ our ~~operations~~favor.

WeDr. Barjinder ~~incurred net losses of $161~~Sohal,~~287and~~ ~~$101,074~~our ~~for~~chief ~~the~~executive ~~years ended December 31~~officer, ~~2016,~~president and ~~2015~~director, ~~respectively~~Dr. As aNitan ~~result~~Arora, our ~~independent~~CFO, ~~registered~~vice ~~public~~president ~~accounting~~and ~~firm~~director ~~has~~and Navjot ~~included~~Nanda, anour ~~explanatory~~secretary ~~paragraph~~and intreasurer, ~~its~~each ~~audit~~own ~~opinion~~33.3% ~~that~~of weHealthmedica, ~~may~~which beis ~~unable~~a towalk-in ~~continue~~health asclinic alocated ~~going~~in ~~concern~~Oakville, Canada. ~~Our~~ ~~limited~~Dr. ~~operating~~Sohal ~~history~~owns ~~and~~100% ~~financial~~of ~~resources~~and ~~raise~~is ~~substantial~~and ~~doubt~~a ~~about~~physician ~~our~~at ~~ability~~Barjinder toSingh ~~continue~~Sohal asMedicine aProfessional ~~going~~Corp., ~~concern~~located ~~and~~in ~~our~~Toronto, Canada, ~~financial~~where ~~statements~~he ~~contain~~is a ~~going~~physician. ~~concern~~Additionally, ~~qualification~~Dr. ~~Our~~ ~~financial~~Arora ~~statements~~and doNavjot ~~not~~Nanda ~~include~~each ~~adjustments~~hold ~~that~~50% ~~might~~of ~~result~~Canadian ~~from~~Decompression ~~the~~and ~~outcome~~Pain ofCenters (“CDPC”), ~~this~~a ~~uncertainty~~Canadian ~~and~~company ifthat weprovides ~~are~~chiropractic ~~unable~~services. toDr. ~~generate~~Arora ~~significant~~also ~~revenue~~serves oras ~~secure~~a ~~financing~~clinic weoperator at ~~may~~Viva beMedical ~~required~~Clinic, towhich ~~cease~~is ora ~~curtail~~walk-in ~~our~~medical ~~operations~~clinic located in Winnipeg, Canada.

WeNone of ~~are~~the anforegoing ~~early~~entities ~~stage~~provides ~~company~~DNA Testing or other services that compete with ~~little~~the orproducts noand ~~historical~~services ~~performance~~we offer. We may compete with these entities for ~~you~~our tomanagement’s ~~base~~time anin ~~investment~~the ~~decision~~future. ~~upon~~Accordingly, the personal interests of our officers and directors may come into conflict with our interests and those of our minority stockholders. We may present our officers and directors with business opportunities, which are mutually desired. Additionally, in the future, we may ~~never~~compete ~~become~~with ~~profitable~~these entities for investment capital, technical resources, key personnel and other opportunities, goods, services, etc. You should carefully consider these potential conflicts of interest before deciding whether to invest in shares of our common stock. We have not yet adopted a policy for resolving such conflicts of interest.

WeOur officers ~~are a recently formed our company. For the years ended December 31, 2016~~ and ~~2015,~~directors wedevote ~~had~~limited ~~revenues~~time ofto ~~$31,886and~~our ~~$20~~business,~~636,~~ ~~respectively. For the years ended December 31, 2016 and 2015, we have a net loss of $161,287 and $101,074, respectively. Accordingly, we have limited historical performance upon~~ which ~~you~~ may ~~evaluate~~negatively ~~our~~impact ~~prospects~~upon ~~for achieving~~ our ~~business~~plan ~~objectives and becoming profitable in light~~ of ~~the risks~~operations, ~~difficulties~~implementation of ~~and uncertainties frequently encountered by early stage companies such as us. Accordingly, before investing in~~ our ~~common~~business ~~stock,~~plan ~~you should consider the challenges, expenses~~ and ~~difficulties~~our ~~that~~potential ~~we will face as an early stage company, and whether we will ever become profitable~~profitability.

WeDr. Barjinder ~~are~~Sohal, ~~dependent~~our onchief ~~the~~executive ~~sale~~officer and director dedicates approximately 140 hours, Dr. Nitan Arora, our CFO, vice president and director dedicate approximately 140 hours and Navjot Nanda spends approximately 140 hours each month to our business. The limited amount of time our ~~securities~~management devotes to ~~fund~~our business activities in the future may be inadequate to implement our plan of operations and develop a profitable business.

WeOur officers ~~received~~and ~~proceeds~~directors ~~from the sale of shares of our common stock which funds our current operations. We presently~~ have ~~cash~~no onexperience ~~hand~~managing ofa ~~only~~public ~~$5,923.13~~company which is ~~not~~required ~~sufficient~~ to ~~fund~~establish ~~our~~and ~~operations~~maintain ~~for~~disclosure ~~a month. We are dependent on the sale of our securities to fund our operations,~~ controls and ~~will~~procedures ~~remain so until we generate sufficient revenues to pay for our operating costs. Our officers~~ and ~~directors~~internal ~~have~~control ~~made~~over ~~no written commitments with respect to providing a source of liquidity in the form of cash advances, loans and/or~~ financial ~~guarantees~~reporting.

11We have never operated as a public company and our management has no experience managing a public company which is required to establish and maintain disclosure controls and procedures and internal control over financial reporting. As a result, we may not be able to operate successfully as a public company, even if our operations are successful. We plan to comply with all of the various rules and regulations, which are required for a public company that is reporting company with the Securities and Exchange Commission. However, if we cannot operate successfully as a public company, your investment may be materially adversely affected.

If we are unable to generate sufficient revenues for our operating expenses we will need financing, which we may be unable to obtain; should we fail to obtain sufficient financing, our revenues will be negatively impacted.15

For the years ended December 31, 2016 and 2015, we had revenues of $31,886 and $20,636 respectively from the sale of our DNA testing kits. For the years ended December 31, 2015, and 2014, we incurred a net loss of $161,287 and $101,074, respectively. Because we have limited revenues and lack historical financial data, including revenue data, our future revenues are unpredictable. We will ~~require~~incur ~~approximately~~additional ~~$8,083 per month or $97,000 over the next 12 months to meet our current and anticipated operational~~ costs, ~~which consist of rent, advertising, salaries~~ and ~~other~~management ~~general,~~time ~~administrative~~related expenses pertaining to ~~comply with the costs of being an~~ SEC reporting ~~company~~obligations due to expected decreased expenses related to becoming a public company relative to the fiscal year of 2015. As at August 15, 2017, we had cash on hand of approximately $5,923.13 which is insufficient to pay our operating expenses for less than one month. We plan to spend $97,000 to implement our plan of operations as described under the heading “Management’s Discussion and ~~Analysis~~SEC ofcompliance ~~Financial Condition~~ matter and ~~Results~~our ofmanagement ~~Operation”~~has ~~on page 23 of this Report. There is~~ no ~~assurance~~experience wein ~~will~~such ~~have sufficient funds available to implement our plan of operations which could cause you to lose your investment~~matters.

~~Until~~Dr. Barjinder weSohal, ~~generate~~our ~~material~~chief ~~operating~~executive ~~revenues~~officer and president, weDr. ~~require~~Nitan ~~additional~~Arora, ~~debt~~our orvice-president, ~~equity~~and ~~funding~~Ms. toNavjot ~~continue~~Nanda, our ~~operations~~secretary, treasurer, and ~~implement~~director, ~~our~~are ~~plan~~responsible offor ~~operations~~managing us, including compliance with SEC reporting obligations and maintaining disclosure controls and procedures and internal control over financial reporting. We ~~intend~~These public reporting requirements and controls are new to ~~raise~~these ~~additional~~individuals ~~funds~~and at times will require us to obtain outside assistance from anlegal, ~~offering~~accounting ofor other professionals that will increase our ~~stock~~costs inof ~~the~~doing ~~future;~~business. ~~however,~~Should ~~this~~we ~~offering~~fail ~~may~~to ~~never~~comply ~~occur,~~with orSEC ifreporting itand ~~occurs,~~internal controls and procedures, we may be ~~unable~~subject to ~~raise~~securities ~~the~~law ~~required~~violations ~~funding. We~~that domay ~~not~~result ~~have~~in ~~any~~additional ~~plans~~compliance costs or ~~specific~~costs ~~agreements~~associated ~~for~~with ~~new~~SEC ~~sources~~judgments or fines, each of ~~funding~~which would increase our costs and wenegatively ~~have~~affect noour ~~agreements~~potential ~~for~~profitability ~~financing~~and inour ~~place~~ability to conduct our business.

~~Our~~You may ~~revenues~~have ~~are~~difficulty ~~highly concentrated~~ in ~~three~~enforcing ~~customers,~~any ~~which~~judgment ~~represented~~against ~~97.09% of~~ our ~~revenues~~officers ~~during~~and ~~the~~directors ~~year~~who ~~ended~~are ~~December~~residents ~~31,~~of ~~2015;~~Canada ~~our~~and ~~revenues~~not ~~could~~of bethe ~~significantly~~U.S., and ~~reduced~~are iflocated ~~these~~outside ~~three~~the ~~customers reduce their orders from us or they cease purchasing DNA test kits from us~~U.S.

~~In 2016, 87%~~ All of our ~~revenues~~officers ~~were~~and ~~from~~directors ~~two~~are ~~different~~located ~~customers.~~outside ~~The~~the ~~remaining~~U.S. ~~13%~~and ofreside ~~revenues~~in ~~were from several patients~~Canada. As a result, ait ~~material~~could ~~portion~~be ofdifficult ~~our~~for ~~revenues~~investors to ~~are~~effect ~~concentrated~~service inof aprocess ~~few customers. Should any~~ of ~~these~~them ~~three~~in ~~customers~~the ~~decrease~~U.S., or ~~cease~~to ~~ordering~~enforce ~~products~~a ~~from~~judgment ~~us,~~obtained ~~our~~against ~~revenues~~them ~~and~~in ~~results~~the ~~of operations will be negatively affected~~U.S.

~~Expenses~~Because we ~~required~~do tonot ~~operate~~have asan aaudit ~~public~~or ~~company~~compensation ~~will~~committee, ~~reduce~~shareholders ~~funds~~will ~~available~~be required to ~~develop~~rely ~~our~~on ~~business~~the ~~and~~members ~~could~~of ~~negatively affect~~ our ~~stock~~board ~~price~~of ~~and~~directors, who ~~adversely~~are ~~affect~~not ~~our results of operations~~independent, ~~cash~~to ~~flow~~perform ~~and~~these ~~financial condition~~functions.

~~Operating~~We do asnot ahave ~~public~~an ~~company~~audit isor ~~more~~compensation ~~expensive~~committee ~~than operating as a private company, including additional funds required to obtain outside assistance from legal, accounting, investor relations,~~ or ~~other~~board ~~professionals~~of ~~that~~directors ~~could~~as bea ~~more~~whole ~~costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements. We anticipate~~ that ~~the~~is ~~cost~~composed of ~~SEC~~independent ~~reporting will be approximately $60,000 annually~~directors. ~~Our~~ ~~failure~~Because our todirectors ~~comply~~are ~~with~~also ~~reporting requirements and other provisions of securities laws could negatively affect~~ our ~~stock~~officers ~~price~~ and ~~adversely~~controlling ~~affect our results of operations~~shareholders, ~~cash~~they ~~flow~~are ~~and~~not ~~financial condition~~independent. If weThere ~~fail~~is ~~to meet these requirements, we will be unable to secure~~ a ~~qualification~~potential ~~for~~conflict ~~quotation~~between their ofor our ~~securities~~interests onand ~~the~~our ~~OTC~~shareholders’ ~~Bulletin Board~~interests, ~~or,~~since ifour wedirectors ~~have~~are ~~secured~~also aour ~~qualification,~~officers wewho ~~may~~will ~~lose~~participate ~~the~~in discussions ~~qualification~~concerning ~~and~~management ~~our~~compensation ~~securities~~and ~~would~~audit noissues ~~longer~~that ~~trade~~may onaffect ~~the~~management ~~OTC Bulletin Board~~decisions. ~~Further,~~ ifUntil we ~~fail~~have toan ~~meet~~audit ~~these~~committee or ~~obligations~~independent ~~and~~directors, ~~consequently~~there ~~fail~~may tobe ~~satisfy~~less ~~our~~oversight ~~SEC~~of ~~reporting~~management ~~obligations,~~decisions ~~investors~~and ~~will~~activities ~~then~~and ~~own~~little ~~stock~~ability infor aminority ~~company~~shareholders to ~~that~~challenge ~~does~~or ~~not~~reverse ~~provide~~those ~~the~~activities ~~disclosure~~and ~~available in quarterly~~decisions, ~~annual~~even ~~reports~~if ~~and~~they ~~other~~are ~~required~~not ~~SEC reports that would be otherwise publicly available leading to increased difficulty~~ in ~~selling~~the ~~their~~best ~~stock~~interests ~~due~~of tominority ~~our becoming a non-reporting issuer~~shareholders.

12We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

~~Risks~~We are ~~Related~~an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to ~~Our~~be ~~Business~~an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years, although we could lose that status sooner if our revenues exceed $1,000,000,000, if we issue more than $1,000,000,000 in non-convertible debt in a three year period, or if the market value of our common stock held by non-affiliates exceeds $100,000,000 as of any April 30 before that time, in which case we would no longer be an emerging growth company as of the following April 30. We cannot predict whether investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

~~We may be subject to significant regulations in the future and may not be able to obtain necessary regulatory clearances to sell our products.~~16

We have ~~presently~~elected ~~sell~~to ~~and~~use ~~ship~~the ~~our~~extended ~~DNA~~transition ~~testing~~period ~~kits~~for ~~only~~complying inwith ~~Canada. Canada~~new ~~does~~or ~~not~~revised ~~presently~~accounting ~~regulate~~standards ~~the~~under ~~sale~~Section 102(b)(2) of ~~over~~ the ~~counter~~JOBS ~~DNA~~Act, ~~testing kits. Countries such as the United States limit the types of DNA testing kits~~ that ~~can~~allows beus ~~sold directly~~ to ~~consumers~~delay ~~specifically related to~~ the ~~diagnosis~~adoption ~~and treatment~~ of ~~diseases~~new ~~and~~or ~~certain~~revised ~~medical~~accounting ~~conditions. Should~~standards ~~Canada~~that ~~adopt~~have ~~future~~different ~~regulations~~effective ~~limiting~~dates for ~~the~~public ~~sale~~and ofprivate ~~our~~companies ~~DNA~~until ~~testing~~those ~~kits~~standards ~~directly~~apply to ~~consumers~~private ~~our revenues will likely decrease~~companies. If weAs ~~expand~~a ~~our~~result ~~business~~of tothis ~~the U.S. or other countries~~election, weour ~~will~~financial statements ~~likely~~may ~~become~~not ~~subject~~be ~~to regulation by the FDA or other~~ comparable ~~agencies of other countries, which may require us~~ to ~~obtain~~companies ~~regulatory~~that ~~approval~~comply orwith ~~clearance~~public ~~before~~company weeffective ~~can market those products~~dates.

~~These~~Risks Related ~~regulatory approval processes may be expensive, time-consuming and uncertain, and our failure~~ to ~~obtain~~Our orCommon ~~comply with these approvals or clearances could harm our business, financial condition and operating results.~~Stock

WeOur officers ~~must~~and bedirectors ~~able~~have tovoting ~~adapt~~control toover ~~rapidly~~all ~~changing~~matters ~~technology~~submitted ~~trends~~to ~~and~~a ~~evolving~~vote ~~industry~~of ~~standards~~our orcommon westockholders, ~~risk~~which will prevent our ~~products~~minority ~~becoming~~shareholders ~~obsolete~~from having the ability to control any of our corporate actions.

~~The~~As of ~~DNA~~the ~~testing~~date ~~market~~of inthis ~~which~~Report, we ~~compete~~had is21,496,404 ~~characterized~~shares byof ~~intensive~~common ~~development~~stock ~~efforts~~outstanding, ~~and~~each ~~rapidly~~entitled ~~advancing~~to ~~technology~~one vote per common share. Our ~~future~~chief ~~success~~executive ~~will~~officer, ~~depend~~president and director, inDr. ~~large~~Barjinder ~~part~~Sohal, ~~upon~~controls ~~our~~6,666,666 ~~ability~~shares, toour ~~anticipate~~vice-president and ~~keep~~director, Dr. ~~pace~~Nitan ~~with~~Arora, ~~advancing~~controls ~~technology~~6,666,666 shares and ~~competing~~our ~~innovations~~secretary, treasurer and director, Ms. We ~~may~~Navjot ~~not~~Nanda, becontrols ~~successful~~6,666,666 inshares. As ~~identifying~~such, ~~developing~~the ~~and~~aggregate ~~marketing~~number ~~new~~of ~~products~~common orshares ~~enhancing~~controlled by our ~~existing~~management ~~products. We~~effectively ~~believe~~entitles ~~that~~them to vote approximately 93% of our outstanding common shares on all matters submitted to a ~~number~~vote of ~~large~~our ~~companies,~~common ~~with~~stockholders. ~~significantly~~As ~~greater~~a ~~financial~~result, ~~manufacturing,~~our ~~marketing~~management has the ability to determine the outcome of all matters submitted to our stockholders for approval, ~~distribution~~including ~~and~~the ~~technical~~election ~~resources~~of directors. Our management’s control of our voting securities may make it impossible to complete some corporate transactions without its support and ~~experience~~may ~~than~~prevent ~~ours~~a change in our control. In addition, ~~are~~this ~~focusing~~ownership oncould discourage the ~~development~~acquisition of ~~visualization~~our ~~products~~common stock ~~for~~by ~~minimally~~potential ~~invasive~~investors ~~surgery~~and could have an anti-takeover effect, possibly depressing the trading price of our common stock.

~~Adverse~~Our common ~~publicity~~stock ofis ~~our~~not ~~DNA~~currently ~~testing~~quoted ~~products~~or listed and ~~any~~may ~~similar~~never ~~products~~be ~~distributed~~quoted or listed by ~~others~~the ~~could~~OTC ~~harm~~Bulletin ~~our~~Board ~~reputation~~or any other listing or quotation service and ~~adversely~~if ~~affect~~listed, no market may ever develop for our ~~revenues~~common stock, or if developed, may not be sustained in the future. Investors may have difficulty in reselling their shares due to the lack of market or state Blue Sky laws.

WeOur common ~~believe~~stock weis ~~are~~currently ~~highly~~not ~~dependent~~quoted ~~upon~~on ~~positive~~any ~~consumer~~market. ~~perceptions~~No ofmarket may ever develop for our common stock, or if developed, may not be sustained in the ~~reliability~~future. The holders of our ~~DNA~~shares ~~testing~~of ~~kits~~common asstock ~~well~~and aspersons ~~similar~~who ~~products~~desire ~~distributed~~to bypurchase ~~other~~them ~~DNA~~in ~~product~~any ~~and~~trading ~~testing~~market that ~~companies. Consumer~~might ~~perception~~develop ofin the ~~reliability~~future ofshould ~~DNA~~be ~~testing~~aware ~~can~~that there might be ~~substantially~~significant ~~influenced~~state bylaw ~~scientific~~restrictions ~~research~~upon orthe ~~findings~~ability of investors to resell our shares. Accordingly, ~~national~~even ~~media~~if ~~attention~~we ~~and~~are ~~other~~successful ~~publicity~~in ~~about~~having the ~~use~~shares ofavailable ~~DNA~~for ~~technologies~~trading on the OTC Bulletin Board, investors should consider any secondary market for our common shares to be a limited one. ~~Adverse~~ ~~publicity~~We ~~from~~intend ~~these~~to ~~sources~~seek coverage and publication of information regarding the ~~reliability~~company in an accepted publication, ~~quality~~which orpermits ~~efficacy~~a of“manual ~~our~~exemption.” ~~products~~This ~~could~~manual ~~harm~~exemption permits ~~our~~a ~~reputation~~security ~~and~~to ~~results~~be ofdistributed ~~operations~~in a particular state without being registered if the company issuing the security has a listing for that security in a securities manual recognized by the state. However, it is not enough for the security to be listed in a recognized manual. The ~~mere~~listing ~~publication~~entry must contain (1) the names of ~~news~~issuers, ~~articles~~officers, orand ~~reports~~directors, ~~asserting~~(2) ~~that~~an ~~over~~issuer’s balance sheet, and (3) a profit and loss statement for either the ~~counter~~fiscal ~~DNA~~year ~~testing~~preceding ~~kits~~the ~~are~~balance ~~not~~sheet ~~reliable~~or for the ~~purposes~~most ~~intended~~recent fiscal ~~particularly~~year ~~where~~of ~~such~~operations. ~~kits~~We ~~are~~may ~~used~~not be able to ~~determine~~secure ~~genetic~~a ~~predisposition~~listing tocontaining ~~certain~~all ~~diseases~~of orthis ~~conditions~~information. ~~could~~Furthermore, ~~have~~the manual exemption is a ~~material~~non-issuer ~~adverse~~exemption ~~effect~~restricted onto ~~our~~secondary ~~business~~trading transactions, ~~financial~~making ~~condition~~it ~~and~~unavailable ~~results~~for issuers selling newly issued securities. Most of ~~operations~~the accepted manuals are those published in Standard and Poor’s, ~~regardless~~Moody’s Investor Service, Fitch’s Investment Service, and Best’s Insurance Reports, and many states expressly recognize these manuals. A smaller number of ~~whether~~states ~~such~~declare ~~news~~that ~~articles~~they or“recognize ~~reports~~securities ~~are~~manuals” ~~scientifically~~but ~~supported~~do not specify the recognized manuals. The following states do not have any provisions and therefore do not expressly recognize the manual exemption: Alabama, Georgia, Illinois, Kentucky, Louisiana, Montana, South Dakota, Tennessee, Vermont and Wisconsin.

~~We may be subject to intellectual property rights claims, which are costly to defend, could require us to pay damages and could limit our ability to sell some of our products.~~17

WeAccordingly, our ~~have~~common noshares ~~secured~~should ~~intellectual~~be ~~property~~considered ~~protection~~totally ~~of the DNA Testing Centers name. Our industry is characterized by vigorous pursuit and protection of intellectual property rights~~illiquid, which ~~has~~inhibits ~~resulted~~investors’ inability ~~protracted~~to ~~and~~resell ~~expensive~~their ~~litigation for several companies~~shares. ~~Third parties may assert claims of misappropriation of trade secrets or infringement of intellectual property rights against us for which we may be liable.~~

13We will be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

IfThe SEC ~~our~~has ~~business~~adopted ~~expands,~~regulations ~~the~~which ~~number~~generally ofdefine ~~products~~so-called ~~and~~“penny ~~competitors~~stocks” into ~~our~~be ~~markets~~an ~~increases~~equity ~~and~~security ~~product~~that ~~overlaps~~has ~~occur,~~a ~~infringement~~market price ~~claims~~of ~~may~~less ~~increase~~than in$5.00 ~~number~~per ~~and~~share ~~significance. Intellectual~~or ~~property~~an ~~lawsuits~~exercise ~~are~~price of less than $5.00 per share, subject to ~~inherent~~certain ~~uncertainties~~exemptions. ~~due~~We toanticipate that ~~the~~our ~~complexity~~common ofstock ~~the~~will ~~technical~~be ~~issues~~a ~~involved~~“penny stock”, and we ~~cannot~~will bebecome ~~certain~~subject ~~that~~to weRule ~~would~~15g-9 beunder ~~successful~~the inExchange ~~defending~~Act, ~~ourselves~~or the ~~against~~“Penny ~~intellectual~~Stock ~~property claims~~Rule”. ~~Further,~~ ~~many~~This ~~potential~~rule ~~litigants~~imposes ~~have~~additional ~~the~~sales ~~capability~~practice torequirements ~~dedicate~~on ~~substantially~~broker-dealers ~~greater~~that ~~resources~~sell such securities to persons other than weestablished ~~can~~customers. toFor ~~enforce~~transactions ~~their~~covered ~~intellectual~~by ~~property~~Rule ~~rights~~15g-9, a broker-dealer must make a special suitability determination for the purchaser and tohave ~~defend~~received ~~claims~~the ~~that~~purchaser’s ~~may~~written beconsent ~~brought~~to ~~against~~the ~~them~~transaction prior to sale. ~~Furthermore,~~ As a ~~successful~~result, ~~claimant~~this ~~could~~rule ~~secure~~may aaffect ~~judgment~~the ~~that~~ability ~~requires~~of usbroker-dealers to ~~pay~~sell ~~substantial~~our ~~damages~~common orshares ~~prevents~~and usmay ~~from~~affect ~~distributing~~the ability of purchasers to sell any of our ~~products~~common shares in the secondary market.

~~Third~~For any ~~parties~~transaction ~~can~~(other ~~purchase~~than an exempt transaction) involving a penny stock, the ~~same~~rules ~~products~~require wedelivery, ~~sell~~prior ~~which~~to ~~may~~such ~~negatively~~transaction, of ~~affect~~a ~~our~~disclosure ~~revenues~~schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made regarding sales commissions payable to both the broker-dealer and the registered representative, and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

We do ~~purchase~~not anticipate that our ~~test~~common ~~components~~stock ~~from~~will ~~Pro~~qualify ~~Printing~~for ~~and~~exemption ~~Mailing~~from ~~Services~~the ~~Inc~~Penny Stock Rule. ~~and~~In ~~finished~~any ~~test~~event, ~~kits~~even ~~previously~~if our common stock is exempt from ~~Pathway~~the ~~Genomics~~Penny ~~Lab~~Stock Rule, ~~both~~we ofwould ~~which~~remain ~~sell~~subject ~~products~~ to ~~other~~Section ~~companies. As~~15(b)(6) ~~such,~~of ~~third~~the ~~parties~~Exchange ~~can~~Act, ~~purchase~~which gives the ~~same~~SEC the ~~products~~authority asto usrestrict ~~which~~any ~~puts~~person usfrom atparticipating in a ~~competitive~~distribution ~~disadvantage~~of ~~and~~penny ~~may~~stock, ~~have~~if the SEC finds that such a ~~negative~~restriction would ~~impact~~be onin ~~our~~the ~~revenues~~public interest.

IfSales of weour ~~fail~~common tostock ~~develop~~under ~~the~~Rule ~~DNA~~144 ~~Testing~~could ~~Centers~~reduce ~~brand~~the ~~cost-effectively,~~price of our ~~business may be adversely affected~~stock.

~~The success~~ None of ~~our products marketed under~~ the ~~DNA~~21,496,404 ~~Testing~~common ~~Centers~~shares ~~brand~~outstanding ~~will~~are ~~depend~~currently ~~upon~~eligible ~~the~~for ~~effectiveness~~resale ofunder ~~our~~Rule ~~marketing efforts~~144. ~~Brand~~ ~~promotion~~In ~~activities~~general, ~~may~~persons ~~not~~holding ~~yield~~restricted securities ~~increased~~in ~~revenue,~~a ~~and~~SEC ~~even~~reporting ifcompany, ~~they~~including doaffiliates, ~~any~~must ~~increased~~hold ~~revenue~~their ~~may~~shares ~~not~~for ~~offset~~a ~~the~~period ~~expenses~~of ~~incurred~~at inleast ~~building~~six ~~the~~months, ~~brands. If~~may wenot sell ~~fail~~more tothan ~~successfully~~one ~~promote~~percent ~~and~~of ~~maintain~~the ~~our~~total ~~brands,~~issued orand ~~incur~~outstanding ~~substantial~~shares ~~expenses~~ in anany ~~unsuccessful~~90-day ~~attempt~~period, ~~to promote~~ and ~~maintain~~must ~~our~~resell ~~brands,~~the weshares ~~may~~in ~~fail~~an tounsolicited brokerage ~~attract~~transaction ~~enough~~at ~~new~~the ~~customers~~market orprice. ~~retain~~If ~~our~~substantial ~~existing~~amounts ~~customers~~of toour ~~the~~common ~~extent~~stock ~~necessary~~become toavailable ~~realize~~for aresale ~~sufficient~~under ~~return~~Rule on144, prevailing ~~our~~market ~~brand-building~~prices ~~efforts,~~for ~~and~~ our ~~business~~common ~~and~~stock ~~results~~will ofbe ~~operations could suffer~~reduced.

~~The~~We may, ~~DNA~~in ~~testing~~the ~~industry~~future, isissue ~~highly~~additional ~~competitive~~securities, ~~and~~which ~~our~~would ~~failure~~reduce toinvestors’ ~~compete~~percent ~~effectively~~of ~~could~~ownership ~~adversely~~and ~~affect~~may dilute our ~~market~~ share~~, financial condition and future growth~~ value.

~~The~~Our Articles ~~DNA~~of ~~testing~~Incorporation ~~industry~~authorize isus ~~highly~~to ~~competitive~~issue ~~with~~490,000,000 ~~respect~~shares toof ~~price,~~common ~~brand~~stock and ~~product~~10,000,000 ~~recognition~~shares ~~and~~of ~~new~~blank ~~product~~check ~~introductions~~preferred stock. ~~Many~~ As of ~~our~~the ~~competitors~~date ~~are~~of ~~larger~~this Annual Report, ~~more~~we ~~established~~had 21,496,404 shares of common stock and ~~possess~~no ~~greater~~preferred ~~financial~~shares outstanding. Accordingly, ~~personnel~~we may issue up to an additional 468,503,596 ~~distribution~~shares of common stock and 10,000,000 shares of blank check preferred stock. The future issuance of common stock may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis including for services or acquisitions or other ~~resources~~corporate ~~than~~actions wethat may have~~. As~~ ~~such,~~the effect of diluting the ~~growth~~value of ~~product~~the ~~sales~~shares isheld ~~highly~~by ~~competitive~~our stockholders, and ~~uncertain~~might have an adverse effect on any trading market for our common stock. IfOur weboard ~~cannot~~of ~~compete~~directors ~~effectively~~may designate the rights, terms weand ~~may~~preferences ~~not~~of beour ~~profitable~~authorized but unissued preferred shares at its discretion including conversion and voting preferences without notice to our shareholders.

~~The purchase of many of our products is discretionary, and may be negatively impacted by adverse trends in the general economy and make it more difficult for us to generate revenues.~~18

~~Our~~There is ~~business~~no isassurance ~~affected~~of bya ~~general~~public ~~economic~~market ~~conditions~~or ~~since~~that our ~~products~~common ~~are~~stock ~~discretionary~~will ~~and~~ever wetrade ~~depend,~~on to a ~~significant~~recognized ~~extent,~~stock ~~upon a number of factors relating to discretionary consumer spending~~exchange. ~~These~~ ~~factors include economic conditions and perceptions of such conditions by consumers~~Therefore, ~~employment~~you ~~rates, the level of consumers' disposable income, business conditions, interest rates, consumer debt levels and availability of credit. Consumer spending on our DNA testing products~~ may be ~~adversely~~unable ~~affected~~to byliquidate ~~changes~~your investment in ~~general~~our ~~economic conditions~~stock.

14There is no established public trading market for our common stock. Our shares have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to support an application for the quotation of our common stock on the OTC Markets quotation system, nor can there be any assurance that such an application for quotation will be approved or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

~~The~~Because we ~~success~~do ofnot ~~our~~expect ~~business~~to ~~depends~~pay ondividends ~~our~~for ~~ability~~the toforeseeable ~~market~~future, ~~and~~investors ~~advertise~~seeking ~~the~~cash ~~products~~dividends weshould ~~sell~~not ~~effectively~~purchase our common stock.

~~Our~~We have ~~ability~~never todeclared ~~establish~~or ~~effective~~paid ~~marketing~~any ~~and~~cash ~~advertising~~dividends ~~campaigns~~on isour ~~the~~common ~~key~~stock. toWe ~~our~~currently ~~success. Our~~intend ~~advertisements~~to ~~promote~~retain ~~our~~future ~~corporate image~~earnings, ~~our~~if ~~DNA~~any, ~~testing~~to finance ~~products~~our ~~and the pricing of such products~~business. IfAs wea ~~are unable to increase awareness of our products~~result, we ~~may~~do not beanticipate ~~able~~paying toany ~~attract~~cash ~~new~~dividends ~~customers. Our~~in ~~marketing~~the ~~activities~~foreseeable ~~may~~future. ~~not~~Our bepayment ~~successful~~of inany future ~~promoting~~dividends ~~the~~will ~~DNA~~be ~~testing~~at ~~products~~the wesole ~~sell~~discretion orof ~~pricing~~our ~~strategies~~Board orof inDirectors ~~retaining~~after ~~and~~considering ~~increasing~~whether ~~our~~we ~~customer~~have ~~base. We~~generated ~~cannot~~sufficient revenues, ~~assure~~our ~~you~~financial ~~that~~condition, ~~our~~operating ~~marketing~~results, ~~programs~~cash ~~will~~needs, begrowth ~~adequate~~plans toand ~~support~~other ~~our~~factors. ~~future growth~~Accordingly, ~~which~~investors ~~may~~that are ~~result~~seeking incash adividends ~~material~~should ~~adverse~~not ~~effect~~purchase on our ~~results~~common ~~of operations~~stock.

~~Our~~As an ~~lack~~issuer of ~~registered~~“penny ~~trademarks~~stock” ~~and~~the ~~trade~~protection ~~names~~provided ~~could~~by ~~potentially~~the ~~harm~~federal ~~our~~securities ~~business~~laws relating to forward looking statements does not apply to us.

~~Trademarks~~Although the ~~and~~federal ~~trade~~securities ~~names~~law ~~distinguish~~provides ~~the~~a ~~various~~safe ~~companies~~harbor ~~from~~for ~~each~~forward-looking ~~other. If~~statements ~~potential~~made ~~distributors~~by ~~and~~a ~~customers~~public ~~are~~company ~~unable~~that tofiles ~~distinguish~~reports ~~our~~under the ~~products~~federal ~~from~~securities ~~those~~laws, ofthis ~~other~~safe ~~companies,~~harbor weis ~~could~~not ~~lose~~available ~~sales~~ to ~~our~~issuers ~~competitors. We~~of dopenny ~~not~~stocks. ~~have~~As ~~any~~a ~~registered trademarks and trade names~~result, soif we ~~only~~are ~~has~~a ~~common~~penny ~~law~~stock we ~~rights~~will ~~with~~not ~~respect~~have tothe ~~infractions~~benefit orof ~~infringements~~this onsafe ~~its~~harbor ~~products. Many~~protection ~~subtleties exist~~ in ~~product~~the ~~descriptions,~~event ~~offering~~of ~~and~~any ~~names~~claim that ~~can~~the ~~easily~~material ~~confuse~~provided ~~distributors~~by ~~and~~us ~~customers. The~~contained a ~~name~~material ofmisstatement ~~our principal products may be found in numerous variations~~ of ~~the~~fact ~~name~~or ~~and~~was ~~descriptions~~misleading in ~~various~~any ~~media~~material ~~and~~respect ~~product~~because ~~labels. This presents a risk~~ of ~~losing potential customers looking for~~ our ~~products~~failure ~~and~~to ~~buying~~include ~~someone~~any ~~else’s~~statements ~~because~~necessary to ~~they~~make ~~cannot~~the ~~differentiate~~statements ~~between~~not ~~them~~misleading.

WeItem 1B. ~~may~~Unresolved beStaff ~~subject to product liability claims and we do not have insurance coverage for such claims which could negatively impact our financial condition.~~Comments

ByAs a ~~selling~~“smaller ~~DNA~~reporting ~~test kits~~company”, we ~~will~~are ~~face~~not anrequired ~~inherent business risk of exposure~~ to ~~product~~provide ~~liability claims in~~ the ~~event~~information ~~that the use of our products results in personal injury or death. Also, in the event that any of our testing kits is defective, we may be~~ required toby ~~recall~~this ~~or replace such products~~Item. We do not maintain product liability insurance coverage to protect us from such claims. A successful product liability claim or series of claims brought against us would negatively impact our business.

~~Risks~~Item 2. ~~Related To Our Management~~Properties

~~Should we lose the services of our management, our financial condition and proposed expansion may be negatively impacted.~~Property

~~Our~~We rent ~~future~~our ~~depends~~office onspace ~~the~~at ~~continued~~2378 ~~contributions~~Parkhaven ~~of Dr. Barjinder Sohal~~Boulevard, ~~our chief executive officer~~Oakville, ~~president and director~~Ontario, ~~Dr.~~L6H ~~Nitan Arora~~0E7, ~~our~~Canada ~~CFO,~~from ~~vice president and director and~~ Navjot Nanda~~, our secretary, treasurer and director, who would each be difficult to replace~~. ~~Their~~ ~~services are critical~~This toproperty ~~the~~is ~~management~~a lease of ~~our~~a ~~business~~400 ~~and~~square ~~operations. We~~foot dooffice ~~not~~that ~~maintain~~is ~~key~~owned ~~man~~by ~~life~~Navjot ~~insurance~~Nanda, ~~on any of~~ our ~~officers~~treasurer, orsecretary, ~~directors~~and director. ~~Should~~ weWe ~~lose~~currently ~~the~~pay ~~services of any of our officers and directors~~$1,000 ~~we may be unable to replace their services with equally competent and experienced personnel~~per month, ~~our operational goals~~ and ~~strategies~~occupy ~~may~~the bepremises ~~adversely~~on ~~affected,~~a ~~which~~month-to-month ~~will negatively affect our potential revenues~~basis.

1519

~~Our officers and directors have other business interests and conflict of interests which may not be resolved in our favor.~~Intellectual Property

~~Dr.~~We have ~~Barjinder~~no ~~Sohal,~~registered ~~our~~or ~~chief~~patented ~~executive~~intellectual ~~officer,~~property. ~~president~~Trademarks and ~~director,~~trade ~~Dr.~~names ~~Nitan~~distinguish ~~Arora,~~the ~~our~~various ~~CFO,~~companies ~~vice~~from ~~president~~each ~~and~~other. If ~~director~~customers ~~and~~are ~~Navjot~~unable ~~Nanda,~~to distinguish our ~~secretary~~products ~~and~~from ~~treasurer~~those of other companies, ~~each~~we ~~own~~could ~~33.3%~~lose ofsales ~~Healthmedica,~~to ~~which~~our iscompetitors. aWe do ~~walk~~not inhave ~~health~~any ~~clinic~~registered ~~located~~trademarks inand ~~Oakville~~trade names, ~~Canada. Dr.~~so ~~Sohal~~we ~~owns~~only ~~100%~~have ofcommon ~~and~~law isrights ~~and~~with arespect ~~physician~~to atinfractions ~~Barjinder~~or ~~Singh~~infringements on ~~Sohal~~its ~~Medicine~~products. ~~Professional~~Many ~~Corp.,~~subtleties ~~located~~exist in ~~Toronto,~~product ~~Canada~~descriptions, ~~where~~offering heand isnames athat ~~physician. Additionally,~~can ~~Dr.~~easily ~~Arora~~confuse ~~and~~customers. ~~Navjot~~The ~~Nanda~~name of ~~each~~our ~~hold~~principal ~~50%~~products ofmay ~~Canadian~~be ~~Decompression~~found ~~and~~in ~~Pain~~numerous ~~Centers~~variations ~~(“CDPC”),~~of athe ~~Canadian~~name ~~company~~and ~~that~~descriptions ~~provides~~in ~~chiropractic~~various ~~services. Dr.~~media ~~Arora~~and ~~also~~product ~~serves~~labels. This aspresents a ~~clinic~~risk ~~operator~~of atlosing ~~Viva~~potential ~~Medical~~customers ~~Clinic,~~looking ~~which~~for isour aproducts ~~walk~~and inbuying ~~medical~~someone ~~clinic~~else’s ~~located~~because inthey ~~Winnipeg,~~cannot differentiate ~~Canada~~between them.

~~None of the foregoing entities provides DNA Testing or other services that compete with the products and services we offer~~Item 3. We ~~may~~Legal compete with these entities for our management’s time in the future. Accordingly, the personal interests of our officers and directors may come into conflict with our interests and those of our minority stockholders. We may present our officers and directors with business opportunities, which are mutually desired. Additionally, in the future, we may compete with these entities for investment capital, technical resources, key personnel and other opportunities, goods, services, etc. You should carefully consider these potential conflicts of interest before deciding whether to invest in shares of our common stock. We have not yet adopted a policy for resolving such conflicts of interest.Proceedings

~~Our~~We know ~~officers~~of ~~and~~no ~~directors~~material, ~~devote~~existing ~~limited~~or ~~time~~pending tolegal ~~our~~proceedings ~~business~~against us, ~~which~~nor ~~may~~are ~~negatively~~we ~~impact~~involved ~~upon~~as ~~our~~a ~~plan~~plaintiff ofin ~~operations,~~any ~~implementation~~material proceeding or pending litigation. There are no proceedings in which any of our ~~business~~directors, ~~plan~~officers ~~and~~or ~~our~~affiliates, ~~potential~~or ~~profitability~~any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

DrItem 4. ~~Barjinder~~Mine ~~Sohal,~~Safety our chief executive officer and director dedicates approximately 140 hours, Dr. Nitan Arora, our CFO, vice president and director dedicates approximately 140 hours and Navjot Nanda spends approximately 140 hours each month to our business. The limited amount of time our management devotes to our business activities in the future may be inadequate to implement our plan of operations and develop a profitable business.Disclosures

~~Our officers and directors have no experience managing a public company which is required to establish and maintain disclosure controls and procedures and internal control over financial reporting~~Not applicable.

We have never operated as a public company and our management has no experience managing a public company which is required to establish and maintain disclosure controls and procedures and internal control over financial reporting. As a result, we may not be able to operate successfully as a public company, even if our operations are successful. We plan to comply with all of the various rules and regulations, which are required for a public company that is reporting company with the Securities and Exchange Commission. However, if we cannot operate successfully as a public company, your investment may be materially adversely affected.PART II

16Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

WeThere is ~~will~~presently ~~incur~~no ~~additional~~established ~~costs~~public ~~and~~trading ~~management~~market ~~time~~for ~~related~~our ~~expenses~~shares ~~pertaining~~of tocommon ~~SEC~~stock. ~~reporting~~We ~~obligations~~anticipate ~~and~~on ~~SEC~~applying ~~compliance~~for ~~matter~~trading ~~and~~of our common ~~management~~stock ~~has~~on the OTCQB. However, we can provide no ~~experience~~assurance inthat ~~such~~our ~~matters~~shares of common stock will be traded on the Bulletin Board or, if traded, that a public market will materialize.

Dr. Barjinder Sohal, our chief executive officer and president, Dr. Nitan Arora, our vice-president, and Ms. Navjot Nanda, our secretary, treasurer, and director, are responsible for managing us, including compliance with SEC reporting obligations and maintaining disclosure controls and procedures and internal control over financial reporting. These public reporting requirements and controls are new to these individuals and at times will require us to obtain outside assistance from legal, accounting or other professionals that will increase our costs of doing business. Should we fail to comply with SEC reporting and internal controls and procedures, we may be subject to securities law violations that may result in additional compliance costs or costs associated with SEC judgments or fines, each of which would increase our costs and negatively affect our potential profitability and our ability to conduct our business.Holders

~~You~~As of ~~may~~the ~~have~~date ~~difficulty~~of inthis ~~enforcing~~Report, ~~any~~we ~~judgment~~had ~~against~~25 ~~our~~shareholders ~~officers and directors who are residents~~ of ~~Canada~~our ~~and~~common ~~not of the U~~stock.~~S., and are located outside the U.S.~~

~~All~~Transfer Agent ~~of our officers~~ and directors are located outside the U.S. and reside in Canada. As a result, it could be difficult for investors to effect service of process of them in the U.S., or to enforce a judgment obtained against them in the U.S.Registrar

~~Because~~Our transfer weagent dois ~~not~~VStock ~~have an audit or compensation committee~~Transfer, ~~shareholders~~LLC ~~will~~with bean ~~required~~office toat ~~rely~~18 onLafayette ~~the~~Place, ~~members of our board of directors~~Woodmere, ~~who~~New ~~are~~York ~~not~~11598 ~~independent,~~and toa ~~perform~~telephone ~~these~~number ~~functions~~of (212) 828-8436.

WeOTCQB Qualification do not have an audit or compensation committee or board of directors as a whole that is composed of independent directors. Because our directors are also our officers and controlling shareholders, they are not independent. There is a potential conflict between their or our interests and our shareholders’ interests, since our directors are also our officers who will participate in discussions concerning management compensation and audit issues that may affect management decisions. Until we have an audit committee or independent directors, there may be less oversight of management decisions and activities and little ability for ~~minority shareholders to challenge or reverse those activities and decisions, even if they are not in the best interests of minority shareholders.~~Quotation

WeTo have ~~are~~our anshares ~~"emerging~~of ~~growth~~common ~~company,"~~stock ~~and~~on wethe ~~cannot~~OTCQB, bea ~~certain~~market ifmaker ~~the~~must ~~reduced~~file ~~reporting~~an ~~requirements~~application ~~applicable~~on toour ~~emerging~~behalf ~~growth~~in ~~companies~~order ~~will~~to make a market for our common stock. ~~less~~We ~~attractive~~have engaged in preliminary discussions with a FINRA Market Maker to ~~investors~~file our application on Form 15c-211 with FINRA, but as of the date of this Report, no filing has been made.

We are an "emerging growth company," as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years, although we could lose that status sooner if our revenues exceed $1,000,000,000, if we issue more than $1,000,000,000 in non-convertible debt in a three year period, or if the market value of our common stock held by non-affiliates exceeds $100,000,000 as of any April 30 before that time, in which case we would no longer be an emerging growth company as of the following April 30. We cannot predict whether investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.20

17Dividends

We have ~~elected~~never todeclared ~~use~~or ~~the~~paid ~~extended~~any ~~transition~~cash ~~period~~dividends ~~for~~on ~~complying~~our ~~with~~common ~~new~~stock. orFor ~~revised accounting standards under Section 102(b)(2) of~~ the ~~JOBS~~foreseeable ~~Act~~future, ~~that~~we ~~allows~~intend us to ~~delay~~retain ~~the~~any ~~adoption~~earnings to offinance ~~new~~the ordevelopment ~~revised accounting standards that have different effective dates for public~~ and ~~private~~expansion ~~companies until those standards apply to private companies. As a result~~ of ~~this~~our ~~election~~business, ~~our~~and ~~financial~~we ~~statements~~do ~~may~~ not beanticipate ~~comparable~~paying toany ~~companies~~cash ~~that~~dividends ~~comply~~on ~~with~~our ~~public~~common ~~company effective dates~~stock.

~~Risks~~Recent Sales ~~Related~~of toUnregistered ~~Our Common Stock~~Securities

Our officers and directors have voting control over all matters submitted to a vote of our common stockholders, which will prevent our minority shareholders from having the ability to control any of our corporate actionsNone.

AsEquity Compensation of the date of this Report, we had 21,496,404 shares of common stock outstanding, each entitled to one vote per common share. Our chief executive officer, president and director, Dr. Barjinder Sohal, controls 6,666,666 shares, our vice-president and director, Dr. Nitan Arora, controls 6,666,666 shares and our secretary, treasurer and director, Ms. Navjot Nanda, controls 6,666,666 shares. As such, the aggregate number of common shares controlled by our management effectively entitles them to vote approximately 93% of our outstanding common shares on all matters submitted to a vote of our common stockholders. As a result, our management has the ability to determine the outcome of all matters submitted to our stockholders for approval, including the election of directors. Our management’s control of our voting securities may make it impossible to complete some corporate transactions without its support and may prevent a change in our control. In addition, this ownership could discourage the acquisition of our common stock by potential investors and could have an anti-takeover effect, possibly depressing the trading price of our common stock.Plans

~~Our~~We ~~common~~do ~~stock is~~ not currently have ~~quoted~~a orstock ~~listed~~option ~~and may never be quoted~~ or ~~listed by the OTC Bulletin Board or any~~ other ~~listing~~equity orincentive ~~quotation~~plan. ~~service and~~We ~~if listed, no market~~ may ~~ever~~adopt ~~develop~~one ~~for our common stock,~~ or ifmore ~~developed,~~such ~~may~~programs ~~not be sustained~~ in the future. ~~Investors~~As ~~may~~of ~~have~~December ~~difficulty~~31, 2017, inwe ~~reselling~~do ~~their~~not ~~shares~~have ~~due~~any tooutstanding ~~the~~stock ~~lack of market or state Blue Sky laws~~options.

Our common stock is currently not quoted on any market. No market may ever develop for our common stock, or if developed, may not be sustained in the future. The holders of our shares of common stock and persons who desire to purchase them in any trading market that might develop in the future should be aware that there might be significant state law restrictions upon the ability of investors to resell our shares. Accordingly, even if we are successful in having the shares available for trading on the OTC Bulletin Board, investors should consider any secondary market for our common shares to be a limited one. We intend to seek coverage and publication of information regarding the company in an accepted publication, which permits a "manual exemption." This manual exemption permits a security to be distributed in a particular state without being registered if the company issuing the security has a listing for that security in a securities manual recognized by the state. However, it is not enough for the security to be listed in a recognized manual. The listing entry must contain (1) the names of issuers, officers, and directors, (2) an issuer's balance sheet, and (3) a profit and loss statement for either the fiscal year preceding the balance sheet or for the most recent fiscal year of operations. We may not be able to secure a listing containing all of this information. Furthermore, the manual exemption is a non-issuer exemption restricted to secondary trading transactions, making it unavailable for issuers selling newly issued securities. Most of the accepted manuals are those published in Standard and Poor's, Moody's Investor Service, Fitch's Investment Service, and Best's Insurance Reports, and many states expressly recognize these manuals. A smaller number of states declare that they “recognize securities manuals” but do not specify the recognized manuals. The following states do not have any provisions and therefore do not expressly recognize the manual exemption: Alabama, Georgia, Illinois, Kentucky, Louisiana, Montana, South Dakota, Tennessee, Vermont and Wisconsin.Convertible Securities

18As of December 31, 2017, we do not have any convertible securities outstanding.

~~Accordingly,~~Purchases of ~~our~~Equity ~~common~~Securities ~~shares~~by ~~should~~the beIssuer ~~considered~~and ~~totally~~Affiliated ~~illiquid, which inhibits investors’ ability to resell their shares.~~Purchasers

WeThere were ~~will~~no beshares ~~subject~~of tocommon ~~penny~~ stock ~~regulations~~or ~~and~~other ~~restrictions~~securities ~~and~~issued ~~you~~to ~~may~~the ~~have~~issuer ~~difficulty~~or ~~selling~~affiliated ~~shares~~purchasers ofduring ~~our~~the ~~common~~year ~~stock~~ended December 31, 2017.

~~The SEC has adopted regulations which generally define so-called “penny stocks” to be an equity security that has a market price of less than $5~~Item 6.00 ~~per~~Selected ~~share~~Financial or an exercise price of less than $5.00 per share, subject to certain exemptions. We anticipate that our common stock will be a “penny stock”, and we will become subject to Rule 15g-9 under the Exchange Act, or the “Penny Stock Rule”. This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers. For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our common shares and may affect the ability of purchasers to sell any of our common shares in the secondary market.Data

~~For any transaction (other than an exempt transaction) involving~~ As a ~~penny~~smaller ~~stock,~~reporting ~~the~~company ~~rules~~we ~~require~~are ~~delivery,~~not ~~prior to such transaction, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also~~ required to beprovide ~~made~~this regarding sales commissions payable to both the broker-dealer and the registered representative, and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information ~~for the penny stock held in the account and information on the limited market in penny stock~~.

~~We do not anticipate that our common stock will qualify for exemption from the Penny Stock Rule~~Item 7. In ~~any~~Management’s ~~event,~~Discussion ~~even~~and ifAnalysis ~~our common stock is exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6)~~ of ~~the~~Financial ~~Exchange~~Condition ~~Act,~~and ~~which~~Results ~~gives the SEC the authority to restrict any person from participating in a distribution~~ of ~~penny stock, if the SEC finds that such a restriction would be in the public interest.~~Operations

~~Sales~~ Results of ~~our common stock under Rule 144 could reduce the price of our stock.~~Operations

~~None~~The following ofsummary the 21,496,404 common shares outstanding are currently eligible for resale under Rule 144. In general, persons holding restricted securities in a SEC reporting company, including affiliates, must hold their shares for a period of atour ~~least~~results ~~six months, may not sell more than one percent~~ of ~~the~~operations ~~total~~should ~~issued~~be ~~and~~read ~~outstanding shares~~ in ~~any~~conjunction ~~90-day~~with ~~period, and must resell the shares in an unsolicited brokerage transaction at the market price. If substantial amounts of~~ our ~~common~~audited ~~stock~~financial ~~become~~statements ~~available~~ for ~~resale~~the ~~under~~years ended ~~Rule~~December ~~144~~31, ~~prevailing~~2017 ~~market~~and ~~prices for our common stock will be reduced~~2016.

WeOur operating ~~may,~~results infor the ~~future,~~years ~~issue~~ended ~~additional~~December ~~securities~~31, ~~which~~2017 ~~would reduce investors’ percent of ownership~~ and ~~may~~2016 ~~dilute~~are ~~our~~summarized ~~share~~as ~~value.~~follows:

Our Articles of Incorporation authorize us to issue 490,000,000 shares of common stock and 10,000,000 shares of blank check preferred stock. As of the date of this Report, we had 21,496,404 shares of common stock and no preferred shares outstanding. Accordingly, we may issue up to an additional 468,503,596shares of common stock and 10,000,000 shares of blank check preferred stock. The future issuance of common stock may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis including for services or acquisitions or other corporate actions that may have the effect of diluting the value of the shares held by our stockholders, and might have an adverse effect on any trading market for our common stock. Our board of directors may designate the rights, terms and preferences of our authorized but unissued preferred shares at its discretion including conversion and voting preferences without notice to our shareholders.

	Year Ended
	December 31,
	2017 $			2016 $
Revenues		49,816			31,866
Operating expenses		73,569			176,544
Net loss		(52,551	)		(161,287	)

19Revenues for the year ended December 31, 2017 were $49,816 as compared to $31,886 for the comparative period in 2016. The $17,930 increase in our revenues is due to increased sales of our test kits.

~~There is no assurance of a public market or that our common stock will ever trade on a recognized stock exchange. Therefore, you may be unable to liquidate your investment in our stock.~~21

There is no established public trading market for our common stock. Our shares have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTC Bulletin Board, nor can there be any assurance that such an application for quotation will be approved or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.Expenses

~~Because~~Our operating weexpenses ~~do not expect to pay dividends~~ for the ~~foreseeable~~years ~~future,~~ended ~~investors~~December ~~seeking~~31, ~~cash~~2017 ~~dividends~~and ~~should~~2016 ~~not~~are ~~purchase~~outlined ~~our~~in ~~common~~the ~~stock.~~table below:

We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future. Our payment of any future dividends will be at the sole discretion of our Board of Directors after considering whether we have generated sufficient revenues, our financial condition, operating results, cash needs, growth plans and other factors. Accordingly, investors that are seeking cash dividends should not purchase our common stock.

	Year Ended
	December 31,
	2017 $			2016 $
Advertising and promotion		5,131			6,174
Depreciation		599			351
Consulting fees		3,039			94,544
Foreign exchange gain		(1,391	)		-
Office and miscellaneous		13,277			14,169
Professional fees		28,201			52,244
Rent		9,809			9,062
Salaries		14,904			-

Total Expenses		73,569		$	176,644

AsOur net anloss ~~issuer~~for ofthe ~~“penny~~year ~~stock”~~ended ~~the~~December ~~protection~~31, ~~provided~~2017 bywas ~~the~~$73,569 ~~federal~~compared ~~securities~~to ~~laws~~a ~~relating~~net toloss ~~forward~~of ~~looking~~$176,644 ~~statements~~during ~~does~~the ~~not~~year ~~apply~~ended toDecember us31, 2016.

~~Although~~ During the ~~federal~~year ~~securities~~ended ~~law~~December ~~provides a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws~~31, ~~this safe harbor is not available to issuers of penny stocks. As a result~~2017, if we ~~are~~incurred aoperating ~~penny~~expenses ~~stock we will not have the benefit~~ of ~~this~~$73,569 ~~safe~~compared ~~harbor~~to ~~protection~~operating inexpenses ~~the event~~ of ~~any~~$176,644 ~~claim that~~ during the ~~material~~year ~~provided~~ended byDecember us31, ~~contained~~2016. aThe ~~material~~decrease ~~misstatement of fact or was misleading~~ in ~~any~~operating ~~material~~expenses ~~respect~~were ~~because~~primarily ofrelated ~~our failure~~ to ~~include~~decreased ~~any~~professional ~~statements~~and ~~necessary to make the statements not misleading~~consulting fees.

~~Item~~Liquidity and ~~1B.~~Capital ~~Unresolved Staff Comments~~Resources

~~As a “smaller reporting company”, we are not required to provide the information required by this Item.~~Working Capital

Item 2. Properties

	At			At
	December 31, 2017			December 31, 2016
	$			$

Current Assets		83,100			6,188
Current Liabilities		161,482			119,541
Working Capital (Deficit)		(78,382	)		(113,353	)

~~Property~~Our current assets as of December 31, 2017 were $83,100 as compared to current assets of $6,188 as of December 31, 2016. The increase was due to increases in cash. As of December 31, 2017, we had a working capital deficit of $78,382 compared to $113,353 as of December 31, 2016.

We rent our office space at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada from Navjot Nanda. This property is a lease of a 400 square foot office that is owned by Navjot Nanda, our treasurer, secretary, and director. We currently pay $1,000 per month, and occupy the premises on a month-to-month basis. 22

20Cash Flows

Intellectual Property

	Year Ended December 31,
	2017			2016

Net Cash Provided by (Used in) Operating Activities		(34,281	)		(80,935	)
Net Cash Provided by (Used in) Investing Activities		Nil			Nil
Net Cash Provided by Financing Activities		118,933			83,086
Effect of Foreign Exchange Rate Changes on Cash		(5,330	)		1,420
Increase in Cash During the Year		79,322			3,571

We have no registered or patented intellectual property. Trademarks and trade names distinguish the various companies from each other. If customers are unable to distinguish our products from those of other companies, we could lose sales to our competitors. We do not have any registered trademarks and trade names, so we only have common law rights with respect to infractions or infringements on its products. Many subtleties exist in product descriptions, offering and names that can easily confuse customers. The name of our principal products may be found in numerous variations of the name and descriptions in various media and product labels. This presents a risk of losing potential customers looking for our products and buying someone else’s because they cannot differentiate between them.Operating Activities

~~Item~~Cash used 3in operating activities was $34,281 for the fiscal year ended December 31, 2017 compared to cash used in operating activities of $80,935 for the fiscal year ended December 31, 2016. ~~Legal~~The ~~Proceedings~~increase in cash used in operating activities was primarily due to increased consulting fees, professional fees, rent, and other expenses.

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.Investing Activities

~~Item~~We used 4.cash ~~Mine~~of ~~Safety~~$Nil ~~Disclosures~~in investing activities during the years ended December 31, 2017 and December 31, 2016.

~~Not applicable.~~Financing Activities

~~PART~~Cash IIprovided from financing activities was $118,933 for the fiscal year ended December 31, 2017 compared to cash provided from activities of $83,086 for the fiscal year ended December 31, 2016. During the year ended December 31, 2017, the Company received proceeds of $100,000 for share subscriptions received and $18,933 from related parties. During the year ended December 31, 2016, the Company received proceeds of $83,086 from related parties.

~~Item~~Our 5cash balance at December 31, 2017 was $83,100 with $161,482 in outstanding liabilities. ~~Market~~The ~~for~~outstanding ~~Registrant’s~~liabilities ~~Common~~consist ~~Equity~~of $32,843 ~~Related~~in ~~Stockholder~~accounts payable ~~Matters~~and accrued liabilities and ~~Issuer~~$128,639 ~~Purchases~~in ofamounts ~~Equity~~due ~~Securities~~to related parties. Our current cash balance is not be sufficient to fund our operating activities over the next 12 months.

There is presently no established public trading market for our shares of common stock. We anticipate on applying for trading of our common stock on the OTCQB. However, we can provide no assurance that our shares of common stock will be traded on the Bulletin Board or, if traded, that a public market will materialize.Going Concern

~~Holders~~The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, which contemplate continuation of our company as a going concern. However, we have an accumulated deficit of $375,833 and working capital deficit of $78,382 as of December 31, 2017, and realized negative cash flows from operations totaling $34,281 for the year ended December 31, 2017.We currently have limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors raise substantial doubt about our ability to continue as a going concern.

AsManagement anticipates ofthat we will be dependent, for the ~~date~~near offuture, ~~this~~on ~~Report~~additional investment capital to fund operating expenses. We intend to position ourselves so that we may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that we ~~had~~will 25be ~~shareholders~~successful in this or any of ~~our~~its ~~common~~endeavors ~~stock~~or become financially viable and continue as a going concern.

~~Transfer Agent and Registrar~~23

~~Our transfer agent is VStock Transfer, LLC with an office at 18 Lafayette Place, Woodmere, New York 11598 and a telephone number~~ Plan of ~~(212) 828-8436.~~Operation

~~OTCQB~~We are ~~Qualification~~now ~~for~~investigating ~~Quotation~~other properties on which exploration could be conducted and other business opportunities to enhance shareholder value. If we are unable to find another property or business opportunity, our shareholders will lose some or all of their investment and our business will likely fail.

To have our shares of common stock on the OTCQB, a market maker must file an application on our behalf in order to make a market for our common stock. We have engaged in preliminary discussions with a FINRA Market Maker to file our application on Form 15c-211 with FINRA, but as of the date of this Report, no filing has been made. Cash Requirements

21Over the next 12 months (beginning January 1, 2017) we intend to carry on business as a medical diagnostic testing products company. We anticipate that we will incur the following operating expenses during this period:

~~Dividends~~Estimated Funding Required During the Next 12 Months

We have never declared or paid any cash dividends on our common stock. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate paying any cash dividends on our common stock.

	Amount
Expense	($)

Consulting fees for research and development		10,000
Fixed asset purchases		5,000
Professional fees		20,000
Rent		12,000
Sales, travel, and marketing		20,000
Other general administrative expenses		30,000
Total		97,000

~~Recent~~We will ~~Sales~~require funds of ~~Unregistered~~approximately ~~Securities~~$97,000 over the next twelve months to operate our business. These funds may be raised through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our shares. There is no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on their investment in our common stock. Further, we may continue to be unprofitable.

~~None.~~Purchase of Significant Equipment

~~Equity~~We do ~~Compensation~~not ~~Plans~~anticipate the purchase or sale of any plant or significant equipment during the next 12 months.

WeOff-Balance Sheet ~~do not currently have a stock option or other equity incentive plan. We may adopt one or more such programs in the future.~~Arrangements

~~Convertible~~We do ~~Securities~~not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

AsCritical Accounting ~~of December 31, 2016, we do not have any outstanding stock options.~~Policies

~~Purchases~~The consolidated financial statements and the related notes of ~~Equity~~our ~~Securities~~company byare prepared in accordance with generally accepted accounting principles in the ~~Issuer~~United States and ~~Affiliated~~are ~~Purchasers~~expressed in US dollars.

~~There were no shares of common stock or other securities issued to the issuer or affiliated purchasers during the year ended December 31, 2016.~~24

~~Item~~Use of ~~6. Selected Financial Data~~estimates

AsThe preparation aof ~~smaller~~consolidated ~~reporting~~financial ~~company~~statements wein ~~are~~conformity ~~not~~with ~~required~~accounting principles generally accepted in the United States necessarily requires management to ~~provide~~make ~~this~~estimates ~~information~~and assumptions that affect the amounts reported in the financial statements. We regularly evaluate estimates and judgment based on historical experience and other relevant facts and circumstances. Actual results could differ from those estimates.

~~Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations~~Revenue Recognition

~~Results~~The Company derives revenue from the sale of ~~Operations~~DNA diagnostic testing kits in relation to analyzing and monitoring an individual’s genetic makeup. In accordance with ASC 605, “Revenue Recognition”, revenue is recognized when persuasive evidence of an arrangement exists, services have been rendered, the sale price is fixed or determinable, and collectability is reasonably assured.

~~The~~Management ~~following~~assesses ~~summary~~the ofbusiness ~~our~~environment, ~~results~~customers’ offinancial ~~operations~~condition, ~~should~~historical becollection experience, ~~read~~accounts inreceivable ~~conjunction~~aging, ~~with~~and ~~our~~customer ~~audited~~disputes ~~financial~~to ~~statements~~determine ~~for~~whether ~~the~~collectability ~~years~~is ~~ended~~reasonably ~~December~~assured. 31If collectability is not considered reasonably assured at the time of sale, ~~2015~~the ~~and~~Company ~~2014~~does not recognize revenue until collection occurs.

~~Our operating results for the years ended December 31, 2015 and 2014 are summarized as follows:~~Stock-based Compensation

	Year Ended
	December 31,
	2016	2015
Revenues	$ 31,886	$ 20,636
Operating expenses	$ 176,544	$ 121,710
Net loss	$ (161,287)	$ (101,074)

The Company records stock-based compensation in accordance with ASC 718, “Compensation – Stock Compensation” and ASC 505, “Equity Based Payments to Non-Employees”, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

Revenues for the year ended December 31, 2016 were $31,886 as compared to $20,636 for the comparative period in 2015. The $11,250 increase in our revenues is primarily due to increased sales of our test kits.25

22Recently issued accounting pronouncements

~~Expenses~~We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

~~Our~~Item 7A. ~~operating~~Quantitative ~~expenses for the years ended December 31, 2016~~ and ~~2015~~Qualitative ~~are~~Disclosures ~~outlined~~about inMarket ~~the table below:~~Risk

	Year Ended
	December 31,
	2016	2015
Advertising and promotion	$ 6,174	$ 3,778
Depreciation	$ 351	$ 545
Consulting fees	$ 94,544	$ 25,994
Office and miscellaneous	$ 14,169	$ 8,850
Professional fees	$ 52,244	$ 60,938
Rent	$ 9,062	$ 9,397
Total Expenses	$ (176,544)	$ (109,502)

As a smaller reporting company we are not required to provide this information.

~~Our net loss for the year ended December 31, 2016 was $161,257 compared to a net loss of $101,074 during the year ended December 31, 2015.~~26

~~During the year ended December 31, 2016, we incurred operating expenses of $176,544 compared to operating expenses of $109,502 during the year ended December 31, 2015~~Item 8. ~~The~~Financial ~~increase~~Statements inand ~~operating~~Supplementary ~~expenses were primarily related to increased consulting fees. .~~Data

~~Liquidity~~DNA TESTING ~~and~~CENTERS, ~~Capital Resources~~CORP.

~~Working~~Consolidated Financial ~~Capital~~Statements

	At	At
	December 31,	December 31,
	2016	2015
Current Assets	$ 6,188	$ 361
Current Liabilities	$ 119,541	$ 6,698
Working Capital (Deficit)	$ (113,353)	$ (6,337)

Years Ended December 31, 2017 and 2016

~~Our current assets as of December 31, 2016 were $6,188 as compared to current assets of $361as of December 31, 2014. The increase was due to increases~~ (Expressed in ~~cash~~US ~~and accounts receivable. As of December 31, 2016, we had a working capital deficit of $113,353 compared to a working capital of $6,337 as of December 31, 2015.~~dollars)

2327

~~Cash~~REPORT OF ~~Flows~~INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

	Year Ended December 31,
	2016	2015
Net Cash Provided by (Used in) Operating Activities	$ (80,935)	$ (112,599)
Net Cash Provided by (Used in) Investing Activities	Nil	Nil
Net Cash Provided by (Used in) Financing Activities	$ 83,086	$ 54,647
Net Effect of Foreign currency Exchange	$ 1,420	$ (6,924)
Increase (Decrease) in Cash and Cash Equivalents During the Period	$ 3,571	$ (64,876)

To the Board of Directors and Stockholders of DNA Testing Centers, Corp.

~~Operating~~Opinion on ~~Activities~~the Consolidated Financial Statements

~~Cash~~We have ~~used~~audited inthe ~~operating~~accompanying ~~activities~~consolidated ~~was~~balance ~~$80~~sheets of DNA Testing Centers,~~935~~ ~~for~~Corp. (the ~~fiscal~~“Company”) ~~year~~as ~~ended~~of December 31, ~~2016~~2017 ~~compared~~and to2016, ~~cash~~and ~~used~~the inrelated ~~operating~~consolidated ~~activities~~statements of ~~$112~~operations and comprehensive loss,~~599~~ stockholders’ deficit, and cash flows for the ~~fiscal~~years ~~year~~then ended ~~December~~and 31related notes (collectively, ~~20145~~the “consolidated financial statements”). In ~~The~~our ~~increase~~opinion, inthe ~~cash~~consolidated ~~used~~financial statements present fairly, in ~~operating~~all ~~activities~~material ~~was~~respects, ~~primarily~~the ~~due~~financial toposition ~~increased~~of ~~consulting~~the Company ~~fees,~~as ~~professional~~at ~~fees~~December 31, ~~rent~~2017 and 2016, and ~~other~~the ~~expenses~~results of their operations and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

~~Investing~~Explanatory Paragraph ~~Activities~~Regarding Going Concern

WeThe accompanying ~~used~~consolidated ~~cash~~financial ofstatements ~~$Nil~~have been prepared assuming the Company will continue as a going concern. As discussed in ~~investing~~Note ~~activities~~1 ~~during~~to the ~~years~~consolidated ~~ended~~financial ~~December~~statements, 31the Company has a working capital deficit, ~~2016~~and has incurred significant operating losses and negative cash flows from operations since inception. As at December 31, ~~2015~~2017, the Company has a working capital deficit of $78,382 and an accumulated deficit of $375,833. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also discussed in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~Financing~~Basis for ~~Activities~~Opinion

~~Cash~~These consolidated ~~provided~~financial ~~from~~statements ~~financing~~are ~~activities~~the ~~was~~responsibility ~~$83,086~~of ~~for~~the Company’s management. Our responsibility is to express an opinion on the ~~fiscal~~Company’s ~~year~~consolidated ~~ended~~financial ~~December~~statements ~~31,~~based ~~2016~~on ~~compared~~our toaudits. ~~cash~~We ~~provided~~are ~~from~~a ~~activities~~public ofaccounting ~~$54,647~~firm ~~for~~registered with the ~~fiscal~~Public ~~year~~Company ~~ended~~Accounting ~~December~~Oversight ~~31,~~Board ~~2015.~~(United ~~The~~States) ~~decrease~~(“PCAOB”) inand ~~cash~~are ~~from~~required ~~financing~~to ~~activities~~be ~~was~~independent ~~primarily~~with respect ~~due~~ to athe ~~decrease~~Company in ~~advances~~accordance ~~from~~with ~~related~~the ~~parties~~U.S. federal securities laws and ~~financing~~the applicable rules and regulations of ~~our~~the ~~common~~Securities and ~~shares~~Exchange ~~issued~~Commission and the PCAOB.

~~Our~~We conducted ~~cash~~our ~~balance~~audits atin ~~December~~accordance ~~31,~~with ~~2016~~the ~~was~~standards ~~$3,778~~of ~~with~~the ~~$119,541~~PCAOB. inThose ~~outstanding~~standards ~~liabilities.~~require ~~The~~that ~~outstanding~~we ~~liabilities~~plan ~~consist~~and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of ~~$30~~material misstatement,~~675~~ inwhether due ~~accounts~~to ~~payable~~error ~~and~~or ~~accrued~~fraud. ~~liabilities~~The ~~and~~Company ~~$88~~is not required to have,~~866~~ innor ~~notes~~were ~~payable~~we engaged to aperform, ~~related~~an ~~party~~audit of its internal controls over financial reporting. ~~Management~~As ~~believes~~part of our ~~current~~audits, ~~cash~~we ~~balance~~are ~~may~~required to obtain an understanding of internal control over financial reporting, but not befor ~~sufficient~~the topurpose ~~fund~~of ~~our~~expressing ~~operating~~an ~~activities~~opinion ~~over~~on the ~~next~~effectiveness 12of ~~months~~the Company’s internal controls over financial reporting. Accordingly, we express no such opinion.

~~Going~~Our audits ~~Concern~~included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

~~The~~/s/ ~~accompanying~~SATURNA ~~financial~~GROUP ~~statements~~CHARTERED ~~have~~PROFESSIONAL ~~been~~ACCOUNTANTS ~~prepared~~LLP inSaturna ~~conformity~~Group ~~with~~Chartered ~~generally~~Professional ~~accepted~~Accountants accounting principles, which contemplate continuation of our company as a going concern. However, we have accumulated deficit of $323,282as of December 31, 2016, and realized negative cash flows from operations totaling $80,935 for the year ended December 31, 2016.We currently have limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors raise substantial doubt about our ability to continue as a going concern. LLP

~~Management anticipates that we will be dependent, for the near future, on additional investment capital to fund operating expenses.~~ We have ~~intend~~served toas ~~position ourselves so that we may be able to raise additional funds through~~ the ~~capital markets. In light of management~~Company’s ~~efforts,~~auditor ~~there~~since ~~are no assurances that we will be successful in this or any of its endeavors or become financially viable and continue as a going concern.~~2016

24Vancouver, Canada

~~Plan~~July of4, ~~Operation~~2019

We are now investigating other properties on which exploration could be conducted and other business opportunities to enhance shareholder value. If we are unable to find another property or business opportunity, our shareholders will lose some or all of their investment and our business will likely fail.28

~~Cash~~DNA TESTING ~~Requirements~~CENTERS, CORP.

~~Over~~Consolidated statements ~~the~~of ~~next~~financial 12 months (beginning January 1, 2017) we intend to carry on business as a medical diagnostic testing products company. We anticipate that we will incur the following operating expenses during this period:position

~~Estimated~~(Expressed in ~~Funding~~U.S. ~~Required During the Next 12 Months~~dollars)

	Amount
		December 31, 2017 $			December 31, 2016 $
Expense	($)
Assets
Consulting Fees for Research and Development	10,000
Current assets
Fixed asset purchases	5,000
Cash			83,100			3,778
Professional fees	20,000
Accounts receivable			–			2,410
Rent	12,000
Total current assets			83,100			6,188
Sales, Travel and Marketing	20,000
Property and equipment (Note 3)			3,476			3,820
Other general administrative expenses	30,000
Total assets			86,576			10,008
Total	97,000
Liabilities
Current liabilities
Accounts payable and accrued liabilities			32,843			30,675
Due to related parties (Note 4)			128,639			88,866
Total liabilities			161,482			119,541
Nature of operations and continuance of business (Note 1)
Stockholders’ deficit
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, nil shares issued and outstanding			–			–
Common stock, $0.0001 par value, 490,000,000 shares authorized, 21,496,404 issued and outstanding			2,149			2,149
Share subscriptions received (Note 5)			100,000			–
Additional paid-in capital			221,318			221,318
Accumulated other comprehensive loss			(22,540	)		(9,718	)
Deficit			(375,833	)		(323,282	)
Total stockholders’ deficit			(74,906	)		(109,533	)
Total liabilities and stockholders’ deficit			86,576			10,008

We(The accompanying ~~will~~notes ~~require~~are ~~funds~~an ofintegral ~~approximately~~part $97,000 over the next twelve months to operate our business. These funds may be raised through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of ~~our~~these ~~shares.~~consolidated ~~There~~financial is no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on their investment in our common stock. Further, we may continue to be unprofitable.statements)

~~Purchase of Significant Equipment~~29

WeDNA TESTING doCENTERS, ~~not anticipate the purchase or sale of any plant or significant equipment during the next 12 months~~CORP.

~~Off-Balance~~Consolidated statements ~~Sheet~~of ~~Arrangements~~operations and comprehensive loss

~~We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes~~ (Expressed in ~~financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors~~U.S. dollars)

Critical Accounting Policies

	Year ended December 31, 2017 $			Year ended December 31, 2016 $

Revenue		49,816			31,886
Direct costs		28,798			16,629

Gross profit		21,018			15,257

Expenses

Advertising and promotion		5,131			6,174
Depreciation		599			351
Consulting fees (Note 5)		3,039			94,544
Foreign exchange gain		(1,391	)		–
Office and miscellaneous		13,277			14,169
Professional fees		28,201			52,244
Rent (Note 4)		9,809			9,062
Salaries		14,904			–

Total expenses		73,569			176,544

Net loss for the year		(52,551	)		(161,287	)

Other comprehensive income (loss)

Foreign currency translation gain (loss)		(12,822	)		696

Comprehensive loss for the year		(65,373	)		(160,591	)

Loss per share, basic and diluted		(0.01	)		(0.01	)

Weighted average shares outstanding		21,496,404			21,336,705

(The accompanying ~~financial statements and the related~~ notes ~~of our company~~ are ~~prepared~~an inintegral ~~accordance~~part ~~with~~of ~~generally~~these ~~accepted~~consolidated ~~accounting~~financial ~~principles in the United States and are expressed in US dollars.~~statements)

2530

~~Use~~DNA TESTING ofCENTERS, ~~estimates~~CORP.

~~The~~Consolidated statements ~~preparation~~ of ~~financial~~stockholders’ statements in conformity with accounting principles generally accepted in the United States necessarily requires management to make estimates and assumptions that affect the amounts reported in the financial statements. We regularly evaluate estimates and judgment based on historical experience and other relevant facts and circumstances. Actual results could differ from those estimates.deficit

~~Cash~~(Expressed in ~~and~~U.S. ~~cash equivalents~~dollars)

Cash equivalents are highly liquid investments with an original maturity of three months or less.

									Accumulated
	Common stock				Share subscriptions		Additional paid-in		other comprehensive						Total stockholders’
	Number of shares		Amount $		received $		capital $		loss $			Deficit $			deficit $

Balance, December 31, 2015		21,146,404		2,114		–		168,853		(10,414	)		(161,995	)		(1,442	)

Common stock issued for services		350,000		35		–		52,465		–			–			52,500

Foreign currency translation adjustment		–		–		–		–		696			–			696

Net loss for the year		–		–		–		–		–			(161,287	)		(161,287	)

Balance, December 31, 2016		21,496,404		2,149		–		221,318		(9,718	)		(323,282	)		(109,533	)

Share subscriptions received		–		–		100,000		–		–			–			100,000

Foreign currency translation adjustment		–		–		–		–		(12,822	)		–			(12,822	)

Net loss for the year		–		–		–		–		–			(52,551	)		(52,551	)

Balance, December 31, 2017		21,496,404		2,149		100,000		221,318		(22,540	)		(375,833	)		(74,906	)

~~Revenue~~(The accompanying ~~Recognition~~notes are an integral part of these consolidated financial statements)

Revenue is recognized when persuasive evidence of an arrangement exists, services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured. This occurs only when the services are rendered.31

~~Income~~DNA TESTING ~~Taxes~~CENTERS, CORP.

~~Deferred~~Consolidated statements ~~tax asset and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts~~ of ~~existing~~cash assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reserve.flows

We(Expressed in ~~have net operating loss carry-forwards available to reduce future taxable income~~U. ~~Future tax benefits for these operating loss carry-forwards are recognized to the extent that realization of these benefits is considered more likely than not~~S. ~~To the extent that we will not realize a future tax benefit, a valuation allowance is established.~~dollars)

Financial instrument

	Year ended December 31, 2017 $			Year ended December 31, 2016 $

Operating activities

Net loss		(52,551	)		(161,287	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		599			351
Stock-based compensation		–			52,500

Changes in operating assets and liabilities:
Accounts receivable		2,410			(2,256	)
Accounts payable and accrued liabilities		2,168			29,757
Due to related parties		13,093			–

Net cash used in operating activities		(34,281	)		(80,935	)

Financing activities

Proceeds from related parties		18,933			83,086
Proceeds from share subscriptions received		100,000			–

Net cash provided by financing activities		118,933			83,086

Effect of foreign exchange rate changes on cash		(5,330	)		1,420

Change in cash		79,322			3,571

Cash, beginning of year		3,778			207

Cash, end of year		83,100			3,778

Supplemental disclosures:
Interest paid		–			–
Income taxes paid		–			–

(The accompanying ~~carrying amount of our financial instruments, consisting of cash equivalents, accounts and~~ notes ~~receivable,~~are ~~accounts~~an ~~and~~integral ~~notes~~part ~~payable, short-term borrowings and certain other liabilities, approximates fair value since the stated rate~~ of ~~interest~~these ~~approximates~~consolidated afinancial ~~market rate of interest.~~statements)

~~Foreign Currency Translation~~32

~~Assets~~DNA ~~and~~TESTING liabilities of Canadian operations are translated into United States dollar equivalents using the exchange rate in effect at the balance sheet date. Revenue and expenses are translated using the average exchange rates during each period. Adjustments resulting from the process of translating foreign functional currency financial statements into U.S. dollars are included in accumulated other comprehensive income in common shareholders' equity. Foreign currency transaction gain and losses are included in the current earnings and totaled $6CENTERS,~~924~~ ~~and $3,490 for the years ended December 31, 2015 and 2014, respectively~~CORP.

26Notes to the consolidated financial statements

~~Property~~Years ended December 31, 2017 and ~~Equipment~~2016

~~Property~~(Expressed and equipment is recorded at cost. Major additions and improvements are capitalized and depreciated over their estimated useful lives. Depreciation of property and equipment is determined using the straight-line method over the useful life, which is estimated at ten years. Gains or losses on the sale or disposal of property and equipment are included in ~~the statements of operations~~U. ~~Maintenance and repairs that do not extend the useful life of the assets are expensed as incurred~~S. dollars)

~~Impairment~~1. ofNATURE ~~Long-Lived~~OF ~~Assets~~OPERATIONS AND CONTINUANCE OF BUSINESS

~~Long-lived~~DNA Testing ~~assets~~Centers, ~~including~~Corp. ~~property~~(the ~~and~~“Company”) ~~equipment~~was ~~are~~incorporated ~~reviewed~~in ~~for~~Florida ~~impairment~~on ~~whenever~~July ~~events~~3, or2014. ~~changes~~On inJuly ~~circumstances~~3, ~~indicate~~2014, ~~that~~ the ~~carrying~~Company ~~amount~~acquired DNA ~~may~~Testing ~~not~~Centers ~~be recoverable. The evaluation~~ of ~~recoverability~~Canada isLtd. ~~performed~~(“DNA ~~using~~Canada”). ~~undiscounted~~DNA ~~estimated~~Canada ~~net~~performs ~~cash~~testing ~~flows generated by the~~ related ~~asset. If an asset is deemed~~ to beanalyzing ~~impaired,~~and ~~the~~monitoring an ~~amount~~individual’s ofgenetic ~~impairment is determined as the amount by which the net carrying value exceeds discounted estimated cash flows~~makeup.

~~Basic~~These consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and ~~diluted~~discharge ~~net~~its ~~income~~liabilities ~~(loss)~~in ~~per~~the ~~share~~normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary equity financing to continue operations, and the attainment of profitable operations. As at December 31, 2017, the Company has an accumulated deficit of $375,833, a working capital deficit of $78,382, and realized negative cash flows from operations totaling $34,281 for the year ended December 31, 2017. The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Basic net income per common share is computed by dividing net income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is determined by dividing the net income by the sum of (1) the weighted average number of common shares outstanding and (2~~) if not anti-dilutive, the effect of stock awards determined utilizing the treasury stock method~~. ~~The~~SIGNIFICANT ~~dilutive~~ACCOUNTING ~~effect of the outstanding awards for the years ended December 31, 2015 and 2014 was -0- shares.~~ POLICIES

~~Recently~~(a) ~~issued~~Basis ~~accounting~~of ~~pronouncements~~Presentation and Consolidation

WeThese consolidated dofinancial ~~not~~statements ~~expect~~and ~~the~~related ~~adoption~~notes ofare ~~recently~~presented ~~issued~~in accordance with accounting ~~pronouncements~~principles togenerally ~~have~~accepted in athe ~~significant~~United ~~impact~~States onand ~~our~~are ~~results~~expressed in U.S. dollars. The consolidated financial statements include the accounts of ~~operations~~the Company and its wholly-owned subsidiary, ~~financial~~DNA ~~position~~Canada. orAll ~~cash~~inter-company ~~flow~~accounts and transactions have been eliminated on consolidation.

~~Item~~(b) ~~7A.~~Use ~~Quantitative~~of ~~and Qualitative Disclosures about Market Risk~~Estimates

AsThe preparation aof ~~smaller~~consolidated financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses in the reporting ~~company~~period. weThe Company regularly evaluates estimates and assumptions related to allowance for doubtful accounts, the useful life and recoverability of property and equipment, fair value of stock-based compensation, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not ~~required~~readily toapparent ~~provide~~from ~~this~~other ~~information~~sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

27(c) Cash and Cash Equivalents

~~Item~~The Company 8.considers ~~Financial~~all ~~Statements~~highly ~~and~~liquid ~~Supplementary~~instruments ~~Data~~with maturity of three months or less at the time of issuance to be cash equivalents.

~~DNA TESTING CENTERS, CORP. Consolidated Financial Statements Years Ended December 31, 2016 and 2015 (Expressed in US dollars)~~33

28DNA TESTING CENTERS, CORP.

~~REPORT~~Notes OFto ~~INDEPENDENT~~the ~~REGISTERED~~consolidated ~~PUBLIC~~financial ~~ACCOUNTING FIRM~~statements

ToYears ~~the~~ended ~~Board~~December of31, ~~Directors~~2017 and ~~Stockholders of DNA Testing Centers, Corp.~~2016

~~We have audited the accompanying consolidated balance sheet of DNA Testing Centers, Corp.~~ (~~the~~Expressed ~~“Company”)~~in ~~as of December 31, 2016, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for the year then ended~~U. ~~These consolidated financial statements are the responsibility of the Company's management~~S. ~~Our responsibility is to express an opinion on these consolidated financial statements based on our audit.~~dollars)

We2. ~~conducted~~SIGNIFICANT ~~our~~ACCOUNTING ~~audit~~POLICIES ~~in accordance with the standards of the Public Company Accounting Oversight Board~~ (~~United States~~continued). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In(d) ~~our~~Accounts opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2016 and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States.Receivable

The Company ~~accompanying~~recognizes ~~consolidated~~allowances ~~financial~~for ~~statements~~doubtful ~~have~~accounts ~~been~~to ~~prepared~~ensure ~~assuming~~accounts ~~the~~receivable ~~Company~~are ~~will~~not ~~continue~~overstated asdue ~~a going concern. As discussed in Note 1~~ to the ~~consolidated~~inability ~~financial~~or ~~statements,~~unwillingness of ~~the~~its ~~Company~~customers ~~has~~to amake ~~working~~required ~~capital deficit and has incurred operating losses since inception~~payments. ~~These~~The ~~factors~~allowance ~~raise~~is ~~substantial~~based ~~doubt~~on ~~about~~ the ~~Company’s~~business ~~ability~~environment, tohistorical ~~continue~~bad asdebt aexpense, ~~going~~the age ~~concern.~~of ~~Management’s~~receivables, ~~plans~~and inthe ~~regard~~specific toidentification ~~these~~of ~~matters~~receivables ~~are also discussed in Note 1 to~~ the ~~consolidated~~Company ~~financial~~considers ~~statements~~at risk. The ~~consolidated~~Company ~~financial~~reviews ~~statements~~the doadequacy of ~~not~~its ~~include~~allowance ~~any~~for ~~adjustments~~doubtful ~~that~~accounts ~~might~~on ~~result~~a ~~from~~regular ~~the outcome of this uncertainty~~basis.

~~/s/~~(e) ~~SATURNA~~Property ~~GROUP~~and ~~CHARTERED PROFESSIONAL ACCOUNTANTS LLP~~Equipment

~~Saturna~~Property and ~~Group~~equipment ~~Chartered~~is ~~Professional~~recorded ~~Accountants~~at ~~LLP~~cost. Depreciation is provided annually at rates and methods over their estimated useful lives. Management reviews the estimates of useful lives of the assets every year and adjusts them on prospective basis, if needed.

~~Vancouver,~~Medical ~~Canada~~equipment 10 years straight-line

~~June~~(f) ~~21,~~Long-Lived ~~2017~~Assets

29In accordance with ASC 360, “Property, Plant, and Equipment”, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

~~REPORT~~(g) OFIncome ~~INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM~~Taxes

ToThe Company accounts for income taxes using the ~~Stockholders~~asset and liability method in accordance with ASC 740, “Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has not recorded any amounts pertaining to uncertain tax positions.

~~DNA~~(h) ~~Testing Centers, Corp.~~Reclassifications

~~2378~~Certain of ~~Parkhaven~~the ~~Blvd~~prior year figures were reclassified to conform to the current year’s presentation.

~~Oakville, ON L6H 0E~~34

~~We have audited the accompanying consolidated balance sheet of~~ DNA ~~Testing~~TESTING ~~Centers~~CENTERS, ~~Corp~~CORP. and its subsidiary (collectively the “Company”) as of December 31, 2015, and the related consolidated statements of operations, stockholders’ equity and cash flows for each of the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

WeNotes ~~conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit~~ to ~~obtain reasonable assurance about whether~~ the ~~financial~~consolidated ~~statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over~~ financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

InYears ~~our~~ended ~~opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of DNA Testing Centers, Corp. and its subsidiary as of~~ December 31, ~~2015~~2017 and ~~the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.~~2016

~~The~~(Expressed ~~accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed~~ in Note 2 to the consolidated financial statements, the Company has accumulated deficit and negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concernU. ~~Management's plans in regard to this matter are also described in Note 2~~S. ~~The financial statements do not include any adjustments that might result from the outcome of this uncertainty.~~dollars)

~~/s/~~2. ~~MaloneBailey,~~SIGNIFICANT ~~LLP~~ACCOUNTING POLICIES (continued)

~~www.malonebailey.com~~(i) Revenue Recognition

~~Houston~~The Company derives revenue from the sale of DNA diagnostic testing kits in relation to analyzing and monitoring an individual’s genetic makeup. In accordance with ASC 605, ~~Texas~~“Revenue Recognition”, revenue is recognized when persuasive evidence of an arrangement exists, services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured.

~~June~~Management assesses 8the business environment, ~~2016~~customers’ financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs.

30(j) Foreign Currency Translation

The Company’s functional and reporting currency is the U.S. dollar. The functional currency of DNA ~~TESTING~~Canada ~~CENTERS~~is the Canadian dollar. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets, ~~CORP~~liabilities and items recorded in income arising from transactions denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.

~~Consolidated~~The assets ~~statements~~and liabilities of ~~financial~~DNA ~~position~~Canada are translated into U.S. dollars using the exchange rate in effect at the balance sheet date. Revenue and expenses are translated using the average exchange rates during the period. Related exchange gains and losses are included in a separate component of stockholders’ equity as accumulated other comprehensive income (loss).

(~~Expressed~~k) inStock-based ~~US dollars)~~Compensation

	December 31, 2016 $	December 31, 2015 $
Assets
Current assets
Cash	3,778	207
Accounts receivable	2,410	154
Total current assets	6,188	361
Property and equipment (Note 3)	3,820	4,895
Total assets	10,008	5,256
Liabilities
Current liabilities
Accounts payable and accrued liabilities	30,675	918
Due to related parties (Note 4)	88,866	5,780
Total liabilities	119,541	6,698
Nature of operations and continuance of business (Note 1)
Stockholders’ deficit
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, nil shares issued and outstanding	–	–
Common stock, $0.0001 par value, 49,000,000 share authorized, 21,496,404 and 21,146,404 issued and outstanding, respectively	2,149	2,114
Additional paid-in capital	221,318	168,853
Accumulated other comprehensive loss	(9,718)	(10,414)
Deficit	(323,282)	(161,995)
Total stockholders’ deficit	(109,533)	(1,442)
Total liabilities and stockholders’ deficit	10,008	5,256

~~Approved~~(l) ~~and~~Financial ~~authorized for issuance on behalf of the Board of Directors on June 21, 2017:~~Instruments

~~/s/~~ASC 820, ~~Barjinder~~“Fair ~~Sohal~~Value ~~/s/~~Measurements ~~Nitan~~and ~~Arora~~Disclosures”, ~~Barjinder~~requires ~~Sohal,~~an ~~Director~~entity ~~Nitan~~to ~~Arora~~maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective ~~Director~~evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

~~(The accompanying notes are an integral part of these consolidated financial statements)~~Level 1

31Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

~~DNA TESTING CENTERS, CORP.~~35

~~Consolidated~~DNA ~~statements~~TESTING ofCENTERS, ~~operations and comprehensive loss~~ CORP.

~~(Expressed~~Notes into USthe ~~dollars)~~consolidated financial statements

	Year ended December 31, 2016 $	Year ended December 31, 2015 $
Revenue	31,886	20,636
Direct costs	16,629	12,208
Gross profit	15,257	8,428
Expenses
Advertising and promotion	6,174	3,778
Depreciation	351	545
Consulting fees (Note 5)	94,544	25,994
Office and miscellaneous	14,169	8,850
Professional fees	52,244	60,938
Rent (Note 4)	9,062	9,397
Total expenses	176,544	109,502
Net loss for the year	(161,287)	(101,074)
Other comprehensive income (loss)
Foreign currency translation gain (loss)	696	(6,924)
Comprehensive loss for the year	(160,591)	(107,998)
Loss per share, basic and diluted	(0.01)	(0.00)
Weighted average shares outstanding	21,336,705	21,026,615

Years ended December 31, 2017 and 2016

(~~The~~Expressed ~~accompanying~~in ~~notes~~U.S. ~~are an integral part of these consolidated financial statements~~dollars)

322. SIGNIFICANT ACCOUNTING POLICIES (continued)

~~DNA~~(l) ~~TESTING~~Financial ~~CENTERS,~~Instruments ~~CORP.~~(continued)

~~Consolidated statements of stockholders’ equity (deficit)~~Level 2

~~(Expressed~~Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in USactive ~~dollars~~markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

	Common stock		Additional paid-in capital $	Accumulated other comprehensive loss $	Deficit $	Total stockholders’ equity (deficit) $
	Number of shares	Amount $
Balance, December 31, 2014	20,784,596	2,078	115,712	(3,490)	(60,921)	53,379
Common stock issued for cash	361,808	36	53,141	–	–	53,177
Foreign currency translation adjustment	–	–	–	(6,924)	–	(6,924)
Net loss for the year	–	–	–	–	(101,074)	(101,074)
Balance, December 31, 2015	21,146,404	2,114	168,853	(10,414)	(161,995)	(1,442)
Common stock issued for services	350,000	35	52,465	–	–	52,500
Foreign currency translation adjustment	–	–	–	696	–	696
Net loss for the year	–	–	–	–	(161,287)	(161,287)
Balance, December 31, 2016	21,496,404	2,149	221,318	(9,718)	(323,282)	(109,533)

Level 3

~~(The~~Level 3 ~~accompanying~~applies ~~notes~~to assets or liabilities for which there are anunobservable ~~integral~~inputs ~~part~~to the valuation methodology that are significant to the measurement of ~~these~~the ~~consolidated~~fair ~~financial~~value ~~statements)~~of the assets or liabilities.

33The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

~~DNA~~(m) ~~TESTING~~Loss ~~CENTERS,~~Per ~~CORP.~~Share

~~Consolidated~~The Company ~~statements~~computes earnings (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of ~~cash~~both ~~flows~~basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing earnings (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

(~~Expressed~~n) inComprehensive ~~US dollars)~~Loss

	Year ended December 31, 2016 $	Year ended December 31, 2015 $
Operating activities
Net loss	(161,287)	(101,074)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	351	545
Stock-based compensation	52,500	–
Changes in operating assets and liabilities:
Accounts receivable	(2,256)	30
Accounts payable and accrued liabilities	29,757	(12,100)
Net cash used in operating activities	(80,935)	(112,599)
Financing activities
Repayment of note payable	–	(4,310)
Proceeds from related parties	83,086	5,780
Proceeds from sale of common stock	–	53,177
Net cash provided by financing activities	83,086	54,647
Effect of foreign exchange rate changes on cash	1,420	(6,924)
Change in cash	3,571	(64,876)
Cash, beginning of year	207	65,083
Cash, end of year	3,778	207
Supplemental disclosures:
Interest paid	–	–
Income taxes paid	–	–

Comprehensive loss consists of net loss and other related gains and losses affecting stockholders’ equity that are excluded from net income or loss. As at December 31, 2017 and 2016, comprehensive loss includes cumulative translation adjustments for changes in foreign currency exchange rates during the period.

(~~The~~o) ~~accompanying~~Recent ~~notes~~Accounting ~~are an integral part of these consolidated financial statements)~~Pronouncements

34In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. This new standard will replace most of the existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. The new standard, as amended, becomes effective in the first quarter of fiscal year 2018, but allows the adoption of the standard one year earlier. The adoption of ASU 2014-09 will not have a material impact on the Company’s consolidated financial statements.

~~NOTE 1 – NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS~~ 36

DNA ~~Testing~~TESTING ~~Centers~~CENTERS, ~~Corp~~CORP. (the “Company”) was incorporated in Florida on July 3, 2014. On July 3, 2014, the Company acquired DNA Testing Centers of Canada Ltd. (“DNA Canada”). DNA Canada performs testing related to analyzing and monitoring an individual’s genetic makeup. The acquisition was treated consolidated as an entity under common control.

~~These~~Notes ~~consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue~~ to ~~realize its assets and discharge its liabilities in~~ the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary equity financing to continue operations, and the attainment of profitable operations. As at December 31, 2016, the Company has an accumulated deficit of $323,282, a working capital deficit of $113,353, and realized negative cash flows from operations totaling $80,935 for the year ended December 31, 2016. The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

~~NOTE~~Years 2ended –December ~~SIGNIFICANT~~31, ~~ACCOUNTING~~2017 ~~POLICIES~~and 2016

~~Basis~~(Expressed ofin ~~Presentation~~U.S. ~~and Consolidation~~dollars)

~~These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in US dollars~~2. ~~The~~SIGNIFICANT ~~consolidated~~ACCOUNTING ~~financial~~POLICIES ~~statements include the accounts of the Company and its wholly-owned subsidiary, DNA Canada. All inter-company accounts and transactions have been eliminated on consolidation.~~(continued)

~~Use~~(o) ofRecent ~~Estimates~~Accounting Pronouncements (continued)

The Company ~~preparation~~has ofimplemented ~~consolidated~~all ~~financial~~new ~~statements in accordance with~~ accounting ~~principles~~pronouncements ~~generally~~that ~~accepted~~are in ~~the~~effect ~~United States requires management to make estimates~~ and ~~assumptions~~ that ~~affect~~may ~~the~~impact ~~reported~~its ~~amounts of assets and liabilities at the date of the~~ consolidated financial statements and ~~the~~does ~~reported~~not ~~amounts~~believe of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to allowance for doubtful accounts, the useful life and recoverability of property and equipment, fair value of stock-based compensation, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that itthere believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are ~~not~~any ~~readily apparent from~~ other ~~sources.~~new ~~The~~accounting ~~actual~~pronouncements ~~results~~that ~~experienced~~have bybeen ~~the~~issued ~~Company~~that ~~may~~might ~~differ~~have ~~materially~~a ~~and adversely from the Company’s estimates. To the extent there are~~ material ~~differences~~impact on ~~between~~its ~~the~~financial ~~estimates~~position ~~and~~or ~~the actual~~ results, ~~future results~~ of operations ~~will be affected~~.

~~Cash~~3. ~~and~~PROPERTY ~~Cash~~AND ~~Equivalents~~EQUIPMENT

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Cost
$

Accumulated
depreciation
$

Foreign currency

translation
loss
$

2017
Net carrying
value
$

2016
Net carrying
value
$

Medical equipment

5,440

1,490

474

3,476

3,820

354. RELATED PARTY TRANSACTIONS

~~NOTE~~(a) 2As at December 31, 2017, the Company owed $1,558 (2016 – ~~SIGNIFICANT~~$1,558) ~~ACCOUNTING~~and ~~POLICIES~~$7,909 (~~continued~~Cdn$9,900) (2016 - $nil) to the Chief Executive Officer of the Company which is non-interest bearing, unsecured, and due on demand. (b) As at December 31, 2017, the Company owed $1,558 (2016 – $1,558) and $84,802 (Cdn$106,149) (2016 – $68,708 (Cdn$92,249)) to the Chief Financial Officer of the Company which are non-interest bearing, unsecured, and due on demand. (c) As at December 31, 2017, the Company owed $1,558 (2016 – $1,558) to a director of the Company which is non-interest bearing, unsecured, and due on demand. (d) As at December 31, 2017, the Company owed $18,375 (Cdn$23,000) (2016 – $6,704 (Cdn$9,000)) to a director of the Company which is non-interest bearing, unsecured, and due on demand. (e) As at December 31, 2017, the Company owed $8,800 (2016 - $5,800) and $879 (Cdn$1,100) (2016 - $nil) to the spouse of a director of the Company which is non-interest bearing, unsecured, and due on demand. (f) As at December 31, 2017, the Company owed $3,200 (Cdn$4,000) (2016 - $2,980 (Cdn$4,000)) to the spouse of a director of the Company which is non-interest bearing, unsecured, and due on demand. (g) During the year ended December 31, 2017, the Company incurred $9,809 (2016 - $9,062) of rent to a director of the Company.

~~Accounts~~5. ~~Receivable~~COMMON STOCK

The Company recognizes allowances for doubtful accounts to ensure accounts receivable are not overstated due to the inability or unwillingness of its customers to make required payments. The allowance is based on the business environment, historical bad debt expense, the age of receivables, and the specific identification of receivables the Company considers at risk. The Company reviews the adequacy of its allowance for doubtful accounts on a regular basis.

	(a)	During the year ended December 31, 2017, the Company received share subscription proceeds of $100,000 for 1,000,000 shares of common stock to be issued at a price of $0.10 per share.

	(b)	On June 15, 2016, the Company issued 350,000 shares of common stock with a fair value of $52,500 for consulting services rendered.

~~Property and Equipment~~37

~~Property~~DNA ~~and~~TESTING equipment is recorded at cost. Depreciation is provided annually at rates and methods over their estimated useful lives. Management reviews the estimates of useful lives of the assets every year and adjusts them on prospective basisCENTERS, ~~if needed~~CORP.

~~Medical~~Notes ~~equipment~~to ~~10%~~the ~~straight-line~~consolidated financial statements

~~Long-Lived~~Years ~~Assets~~ended December 31, 2017 and 2016

In(Expressed ~~accordance with ASC 360, “Property, Plant, and Equipment”, the Company tests long-lived assets or asset groups for recoverability when events or changes~~ in ~~circumstances indicate that their carrying amount may not be recoverable~~U. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful lifeS. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.dollars)

~~Revenue~~6. ~~Recognition~~INCOME TAXES

The Company ~~derives~~has ~~revenue~~net ~~from~~operating ~~the~~losses ~~sale~~carried forward of ~~DNA~~$116,390 ~~diagnostic~~available ~~testing~~to ~~kits~~offset intaxable ~~relation~~income toin ~~analyzing~~future ~~and~~years ~~monitoring~~which ancommence expiring ~~individual’s~~in ~~genetic~~the ~~makeup~~year 2035. InAs ~~accordance~~of ~~with~~December ~~ASC 605~~31, ~~“Revenue Recognition”~~2017, ~~revenue~~the isCompany ~~recognized~~had ~~when~~net ~~persuasive~~operating ~~evidence~~loss ofcarryforwards anfor ~~arrangement~~foreign ~~exists,~~income ~~services~~tax ~~have~~purposes of ~~been rendered~~$259,443 ~~the~~which ~~sales~~expire ~~price~~beginning isin ~~fixed~~the oryear ~~determinable, and collectability is reasonably assured~~2034.

~~Management~~The Company ~~assesses~~is ~~the~~subject ~~business~~to ~~environment,~~United ~~customers’~~States ~~financial~~federal ~~condition, historical collection experience, accounts receivable aging,~~ and ~~customer~~state ~~disputes~~income totaxes ~~determine~~at ~~whether~~an ~~collectability~~approximate israte ~~reasonably~~of ~~assured~~35%. IfThe ~~collectability~~reconciliation isof ~~not~~the ~~considered~~provision for ~~reasonably~~income ~~assured~~taxes at the ~~time~~United ofStates ~~sale,~~federal statutory rate compared to the Company’s ~~does~~income ~~not~~tax ~~recognize~~expense ~~revenue~~as ~~until~~reported ~~collection~~is as ~~occurs.~~follows:

Income Taxes

	2017 $			2016 $

Net loss before income taxes		(52,551	)		(161,287	)
Statutory income tax rate		35	%		35	%

Expected income tax recovery		(18,392	)		(56,450	)
Tax rate difference for foreign jurisdiction		2,974			5,334
Change in enacted tax rate		16,294			–
Change in valuation allowance		(876	)		51,116

Income tax provision		–			–

The significant ~~Company~~components ~~accounts~~of ~~for~~deferred income ~~taxes using the asset and liability method in accordance with ASC 740, “Income Taxes”. The asset and liability method provides that deferred~~ tax assets and liabilities ~~are~~as ~~recognized~~at ~~for~~December ~~the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities~~31, ~~and~~2017 ~~for operating loss~~ and ~~tax~~2016 ~~credit carry-forwards. Deferred tax assets and liabilities~~ are ~~measured~~as using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has not recorded any amounts pertaining to uncertain tax positions.follows:

	2017 $			2016 $

Net operating losses carried forward		93,194			94,070
Valuation allowance		(93,194	)		(94,070	)

Net deferred income tax asset		–			–

~~NOTE~~On December 222, –2017, ~~SIGNIFICANT~~the ~~ACCOUNTING~~President ~~POLICIES~~of the United States signed into law the Tax Cuts and Jobs Act (~~continued~~the “Act”). The Act amends the Internal Revenue Code to reduce tax rates and modify policies, credits, and deductions for individuals and businesses. For businesses, the Act reduces the corporate tax rate from a maximum of 35% to a flat 21% rate. The rate reduction is effective on January 1, 2018. As a result of the rate reduction, the Company has reduced the deferred tax asset balance as of December 31, 2017 by $16,294. Due to the Company’s full valuation allowance position, there was no net impact on the Company’s income tax provision at December 31, 2017 as the reduction in the deferred tax asset balance was fully offset by a corresponding decrease in the valuation allowance.

~~Foreign~~In conjunction ~~Currency~~with ~~Translation~~the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has recognized the provisional tax impacts related to the revaluation of deferred tax assets and liabilities at December 31, 2017. There was no net impact on the Company’s consolidated financial statements for the year ended December 31, 2017 as the corresponding adjustment was made to the valuation allowance. The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act.

~~The Company’s functional and reporting currency is the US dollar~~7. ~~The~~SUBSEQUENT functional currency of DNA Canada is the Canadian dollar. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets, liabilities and items recorded in income arising from transactions denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.EVENT

~~The~~On ~~assets~~January ~~and~~29, ~~liabilities~~2018, ~~of DNA Canada are translated into US dollars using~~ the Company ~~exchange~~paid ~~rate~~a inshareholder ~~effect~~of at the ~~balance~~Company ~~sheet date. Revenue and expenses are translated using the average exchange rates during the period. Related exchange gains and losses are included in~~ a ~~separate~~return ~~component~~ of ~~stockholders’~~capital ~~equity~~of ~~as accumulated other comprehensive income (loss)~~$15,000.

~~Stock-based Compensation~~38

~~The~~Item 9. ~~Company~~Changes ~~records stock-based compensation~~ in ~~accordance with ASC 718, “Compensation – Stock Compensation”~~ and ~~ASC~~Disagreements ~~505,~~With ~~“Equity~~Accountants Based Payments to Non-Employees”, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on ~~the~~Accounting ~~fair~~and ~~value~~Financial ~~of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.~~ Disclosure

~~Financial~~There were ~~Instruments~~no disagreements with our accountants related to accounting principles or practices, financial statement disclosure, internal controls or auditing scope or procedure during the two fiscal years and subsequent interim periods.

~~ASC~~Item 9A. ~~820,~~Controls ~~“Fair Value Measurements~~ and Disclosures”, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:Procedures

~~Level~~Evaluation of 1Disclosure Controls and Procedures

~~Level~~Under the 1supervision ~~applies~~and with the participation of our management, including chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer), we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on this evaluation, our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer) concluded as of the evaluation date that our disclosure controls and procedures were not effective such that the material information required to ~~assets~~be orincluded ~~liabilities~~in ~~for~~our ~~which~~SEC ~~there~~reports ~~are~~is ~~quoted~~accumulated ~~prices~~and communicated to our management, including our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer), recorded, processed, summarized and reported within the time periods specified in ~~active~~SEC rules ~~markets~~and ~~for~~forms ~~identical~~relating ~~assets~~to orour ~~liabilities~~company, particularly during the period when this report was being prepared.

~~Level~~Management’s Annual 2Report on Internal Control Over Financial Reporting

~~Level~~Our management 2is ~~applies~~responsible ~~to assets or liabilities~~ for ~~which~~establishing ~~there~~and ~~are~~maintaining ~~inputs~~adequate ~~other~~internal ~~than~~control ~~quoted~~over ~~prices~~financial ~~that~~reporting, ~~are~~as ~~observable for the asset or liability~~ such asterm ~~quoted~~is defined ~~prices for similar assets or liabilities~~ in ~~active~~Rules ~~markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions~~ 13a-15(~~less active markets~~f); orand ~~model~~15d-~~derived~~15(f) ~~valuations~~under inthe ~~which~~Exchange ~~significant inputs are observable or can be derived principally from~~Act, orfor ~~corroborated~~the ~~by, observable market data~~company.

~~Level~~Internal control over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of its management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

~~Level~~Management recognizes 3that ~~applies~~there are inherent limitations in the effectiveness of any system of internal control, and accordingly, even effective internal control can provide only reasonable assurance with respect to ~~assets~~financial statement preparation and may not prevent or detect ~~liabilities~~material ~~for~~misstatements. ~~which~~In ~~there~~addition, ~~are~~effective ~~unobservable~~internal ~~inputs~~control toat ~~the~~a ~~valuation~~point ~~methodology~~in ~~that~~time ~~are~~may ~~significant~~become toineffective ~~the~~in ~~measurement~~future periods because of ~~the~~changes ~~fair~~in ~~value~~conditions ofor due to deterioration in the ~~assets~~degree orof ~~liabilities~~compliance with our established policies and procedures.

~~The~~A material ~~Company’s~~weakness ~~financial~~is ~~instruments~~a ~~consist~~significant ~~principally of cash~~deficiency, ~~accounts~~or ~~receivable,~~combination ~~accounts~~of ~~payable~~significant ~~and accrued liabilities~~deficiencies, ~~and~~that ~~amounts~~results ~~due~~in tothere ~~related~~being ~~parties.~~a ~~Pursuant~~more than toremote ~~ASC~~likelihood ~~820,~~that ~~the~~a ~~fair~~material ~~value~~misstatement of ~~cash~~the isannual ~~determined~~or ~~based~~interim ~~on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other~~ financial ~~instruments~~statements ~~approximate~~will ~~their~~not ~~current~~be ~~fair~~prevented ~~values because of their nature and respective maturity dates~~ or ~~durations~~detected.

3739

~~NOTE~~Under the 2supervision –and ~~SIGNIFICANT~~with ~~ACCOUNTING~~the ~~POLICIES~~participation of our chief executive officer (~~continued~~our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer), management conducted an evaluation of the effectiveness of our internal control over financial reporting, as of December 31, 2016, based on the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our evaluation under this framework, management concluded that our internal control over financial reporting was not effective as of the evaluation date due to the factors stated below.

~~Loss~~Management assessed ~~Per~~the ~~Share~~effectiveness of our company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:

~~The~~- ~~Company~~Lack ~~computes earnings (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation~~ of ~~both~~proper ~~basic~~segregation ~~and diluted earnings per share (“EPS”) on the face~~ of ~~the~~duties ~~statement~~due ~~of operations. Basic EPS is computed by dividing earnings (loss) available~~ to ~~common~~limited ~~shareholders~~personnel; ~~(numerator)~~- byLack ~~the weighted average number~~ of ~~shares~~a ~~outstanding~~formal ~~(denominator)~~review ~~during~~process ~~the~~that ~~period.~~includes ~~Diluted~~multiple ~~EPS~~levels gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of ~~shares~~review ~~assumed to be purchased~~ from ~~the~~adequate ~~exercise~~personnel ofwith ~~stock~~requisite ~~options or warrants~~expertise. ~~Diluted~~- ~~EPS~~Lack ~~excludes~~of ~~all~~written ~~dilutive~~policies ~~potential~~and ~~shares~~procedures iffor ~~their~~accounting ~~effect~~and isfinancial ~~anti-dilutive~~reporting.

~~Comprehensive~~We do ~~Loss~~not have a functioning audit committee or outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

~~Comprehensive~~Management is ~~loss~~committed ~~consists~~to ofimproving ~~net~~its ~~loss~~internal controls and ~~other~~will ~~related~~(1) ~~gains~~continue ~~and~~to ~~losses~~use ~~affecting~~third ~~stockholders’~~party ~~equity~~specialists ~~that~~to ~~are~~address ~~excluded~~shortfalls ~~from~~in staffing ~~net~~and ~~income~~to orassist ~~loss.~~our Ascompany atwith ~~December~~accounting 31and finance responsibilities, ~~2016~~(2) ~~and~~increase ~~2015,~~the ~~comprehensive~~frequency ~~loss~~of ~~includes~~independent ~~cumulative~~reconciliations of ~~translation~~significant ~~adjustments~~accounts ~~for~~which ~~changes~~will inmitigate ~~foreign~~the ~~currency~~lack ~~exchange~~of ~~rates~~segregation ~~during~~of duties until there are sufficient personnel and (3) may consider appointing outside directors and audit committee members in the ~~period~~future.

~~Reclassifications~~Management, including our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer), has discussed the material weakness noted above with our independent registered public accounting firm. Due to the nature of this material weakness, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected.

~~Certain~~This annual report does not include an attestation report of ~~the~~our ~~prior~~registered ~~year~~public ~~figures~~accounting ~~were~~firm ~~reclassified~~regarding internal control over financial reporting. Management’s report was not subject to ~~conform~~attestation by our registered public accounting firm pursuant to temporary rules of the ~~current~~SEC ~~year~~that permit us to provide only management’s ~~presentation~~report in this annual report.

~~Recent~~Changes in ~~Accounting~~Internal ~~Pronouncements~~Controls Over Financial Reporting

~~The~~There have ~~Company~~been ~~has~~no ~~implemented~~changes ~~all new accounting pronouncements that are~~ in ~~effect~~our ~~and~~internal ~~that~~controls ~~may~~over ~~impact its consolidated~~ financial ~~statements~~reporting ~~and does not believe~~ that ~~there~~occurred ~~are~~during ~~any~~the ~~other~~year ~~new~~ended ~~accounting~~December ~~pronouncements~~31, 2017 that have ~~been~~materially ~~issued~~or ~~that~~are ~~might~~reasonably ~~have~~likely ato ~~material~~materially ~~impact~~affect, onour ~~its~~internal ~~financial~~controls ~~position~~over orfinancial ~~results of operations~~reporting.

~~NOTE~~Item 9B. 3Other ~~– PROPERTY AND EQUIPMENT~~Information

	Cost $	Accumulated depreciation $	Foreign currency translation $	2016 Net carrying value $	2015 Net carrying value $
Medical equipment	5,440	809	811	3,820	4,895

None.

~~NOTE 4 – RELATED PARTY TRANSACTIONS~~40

~~(a)~~PART III

AsItem 10. ~~at December 31~~Directors, ~~2016, the Company owed $1,558 (2015 – $nil) to the Chief~~ Executive ~~Officer~~Officers ~~of the Company which is non-interest bearing, unsecured,~~ and ~~due~~Corporate ~~on demand.~~Governance

~~(b)~~The following table sets forth the name, age, and position of our executive officers and directors. Executive officers are elected annually by our Board of Directors. Each executive officer holds his office until he resigns, is removed by the Board, or his successor is elected and qualified. Directors are elected annually by our shareholders at the annual meeting. Each director holds his office until his successor is elected and qualified or his earlier resignation or removal.

As at December 31, 2016, the Company owed $1,558 (2015 – $nil) and $68,708 (Cdn$92,249) (2015 – $nil to the Chief Financial Officer of the Company which are non-interest bearing, unsecured, and due on demand.

Name	Position Held with our Company	Age	Date First Elected or Appointed

Dr. Barjinder Sohal	Chief Executive Officer, President, Director	43	July 3, 2014

Dr. Nitan Arora	CFO, Vice President, Director	44	July 3, 2014

Navjot Nanda	Treasurer and Secretary, Director	40	July 3, 2014

~~(c)~~Dr. Barjinder S. Sohal, Chief Executive Officer, President and Director

AsFrom 2007 atuntil ~~December 31~~present, ~~2016~~Dr. Barjinder Sohal has been a family physician and owner of Barjinder Singh Sohal Medicine Professional Corp. Dr. Sohal was an indirect owner of our wholly-owned subsidiary, ~~the~~DNA ~~Company~~Testing ~~owed~~Centers $1of Canada,~~558~~ ~~(2015~~Ltd., –where ~~$nil)~~he toparticipated ain research ~~director~~and development of ~~the~~our ~~Company~~DNA ~~which~~testing isbusiness. ~~non-interest~~In ~~bearing~~2010, ~~unsecured~~Dr. Sohal co-founded Healthmedica, ~~and~~where ~~due~~he onis ~~demand~~a director and an owner.

~~(d)~~Dr. Sohal obtained a doctorate of medicine from the University of Manitoba in 2001. He received a Bachelor of Science from the University of Manitoba in 1997.

As our ~~at December 31~~director, ~~2016,~~Dr. ~~the~~Sohal ~~Company~~provides ~~owed~~his ~~$6,704~~experience ~~(Cdn$9,000)~~in ~~(2015 – $nil) to a director of~~ the ~~Company~~medical ~~which~~field ~~is non-interest bearing, unsecured,~~ and ~~due~~medical ~~on demand~~research.

38Dr. Nitan Arora, CFO, Vice President and Director

~~NOTE~~From 2009 4until –present, ~~RELATED~~Dr. ~~PARTY~~Nitan ~~TRANSACTIONS~~Arora ~~(continued)~~was the founder and owner of our wholly-owned subsidiary, DNA Testing Centers of Canada, Ltd., where he participated in the research and development of our DNA testing business. In 2010, Dr. Arora co-founded Healthmedica with Dr. Sohal, where he is a director and an owner.

~~(e)~~In 2007, Dr. Arora founded Canadian Decompression and Pain Centers, where he is a director and an owner. Dr. Arora is a practicing chiropractic physician at Healthmedica and a clinic operator at Viva Medical Clinic in Winnipeg.

AsDr. Arora atobtained ~~December~~a ~~31,~~doctorate ~~2016,~~of ~~the~~Chiropractic ~~Company~~Medicine ~~owed~~from ~~$5,800~~Life ~~(2015~~University -in ~~$nil)~~2000, toand ~~the~~received ~~spouse of~~ a ~~director~~Bachelor of ~~the~~Science ~~Company~~from ~~which~~the University isof ~~non-interest~~Winnipeg ~~bearing,~~in ~~unsecured, and due on demand~~1996.

~~(f)~~41

As our ~~at December 31~~director, ~~2016,~~Dr. ~~the~~Arora ~~Company~~provides ~~owed~~his ~~$2,980~~expansive ~~(Cdn$4,000)~~experience ~~(2015~~in ~~- $5,780 (Cdn$8,000)) to~~ the ~~spouse~~medical ~~of a director of the Company which is non-interest bearing, unsecured, and due on demand~~field.

~~(g)~~Navjot Nanda, Secretary, Treasurer and Director

~~During~~From 2007 ~~the~~until ~~year~~present, ~~ended~~Ms. ~~December~~Nanda ~~31,~~has ~~2016,~~been ~~the~~an ~~Company~~owner ~~incurred~~and ~~$9,062~~director ~~(2015~~of Canadian Decompression and Pain Centers. Ms. Nanda was a founder and owner of our wholly-owned $9subsidiary,~~397)~~ DNA Testing Centers of ~~rent~~Canada, toLtd., awhere ~~director~~she participated in developing our marketing plan for DNA tests and coordination of ~~the~~DNA ~~Company~~results. Her duties included marketing, coordinating sponsorships and outreach events for local charities.

~~NOTE~~Ms. Nanda 5received –a ~~COMMON~~Bachelor ~~STOCK~~of Arts in Law and Society from York University in 2004, and a Bachelor of Arts in 2002 from the University of Toronto.

~~(a)~~As our director, Ms. Nanda provides her expansive experience in marketing for various types of medical related businesses.

~~On June 15, 2016, the Company issued 350,000 shares of common stock with a fair value of $52,500 for consulting services rendered.~~Family Relationships

~~(b)~~Kuldeep Dhanoa is the mother of Navjot Nanda, our treasurer, secretary, and director.

InTarsem Singh ~~May~~Sohal ~~2015,~~and ~~the~~Charnjit ~~Company~~Kaur ~~issued~~Sohal ~~361,808~~are ~~shares~~the parents of ~~common~~Ranjit ~~stock~~Kaur atSohal $0and Dr.15 ~~per~~Barjinder ~~share~~Sohal, ~~for~~our ~~proceeds~~chief ofexecutive ~~$53~~officer,~~177~~ president and director.

~~NOTE~~Kamlesh Arora 6is –the ~~CONCENTRATIONS~~mother of Pushp Arora and Nitan Arora, our CFO, vice president and director.

InRam Tirth ~~2016,~~Singh ~~revenues~~Sohal ~~were~~is ~~from~~the ~~two~~uncle ~~different customers who accounted for 87%~~ of ~~the revenues~~Dr. InBarjinder ~~2015~~Sohal, ~~revenues~~our ~~were~~chief ~~from~~executive ~~three~~officer, ~~different~~president ~~customers~~and ~~who accounted for 88% of the revenues~~director.

~~NOTE~~Other than 7the –foregoing, ~~INCOME~~there ~~TAXES~~are no family relationships among our directors and executive officers and shareholders.

~~The Company has net operating losses carried forward of $323,282 available to offset taxable income in future years which commence expiring in fiscal 2034.~~Legal Proceedings

~~The~~No officer, ~~Company~~director, isor ~~subject~~persons tonominated ~~United~~for ~~States~~such ~~federal~~positions, ~~and~~promoter ~~state~~or ~~income~~significant ~~taxes~~employee athas anbeen ~~approximate~~involved ~~rate~~in ~~of 35%. The reconciliation of~~ the ~~provision~~last ~~for~~ten years ~~income~~in ~~taxes~~any atof the ~~United States federal statutory rate compared to the Company’s income tax expense as reported is as follows~~following:

	2016 $	2015 $
Net loss before income taxes	(161,287)	(101,074)
Statutory income tax rate	35%	35%
Expected income tax recovery	(56,450)	(35,376)
Tax rate difference for foreign jurisdiction	5,334	8,566
Change in valuation allowance	51,116	26,810
Income tax provision	–	–

	●	Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time,
	●	Any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses),
	●	Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities,
	●	Being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.

~~The significant components of deferred income tax assets and liabilities as at December 31, 2016 and 2015 are as follows:~~42

	2016 $	2015 $
Net operating losses carried forward	94,070	42,954
Valuation allowance	(94,070)	(42,954)
Net deferred income tax asset	–	–

	●	Having any government agency, administrative agency, or administrative court impose an administrative finding, order, decree, or sanction against them as a result of their involvement in any type of business, securities, or banking activity.
	●	Being the subject of a pending administrative proceeding related to their involvement in any type of business, securities, or banking activity.
	●	Having any administrative proceeding been threatened against you related to their involvement in any type of business, securities, or banking activity.

39Code of Business Conduct and Ethics

~~Item~~We do 9.not ~~Changes~~have inany standing audit, nominating, and ~~Disagreements~~compensation ~~With~~committees ~~Accountants~~of onthe ~~Accounting~~board ~~and~~of ~~Financial~~directors, ~~Disclosure~~or committees performing similar functions. We do not currently have a Code of Ethics applicable to our principal executive, financial, or accounting officer. All Board actions have been taken by Written Action rather than formal meetings.

~~There~~Identification of ~~were~~Significant no disagreements with our accountants related to accounting principles or practices, financial statement disclosure, internal controls or auditing scope or procedure during the two fiscal years and subsequent interim periods.Employees

~~Item~~We have 9Ano significant employees, other than Dr. ~~Controls~~Barjinder Sohal, our president, chief executive officer and ~~Procedures~~director, Dr. Nitan Arora our CFO, vice president and director, and Navjot Nanda our secretary, treasurer and director.

~~Evaluation~~ Conflicts of ~~Disclosure Controls and Procedures~~Interest

~~Under~~We believe ~~the~~that ~~supervision and with the participation of~~ our ~~management,~~directors ~~including~~who ~~chief~~are ~~executive~~also ~~officer~~officers ~~(our~~may ~~principal~~be ~~executive~~subject ~~officer)~~to ~~and~~conflicts ~~our chief financial officer (our principal financial officer and principal accounting officer), we have conducted an evaluation~~ of ~~the~~interest. ~~effectiveness~~The ofconflicts ~~the design and operation~~ of ~~our~~interest ~~disclosure~~arise ~~controls~~from a ~~and~~conflict ~~procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act~~ of ~~1934,~~duties ~~as of the end of the period covered by this report. Based on this evaluation, our chief executive officer (our principal executive officer)~~ and ~~our~~also ~~chief~~being ~~financial~~unable officer (our principal financial officer and principal accounting officer) concluded as of the evaluation date that our disclosure controls and procedures were not effective such that the material information required to bedevote ~~included~~full intime ~~our SEC reports is accumulated and communicated~~ to our ~~management,~~operations. ~~including~~No ~~our~~policy ~~chief~~has ~~executive~~been ~~officer~~implemented ~~(our~~or ~~principal~~will ~~executive~~be officer) and our chief financial officer (our principal financial officer and principal accounting officer), recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating implemented to ~~our~~address ~~company,~~conflicts ~~particularly~~of ~~during the period when this report was being prepared~~interest.

~~Management’s~~Committees of ~~Annual~~the ~~Report on Internal Control Over Financial Reporting~~Board

~~Our~~All proceedings ~~management~~of isour ~~responsible~~board ~~for~~of ~~establishing~~directors were conducted by resolutions consented to in writing by all the directors and ~~maintaining~~filed ~~adequate~~with the ~~internal~~minutes ~~control~~of ~~over~~the ~~financial~~proceedings ~~reporting,~~of asthe ~~such~~directors. ~~term~~Such isresolutions ~~defined~~consented to in ~~Rules~~writing ~~13a-15(f)~~by ~~and~~the ~~15d-15(f)~~directors ~~under~~entitled to vote on that resolution at a meeting of the ~~Exchange~~directors ~~Act~~are, ~~for~~according to the corporate laws of the state of Nevada and the bylaws of our company, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

~~Internal~~Our audit ~~control~~committee ~~over~~consists ~~financial reporting includes those policies and procedures that: (1) pertain to the maintenance~~ of ~~records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of~~ our ~~assets;~~entire ~~(2)~~board ~~provide reasonable assurance that transactions are recorded as necessary to permit preparation~~ of ~~financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of its management and~~ directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

~~Management~~Our company ~~recognizes~~currently ~~that~~does ~~there~~not ~~are~~have ~~inherent limitations in the effectiveness of any system of internal control~~nominating, ~~and~~compensation ~~accordingly,~~committees ~~even~~or ~~effective~~committees ~~internal~~performing ~~control~~similar ~~can~~functions ~~provide~~nor ~~only~~does ~~reasonable~~our ~~assurance~~company have ~~with~~a ~~respect~~written tonominating, ~~financial~~compensation ~~statement preparation and may not prevent~~ or ~~detect~~audit ~~material~~committee ~~misstatements~~charter. InOur ~~addition,~~board ~~effective~~of ~~internal~~directors ~~control~~does atnot abelieve ~~point~~that init ~~time~~is ~~may~~necessary to ~~become~~have ~~ineffective~~such incommittees ~~future periods~~ because ofit ~~changes~~believes inthat ~~conditions~~the orfunctions ~~due~~of tosuch ~~deterioration~~committees incan ~~the~~be ~~degree~~adequately ofperformed ~~compliance~~by ~~with~~ our ~~established policies and procedures~~directors.

AOur company ~~material~~does ~~weakness~~not ishave aany ~~significant~~defined ~~deficiency,~~policy or ~~combination~~procedure requirements for shareholders to submit recommendations or nominations for directors. The directors believe that, given the early stage of ~~significant~~our ~~deficiencies~~development, ~~that~~a ~~results~~specific innominating ~~there~~policy ~~being~~would be premature and of little assistance until our business operations develop to a more ~~than~~advanced ~~remote~~level. ~~likelihood~~Our ~~that~~company adoes ~~material~~not ~~misstatement~~currently have any specific or minimum criteria for the election of nominees to the ~~annual~~board orof ~~interim~~directors ~~financial~~and ~~statements~~we ~~will~~do not behave ~~prevented~~any specific process or procedure ~~detected~~for evaluating such nominees. Our directors assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

4043

~~Under~~A shareholder ~~the~~who ~~supervision~~wishes ~~and~~to communicate with ~~the~~our ~~participation~~board of ~~our~~directors ~~chief~~may ~~executive~~do ~~officer~~so ~~(our~~by ~~principal~~directing ~~executive~~a ~~officer)~~written ~~and~~request ~~our~~addressed ~~chief~~to ~~financial officer (~~our ~~principal financial officer and principal accounting officer)~~president, at ~~management conducted an evaluation of~~ the ~~effectiveness~~address ofappearing ~~our internal control over financial reporting, as of December 31, 2016, based~~ on the ~~framework~~first ~~set~~page ~~forth in Internal Control-Integrated Framework issued by the Committee~~ of ~~Sponsoring Organizations of the Treadway Commission (COSO). Based on our evaluation under~~ this ~~framework,~~annual ~~management concluded that our internal control over financial reporting was not effective as of the evaluation date due to the factors stated below~~report.

~~Management~~Audit Committee ~~assessed the effectiveness of our company’s internal control over financial reporting as of evaluation date~~ and ~~identified~~Audit ~~the~~Committee ~~following~~Financial ~~material weaknesses:~~Expert

-Our board ~~Lack~~ of ~~proper~~directors ~~segregation~~has ofdetermined ~~duties~~that ~~due~~it todoes ~~limited~~not ~~personnel;~~have -a ~~Lack~~member of aour ~~formal~~audit ~~review~~committee ~~process~~ that ~~includes~~qualifies ~~multiple~~as ~~levels~~an of“audit ~~review~~committee financial ~~from~~expert” ~~adequate~~as ~~personnel~~defined ~~with~~in ~~requisite~~Item ~~expertise.~~407(d)(5)(ii) of Regulation S-K, ~~Lack~~and is “independent” as the term is used in Item 7(d)(3)(iv) of ~~written~~Schedule ~~policies~~14A ~~and~~under ~~procedures~~the ~~for~~Securities ~~accounting~~Exchange ~~and~~Act ~~financial~~of ~~reporting~~1934, as amended.

We believe that the members of our board of directors, who act as our audit committee in fulfilling that function, are collectively capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. We believe that retaining an independent director who would qualify as an “audit committee financial expert” would be overly costly and burdensome and is not warranted in our circumstances given the early stages of our development and the fact that we have not generated any material revenues to date. In addition, we currently do not have anominating, ~~functioning~~compensation or audit ~~committee~~committees or ~~outside~~committees ~~directors~~performing onsimilar ~~our~~functions nor do we have a written nominating, compensation or audit committee charter. Our board of directors, ~~resulting~~does innot ~~ineffective~~believe ~~oversight~~that init ~~the~~is ~~establishment~~necessary ~~and~~to ~~monitoring~~have such committees because it believes the functions of ~~required~~such ~~internal~~committees ~~controls~~can ~~and~~be ~~procedures~~adequately performed by our board of directors.

~~Management~~Item 11. isExecutive committed to improving its internal controls and will (1) continue to use third party specialists to address shortfalls in staffing and to assist our company with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (3) may consider appointing outside directors and audit committee members in the future.Compensation

~~Management,~~The particulars ~~including~~of ~~our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer), has discussed~~ the ~~material~~compensation ~~weakness~~paid ~~noted above with our independent registered public accounting firm. Due~~ to the ~~nature~~following of this material weakness, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected.persons:

~~This~~(a) ~~annual~~our ~~report~~principal ~~does~~executive ~~not~~officer; ~~include~~(b) anour ~~attestation~~principal ~~report~~financial officer; (c) each of our ~~registered~~three ~~public~~most ~~accounting~~highly ~~firm~~compensated ~~regarding~~executive ~~internal~~officers ~~control~~who ~~over~~were ~~financial~~serving ~~reporting.~~as ~~Management’s~~executive ~~report~~officers ~~was~~at ~~not~~the ~~subject~~end toof ~~attestation~~the byyears ~~the~~ended ~~our~~December ~~registered~~31, ~~public~~2017 ~~accounting~~and ~~firm~~2016; ~~pursuant~~and (d) up to ~~temporary~~two ~~rules~~additional ofindividuals for whom disclosure would have been provided under (b) but for the ~~SEC~~fact that ~~permit~~the usindividual towas ~~provide~~not ~~only~~serving ~~management’s~~as ~~report~~our inexecutive ~~this~~officer ~~annual~~at ~~report~~the end of the years ended December 31, 2017 and 2016.

~~Changes in Internal Controls Over Financial Reporting~~44

~~There~~who we ~~have~~will ~~been~~collectively norefer ~~changes~~to inas ~~our~~the ~~internal~~named ~~controls~~executive ~~over~~officers ~~financial~~of ~~reporting~~our ~~that~~company, ~~occurred~~are ~~during~~set ~~the~~out ~~year~~in ~~ended~~the ~~December~~following 31summary compensation table, ~~2016~~except that ~~have~~no ~~materially~~disclosure oris ~~are~~provided ~~reasonably~~for ~~likely~~any tonamed ~~materially~~executive ~~affect~~officer, other than our ~~internal~~principal ~~controls~~executive ~~over~~officers, ~~financial~~whose total ~~reporting.~~compensation did not exceed $100,000 for the respective fiscal year:

Item 9B. Other Information

Name and Principal Position	Year Ended Dec. 31		Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation Earnings ($)		Non-Qualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)

Dr. Barjinder Sohal,		2017		0		0		0		0		0		0		0		0
Chief Executive Officer, President, Director		2016		0		0		0		0		0		0		0		0

Dr. Nitan Arora,		2017		0		0		0		0		0		0		0		0
Vice President, Director		2016		0		0		0		0		0		0		0		0

Navjot Nanda,		2017		0		0		0		0		0		0		0		0
Treasurer, Secretary, Director		2016		0		0		0		0		0		0		0		0

~~None.~~Employment Agreements with Management

41Our board of directors determines the compensation paid to our executive officers, based upon the years of service to us, whether services are provided on a full time basis and the experience and level of skill required.

~~PART~~We may ~~III~~award our officers and directors shares of common stock as non-cash compensation as determined by the board of directors from time to time. The board will base its decision to grant common stock as compensation on the level of skill required to perform the services rendered and time committed to providing services to us.

~~Item~~Outstanding Equity ~~10.~~Awards ~~Directors,~~at ~~Executive~~the ~~Officers~~End ~~and~~of ~~Corporate~~the ~~Governance~~Fiscal Year

~~The~~We do ~~following~~not ~~table~~have ~~sets~~and ~~forth~~have ~~the~~never ~~name,~~had ~~age,~~any ~~and~~equity ~~position~~compensation ofplans ~~our~~and ~~executive~~therefore ~~officers~~no ~~and~~equity ~~directors. Executive~~awards ~~officers~~ are ~~elected~~outstanding ~~annually~~as ~~by our Board~~ of ~~Directors. Each executive officer holds his office until he resigns, is removed by~~ the ~~Board,~~date orof this ~~his successor is elected and qualified~~Report. ~~Directors are elected annually by our shareholders at the annual meeting. Each director holds his office until his successor is elected and qualified or his earlier resignation or removal.~~

Name	Position Held with our Company	Age	Date First Elected or Appointed
Dr. Barjinder Sohal	Chief Executive Officer, President, Director	42	July 3, 2014
Dr. Nitan Arora	CFO, Vice President, Director	43	July 3, 2014
Navjot Nanda	Treasurer and Secretary, Director	39	July 3, 2014

Director Compensation

~~Dr.~~Our directors ~~Barjinder~~do S.not ~~Sohal,~~receive ~~Chief~~any ~~Executive~~other ~~Officer,~~compensation ~~President~~for ~~and~~serving ~~Director~~on the board of directors.

~~From 2007 until present, Dr. Barjinder Sohal has been a family physician~~ Bonuses and ~~owner~~Deferred of Barjinder Singh Sohal Medicine Professional Corp. Dr. Sohal was an indirect owner of our wholly-owned subsidiary, DNA Testing Centers of Canada, Ltd., where he participated in research and development of our DNA testing business. In 2010, Dr. Sohal co-founded Healthmedica, where he is a director and an owner.Compensation

~~Dr.~~We do ~~Sohal~~not ~~obtained~~have aany ~~doctorate~~bonus, ofdeferred ~~medicine~~compensation ~~from~~or ~~the~~retirement ~~University of Manitoba in 2001~~plan. HeAll ~~received~~decisions aregarding ~~Bachelor~~compensation ofare ~~Science~~determined ~~from~~by ~~the~~our ~~University~~ board of ~~Manitoba in 1997~~directors.

~~As our director, Dr. Sohal provides his experience in the medical field~~ Options and ~~medical~~Stock ~~research.~~Appreciation Rights

DrWe do not currently have a stock option or other equity incentive plan. ~~Nitan~~We ~~Arora,~~may ~~CFO,~~adopt ~~Vice~~one ~~President~~or ~~and~~more ~~Director~~such programs in the future.

~~From 2009 until present, Dr. Nitan Arora was the founder and owner~~ Payment of ~~our wholly~~Post-~~owned~~Termination subsidiary, DNA Testing Centers of Canada, Ltd., where he participated in the research and development of our DNA testing business. In 2010, Dr. Arora co-founded Healthmedica with Dr. Sohal, where he is a director and an owner.Compensation

InWe do ~~2007,~~not ~~Dr.~~have ~~Arora~~change-in-control ~~founded~~agreements ~~Canadian~~with ~~Decompression~~any ~~and~~of ~~Pain~~our ~~Centers,~~directors ~~where~~or heexecutive isofficers, ~~a director~~ and anwe ~~owner. Dr.~~are ~~Arora~~not isobligated ato ~~practicing~~pay ~~chiropractic~~severance or ~~physician~~other atenhanced ~~Healthmedica~~benefits ~~and~~to aexecutive ~~clinic~~officers ~~operator~~upon attermination ~~Viva~~of ~~Medical~~their ~~Clinic in Winnipeg~~employment.

~~Dr. Arora obtained a doctorate of Chiropractic Medicine from Life University in 2000, and received a Bachelor of Science from the University of Winnipeg in 1996.~~45

42Involvement in Certain Legal Proceedings

AsThere have been no events under any bankruptcy act, no criminal proceedings, no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any of our ~~director~~directors, ~~Dr.~~executive ~~Arora~~officers, ~~provides~~promoters ~~his~~or ~~expansive~~control ~~experience~~persons induring the past ~~medical~~ten ~~field~~years.

~~Navjot~~Board of ~~Nanda, Secretary, Treasurer and Director~~Directors

~~From~~All directors ~~2007~~hold office until ~~present,~~the ~~Ms.~~next ~~Nanda~~annual ~~has~~meeting ~~been an owner and director~~ of ~~Canadian~~shareholders ~~Decompression~~ and ~~Pain~~until ~~Centers. Ms.~~their ~~Nanda~~successors ~~was~~have abeen ~~founder~~duly elected and ~~owner of our wholly-owned subsidiary, DNA Testing Centers of Canada, Ltd~~qualified., Officers ~~where~~are ~~she~~elected ~~participated~~by inand ~~developing~~serve ~~our~~at ~~marketing~~the ~~plan~~discretion ~~for~~of ~~DNA~~the ~~tests~~board ~~and coordination~~ of ~~DNA results~~directors. ~~Her duties included marketing, coordinating sponsorships and outreach events for local charities.~~

~~Ms.~~Our directors ~~Nanda~~are ~~received~~reimbursed afor ~~Bachelor~~expenses ofincurred ~~Arts~~by them in ~~Law~~connection ~~and~~with ~~Society~~attending ~~from~~board ~~York~~meetings, ~~University~~but inthey ~~2004,~~do ~~and~~not areceive ~~Bachelor~~any other ofcompensation ~~Arts~~for inserving ~~2002~~on ~~from~~ the ~~University~~board of ~~Toronto~~directors.

AsIndebtedness of ~~our director~~Directors, ~~Ms.~~Senior ~~Nanda~~Officers, ~~provides~~Executive ~~her~~Officers ~~expansive~~and ~~experience~~Other ~~in marketing for various types of medical related businesses.~~Management

~~Family~~None of ~~Relationships~~our directors or executive officers or any associate or affiliate of our company during the last two fiscal years is or has been indebted to our company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently outstanding.

~~Kuldeep Dhanoa is the mother of Navjot Nanda, our treasurer, secretary, and director.~~ Indemnification

~~Tarsem~~Under our ~~Singh~~Bylaws, ~~Sohal~~we ~~and~~may ~~Charnjit~~indemnify ~~Kaur~~our ~~Sohal~~officers or directors who are ~~the~~made ~~parents~~a party to any proceeding, including a lawsuit, because of their ~~Ranjit~~position, ~~Kaur~~if ~~Sohal~~they acted in good faith and ~~Dr.~~in ~~Barjinder~~a ~~Sohal~~manner, they reasonably believed to be in our ~~chief~~best ~~executive~~interest. ~~officer~~We may advance expenses incurred in defending a proceeding. To the extent that our officers or directors are successful on the merits in a proceeding as to which they are to be indemnified, ~~president~~we must indemnify them against all expenses incurred, including attorney’s fees. With respect to a derivative action, indemnity may be made only for expenses actually and ~~director~~reasonably incurred in defending the proceeding, and if the officers or directors are judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.

~~Kamlesh~~Regarding indemnification ~~Arora~~for isliabilities arising under the ~~mother~~Securities Act of ~~Pushp~~1933, ~~Arora~~which ~~and~~may ~~Nitan~~be ~~Arora~~permitted to directors or officers under Nevada law, ~~our~~we ~~CFO~~are informed that, ~~vice~~in ~~president~~the opinion of the SEC, indemnification is against public policy, as expressed in the Act and ~~director~~is, therefore, unenforceable.

~~Ram Tirth Singh Sohal is the uncle of Dr. Barjinder Sohal, our chief executive officer, president and director.~~46

~~Other~~Item 12. ~~than~~Security ~~the~~Ownership ~~foregoing,~~of ~~there~~Certain ~~are~~Beneficial noOwners ~~family~~and ~~relationships~~Management ~~among our directors~~ and ~~executive~~Related ~~officers~~Stockholder ~~and shareholders.~~Matters

~~Legal~~The following ~~Proceedings~~table sets forth, as of December 31, 2017, the total number of shares owned beneficially by each of our directors, named executive officers, individually and as a group, and the present owners of 5% or more of our total outstanding shares. The stockholder listed below has direct ownership of his shares and possesses sole voting and dispositive power with respect to the shares.

No officer, director, or persons nominated for such positions, promoter or significant employee has been involved in the last ten years in any of the following:

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership (1)	Percentage of Class

Dr. Barjinder Sohal (2) Unit 8 - 1200, Waverley Street Winnipeg, Manitoba R3T 0P4	6,666,666 Common Shares	31%

Dr. Nitan Arora (3) Unit 8 - 1200, Waverley Street Winnipeg, Manitoba R3T 0P4	6,666,666 Common Shares	31%

Navjot Nanda (4) Unit 8 - 1200, Waverley Street Winnipeg, Manitoba R3T 0P4	6,666,666 Common Shares	31%

*Directors and Executive Officers as a Group*	19,999,998 Common Shares	93%

*5%+ Shareholders*
None.	Nil Common Shares	0%

(1)	Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person’s actual ownership or voting power with respect to the number of shares of common stock actually outstanding on August 15, 2017. As of August 15, 2017, there were 21,496,404 shares of our company’s common stock issued and outstanding.
(2)	Dr. Barjinder Sohal is our company’s president, and director.
(3)	Dr. Nitan Arora is our company’s vice president, CFO and director
(4)	Navjot Nanda is a Director, secretary and Treasurer of our company.

~~Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time,~~47

·Changes in Control

~~Any~~We do ~~conviction~~not incurrently ahave ~~criminal~~any ~~proceeding~~arrangements orwhich ~~being~~if ~~subject~~consummated tomay aresult ~~pending~~in ~~criminal~~a ~~proceeding~~change ~~(excluding~~of ~~traffic~~control ~~violations~~of ~~and~~our ~~other minor offenses),~~company.

·Item 13. Certain Relationships and Related Transactions, and Director Independence

~~Being~~The following ~~subject~~includes toa ~~any~~summary ~~order~~of transactions since the beginning of the December 31, ~~judgment~~2012 fiscal year, or ~~decree~~any currently proposed transaction, ~~not~~in ~~subsequently~~which ~~reversed,~~we ~~suspended~~were or ~~vacated~~is to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of ~~any~~the ~~court~~average of ~~competent~~our ~~jurisdiction~~total assets at year end for the last two completed fiscal years, ~~permanently~~and in which any related person had or ~~temporarily~~will ~~enjoining,~~have ~~barring,~~a ~~suspending~~direct or ~~otherwise~~indirect ~~limiting~~material ~~his~~interest ~~involvement~~(other inthan ~~any~~compensation ~~type~~described ofunder ~~business~~“Executive Compensation”). We believe the terms obtained or consideration that we paid or received, ~~securities~~as applicable, in connection with the transactions described below were comparable to terms available or ~~banking~~the ~~activities~~amounts that would be paid or received, as applicable, in arm’s-length transactions.

·We rent our office space at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada from Navjot Nanda. This property is a lease of a 400 square foot office that is owned by Navjot Nanda, our treasurer, secretary, and director. We currently pay $1,000 per month, on a month to month lease, for office use including utilities. During the year ended December 31, 2016, we incurred $9,062 (2015 - $9,397) of rent.

~~Being~~As at ~~found~~December by31, a2017, ~~court~~we ofowed ~~competent~~$1,558 ~~jurisdiction~~ (in2016 a– ~~civil action)~~$1,558) ~~the~~and ~~Commission~~$7,909 or(Cdn$9,900) ~~the~~(2016 ~~Commodity~~- ~~Futures~~$nil) ~~Trading Commission~~ to ~~have~~Dr. ~~violated~~Barjinder aSohal, ~~federal~~our orChief Executive ~~state~~Officer, ~~securities or commodities law~~president, and ~~the~~director, ~~judgment~~which ~~has~~amount ~~not~~is ~~been~~non-interest ~~reversed~~bearing, ~~suspended~~unsecured, orand ~~vacated~~due on demand.

43As at December 31, 2017, we owed $1,558 (2016 – $1,558) and $84,802 (Cdn$106,149) (2016 – $68,708 (Cdn$92,249)) to Dr. Nitan Arora, our Chief Financial Officer, which amounts are non-interest bearing, unsecured, and due on demand.

·As at December 31, 2017, we owed $18,375 (Cdn$23,000) (2016 – $6,704 (Cdn$9,000)) to a director of the Company which is non-interest bearing, unsecured, and due on demand.

~~Having~~As at ~~any~~December ~~government~~31, ~~agency~~2017, ~~administrative~~we ~~agency~~owed $8,800 or(2016 ~~administrative~~- ~~court~~$5,800) ~~impose~~and an$879 ~~administrative finding~~(Cdn$1,100) ~~order,~~(2016 ~~decree,~~- or$nil) ~~sanction~~to ~~against~~the ~~them~~spouse asof a ~~result~~director of ~~their~~the ~~involvement~~Company which inis ~~any~~non-interest ~~type of business~~bearing, ~~securities~~unsecured, orand ~~banking~~due ~~activity~~on demand.

·As at December 31, 2017, we owed $3,200 (Cdn$4,000) (2016 - $2,980 (Cdn$4,000)) to the spouse of a director of the Company which is non-interest bearing, unsecured, and due on demand.

~~Being~~ During the ~~subject~~year ofended aDecember ~~pending~~31, ~~administrative~~2017, ~~proceeding~~we ~~related~~incurred to$9,809 ~~their~~(2016 ~~involvement~~- in$9,062) ~~any~~of ~~type~~rent ofto ~~business,~~a ~~securities,~~director orof ~~banking~~the ~~activity~~Company.

·Promoters and Certain Control Persons

~~Having~~Other than ~~any~~the ~~administrative~~directors ~~proceeding~~and ~~been~~officers ~~threatened against you related to their involvement in any type~~ of ~~business,~~our ~~securities~~company, orwe ~~banking~~have ~~activity~~no promoters.

~~Code of Business Conduct and Ethics~~48

We do not have any standing audit, nominating, and compensation committees of the board of directors, or committees performing similar functions. We do not currently have a Code of Ethics applicable to our principal executive, financial, or accounting officer. All Board actions have been taken by Written Action rather than formal meetings.Corporate Governance

~~Identification~~We currently act with three directors, consisting of ~~Significant~~Dr. ~~Employees~~Barjinder Sohal, Dr. Nitan Arora, and Navjot Nanda.

We do not have noa ~~significant~~standing ~~employees~~audit, ~~other~~compensation ~~than~~or Drnominating committee, but our entire board of directors acts in such capacities. We ~~Barjinder~~believe ~~Sohal,~~that our ~~president,~~board ~~chief~~of ~~executive~~directors ~~officer~~is capable of analyzing and ~~director,~~evaluating Drour financial statements and understanding internal controls and procedures for financial reporting. ~~Nitan~~The ~~Arora~~board of directors of our ~~CFO~~company does not believe that it is necessary to have a standing audit, ~~vice~~compensation ~~president~~or ~~and~~nominating ~~director~~committee because we believe that the functions of such committees can be adequately performed by the board of directors. Additionally, we believe that retaining an independent director who would qualify as an “audit committee financial expert” would be overly costly and ~~Navjot~~burdensome ~~Nanda~~and is not warranted in our ~~secretary,~~circumstances ~~treasurer~~given ~~and~~the ~~director~~early stages of our development.

~~Conflicts of Interest~~Director Independence

We currently ~~believe~~do ~~that~~not ~~our~~have ~~directors~~any ~~who~~independent ~~are~~directors, ~~also~~as ~~officers~~the ~~may~~term be“independent” ~~subject~~is todefined ~~conflicts~~by ofthe ~~interest.~~rules ~~The conflicts~~ of ~~interest~~the ~~arise~~NASDAQ ~~from a conflict of duties and also being unable to devote full time to our operations~~Stock Market. ~~No policy has been implemented or will be implemented to address conflicts of interest.~~

~~Committees~~Item 14. ofPrincipal ~~the~~Accounting ~~Board~~Fees and Services

~~All~~The aggregate ~~proceedings~~fees ofbilled ~~our~~for ~~board~~the ofmost ~~directors~~recently ~~were~~completed ~~conducted~~fiscal byyears ~~resolutions~~ended ~~consented~~December to31, in2016 ~~writing~~and by2015 ~~all~~for ~~the~~professional ~~directors~~services rendered ~~and~~by ~~filed with~~ the ~~minutes~~principal ofaccountant for the ~~proceedings~~audit of ~~the~~our ~~directors.~~annual ~~Such~~financial ~~resolutions~~statements ~~consented~~and toreview inof ~~writing~~the byfinancial ~~the~~statements ~~directors~~included in ~~entitled~~our toquarterly ~~vote~~reports on ~~that~~Form ~~resolution~~10-Q atand aservices ~~meeting~~that ~~of the directors~~ are, ~~according~~normally toprovided by the ~~corporate~~accountant ~~laws~~in ofconnection ~~the~~with ~~state~~statutory ~~of Nevada~~ and regulatory ~~the~~filings ~~bylaws~~or ofengagements ~~our~~for ~~company,~~these asfiscal ~~valid~~periods ~~and~~were ~~effective~~ as ~~if they had been passed at a meeting of the directors duly called and held.~~follows:

Our audit committee consists of our entire board of directors.

	Year Ended
	December 31, 2017		December 31, 2016
		$		$
Audit Fees		CAD10,000		23,937
Audit Related Fees		CAD7,000		2,381
Tax Fees		Nil		Nil
All Other Fees		Nil		530
Total		CAD17,000		26,848

Our board ~~company~~of ~~currently~~directors ~~does~~pre-approves ~~not~~all ~~have~~services ~~nominating,~~provided ~~compensation~~by ~~committees or committees performing similar functions nor does~~ our ~~company~~independent ~~have a written nominating, compensation or audit committee charter~~auditors. ~~Our~~All ~~board~~ of ~~directors~~the ~~does~~above ~~not~~services ~~believe~~and ~~that~~fees itwere isreviewed and ~~necessary~~approved toby ~~have such committees because it believes that~~ the ~~functions~~board of ~~such~~directors ~~committees~~either ~~can~~before beor ~~adequately~~after ~~performed~~the byrespective ~~our~~services ~~directors~~were rendered.

Our board ~~company~~of ~~does not have any defined policy or procedure requirements for shareholders to submit recommendations or nominations for~~ directors. ~~The~~has ~~directors~~considered ~~believe that, given~~ the ~~early~~nature ~~stage of our development, a specific nominating policy would be premature~~ and amount of ~~little~~fees ~~assistance~~billed ~~until~~by our ~~business~~independent ~~operations~~auditors ~~develop~~and tobelieves athat ~~more~~the ~~advanced~~provision of ~~level.~~services ~~Our company does not currently have any specific or minimum criteria~~ for ~~the~~activities ~~election~~unrelated ~~of nominees~~ to the ~~board~~audit ofis ~~directors~~compatible ~~and~~with wemaintaining doour ~~not~~independent ~~have~~auditors’ ~~any specific process or procedure for evaluating such nominees~~independence. ~~Our directors assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.~~

4449

A shareholder who wishes to communicate with our board of directors may do so by directing a written request addressed to our president, at the address appearing on the first page of this annual report.PART IV

~~Audit~~Item 15. ~~Committee~~Exhibits, ~~and Audit Committee~~ Financial ~~Expert~~Statement Schedules

~~Our board of directors has determined that it does not have a member of our audit committee that qualifies as an “audit committee financial expert” as defined in Item 407~~(da)~~(5)(ii)~~ Financial ~~of Regulation S-K, and is “independent” as the term is used in Item 7(d)(3)(iv) of Schedule 14A under the Securities Exchange Act of 1934, as amended.~~Statements

We believe that the members of our board of directors, who act as our audit committee in fulfilling that function, are collectively capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. We believe that retaining an independent director who would qualify as an “audit committee financial expert” would be overly costly and burdensome and is not warranted in our circumstances given the early stages of our development and the fact that we have not generated any material revenues to date. In addition, we currently do not have nominating, compensation or audit committees or committees performing similar functions nor do we have a written nominating, compensation or audit committee charter. Our board of directors does not believe that it is necessary to have such committees because it believes the functions of such committees can be adequately performed by our board of directors.

	(1)	Consolidated financial statements for our company are listed in the index under Item 8 of this document

	(2)	All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

~~Item 11. Executive Compensation~~(b) Exhibits

The particulars of the compensation paid to the following persons:

Exhibit Number		Exhibit Description

(3)		Articles of Incorporation; Bylaws

3.1		Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).

3.2		Bylaws of DNA Testing Centers, Corp. (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).

(10)		Material Contracts

10.1		Lease Agreement between Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).

10.2		Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).

10.3		Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A filed on October 24, 2014).

10.4		Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).

10.5		Agreement between DNA Testing Centers Corp and DNA Testing Centers of Canada, Ltd. (incorporated by reference to our Registration Statement on Form S-1 filed on January 28, 2015).

10.6		Amending Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).

(a) our principal executive officer; (b) our principal financial officer; (c) each of our three most highly compensated executive officers who were serving as executive officers at the end of the years ended December 31, 2015 and 2014; and (d) up to two additional individuals for whom disclosure would have been provided under (b) but for the fact that the individual was not serving as our executive officer at the end of the years ended December 31, 2016 and 2015.50

10.7		Amending Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).

10.8		Amending Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).

(31)		Rule 13a-14(a) / 15d-14(a) Certifications

31.1*		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer

31.2*		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer

(32)		Section 1350 Certifications

32.1*		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer

32.2*		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer

101**		Interactive Data File (Form 10-K for the year ended December 31, 2015 furnished in XBRL).
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

~~who~~* weFiled will collectively refer to as the named executive officers of our company, are set out in the following summary compensation table, except that no disclosure is provided for any named executive officer, other than our principal executive officers, whose total compensation did not exceed $100,000 for the respective fiscal year:herewith.

Name and Principal Position	Year Ended Dec. 31	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation Earnings ($)	Non-Qualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Dr. Barjinder Sohal, Chief Executive Officer, President, Director	2016	0	0	0	0	0	0	0	0
	2015	0	0	0	0	0	0	0	0
Dr. Nitan Arora, Vice President, Director	2016	0	0	0	0	0	0	0	0
	2015	0	0	0	0	0	0	0	0
Navjot Nanda, Treasurer, Secretary, Director	2016	0	0	0	0	0	0	0	0
	2015	0	0	0	0	0	0	0	0

Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

~~Employment Agreements with Management~~51

On September 1, 2014, we entered into an agreement with Dr. Barjinder Sohal, our chief executive officer and president, to provide services to us. The agreement has a term of three years and requires us to pay $700.00 per month to Dr. Sohal for his services. On September 15, 2015, we entered into an amending agreement with Dr. Barjinder Sohal to amend his agreement with us whereby any compensation may be paid in either cash and/or common shares of the company.SIGNATURES

46In accordance with Section 13 or 15(d) of the Securities Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

On September 1, 2014, we entered into an agreement with Dr. Nitan Arora, our CFO and vice president, to provide services to us. The agreement has a term of three years and requires us to pay $700.00 per month to Dr. Arora for his services. All amounts due under the agreement will accrue until October 30, 2015. On September 15, 2015, we entered into an amending agreement with Dr. Nitan Arora to amend his agreement with us whereby any compensation may be paid in either cash and/or common shares of the company.

	DNA TESTING CENTERS, CORP.
	(Registrant)

Dated: July 9, 2019	/s/ Barjinder Sohal
	Dr. Barjinder Sohal
	President, Chief Executive Officer and Director (Principal Executive Officer)

Dated: July 9, 2019	/s/ Nitan Arora
	Nitan Arora
	Chief Financial Officer, Vice President and Director (Principal Financial Officer, Principal Accounting Officer)

OnPursuant to ~~September~~the 1,requirements ~~2014,~~of wethe ~~entered~~Securities ~~into~~Exchange anAct ~~agreement~~of ~~with Mrs. Navjot Nanda~~1934, ~~our~~this ~~secretary~~report ~~and~~has ~~treasurer~~been tosigned ~~provide~~below ~~services~~by tothe ~~us. The~~following ~~agreement~~persons ~~has~~on ~~a term~~ behalf of ~~three~~the ~~years~~registrant and requires us to pay $700.00 per month to Ms. Nanda for her services. On September 15, 2015, we entered into an amending agreement with Ms. Nanda to amend his agreement with us whereby any compensation may be paid in ~~either~~the ~~cash~~capacities and~~/or~~ ~~common~~on ~~shares of~~ the ~~company~~dates indicated.

Our board of directors determines the compensation paid to our executive officers, based upon the years of service to us, whether services are provided on a full time basis and the experience and level of skill required.

Dated: July 9, 2019	/s/ Barjinder Sohal
	Dr. Barjinder Sohal
	President, Chief Executive Officer and Director (Principal Executive Officer)

Dated: July 9, 2019	/s/ Navjot Nanda
	Navjot Nanda
	Treasurer, Secretary and Director

Dated: July 9, 2019	/s/ Nitan Arora
	Nitan Arora
	Chief Financial Officer, Vice President and Director
	(Principal Financial Officer, Principal Accounting Officer)

We may award our officers and directors shares of common stock as non-cash compensation as determined by the board of directors from time to time. The board will base its decision to grant common stock as compensation on the level of skill required to perform the services rendered and time committed to providing services to us.52

Outstanding Equity Awards at the End of the Fiscal Year

We do not have and have never had any equity compensation plans and therefore no equity awards are outstanding as of the date of this Report.

Director Compensation

Our directors do not receive any other compensation for serving on the board of directors.

Bonuses and Deferred Compensation

We do not have any bonus, deferred compensation or retirement plan. All decisions regarding compensation are determined by our board of directors.

Options and Stock Appreciation Rights

We do not currently have a stock option or other equity incentive plan. We may adopt one or more such programs in the future.

Payment of Post-Termination Compensation

We do not have change-in-control agreements with any of our directors or executive officers, and we are not obligated to pay severance or other enhanced benefits to executive officers upon termination of their employment.

Involvement in Certain Legal Proceedings

There have been no events under any bankruptcy act, no criminal proceedings, no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any of our directors, executive officers, promoters or control persons during the past ten years.

Board of Directors

All directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. Officers are elected by and serve at the discretion of the board of directors.

Our directors are reimbursed for expenses incurred by them in connection with attending board meetings, but they do not receive any other compensation for serving on the board of directors.

Indebtedness of Directors, Senior Officers, Executive Officers and Other Management

None of our directors or executive officers or any associate or affiliate of our company during the last two fiscal years is or has been indebted to our company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently outstanding.

Indemnification

Under our Bylaws, we may indemnify our officers or directors who are made a party to any proceeding, including a lawsuit, because of their position, if they acted in good faith and in a manner they reasonably believed to be in our best interest. We may advance expenses incurred in defending a proceeding. To the extent that our officers or directors are successful on the merits in a proceeding as to which they are to be indemnified, we must indemnify them against all expenses incurred, including attorney’s fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officers or directors are judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.

Regarding indemnification for liabilities arising under the Securities Act of 1933, which may be permitted to directors or officers under Nevada law, we are informed that, in the opinion of the SEC, indemnification is against public policy, as expressed in the Act and is, therefore, unenforceable.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth, as of April 25, 2016, the total number of shares owned beneficially by each of our directors, named executive officers, individually and as a group, and the present owners of 5% or more of our total outstanding shares. The stockholder listed below has direct ownership of his shares and possesses sole voting and dispositive power with respect to the shares.

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership (1)	Percentage of Class
Dr. Barjinder Sohal (2) Unit 8 - 1200, Waverley Street Winnipeg, Manitoba R3T 0P4	6,666,666 Common Shares	31%
Dr. Nitan Arora (3) Unit 8 - 1200, Waverley Street Winnipeg, Manitoba R3T 0P4	6,666,666 Common Shares	31%
Navjot Nanda (4) Unit 8 - 1200, Waverley Street Winnipeg, Manitoba R3T 0P4	6,666,666 Common Shares	31%
Directors and Executive Officers as a Group	19,999,998 Common Shares	93%
5%+ Shareholders
None.	Nil Common Shares	0%

(1) Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person’s actual ownership or voting power with respect to the number of shares of common stock actually outstanding on August 15, 2017. As of August 15, 2017, there were 21,496,404 shares of our company’s common stock issued and outstanding.

(2)	Dr. Barjinder Sohal is our company’s president, and director.
(3)	Dr. Nitan Arora is our company’s vice president, CFO and director
(4)	Navjot Nanda is a Director, secretary and Treasurer of our company.

Changes in Control

We do not currently have any arrangements which if consummated may result in a change of control of our company.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The following includes a summary of transactions since the beginning of the December 31, 2012 fiscal year, or any currently proposed transaction, in which we were or is to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation described under “Executive Compensation”). We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm’s-length transactions.

We rent our office space at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada from Navjot Nanda. This property is a lease of a 400 square foot office that is owned by Navjot Nanda, our treasurer, secretary, and director. We currently pay $1,000 per month, on a month to month lease, for office use including utilities. During the year ended December 31, 2016, we incurred $9,062 (2015 - $9,397) of rent.

As at December 31, 2016, we owed $1,558 (2015 – $nil) to Dr. Barjinder Sohal, our Chief Executive Officer, president, and director, which amount is non-interest bearing, unsecured, and due on demand.

As at December 31, 2016, we owed $1,558 (2015 – $nil) and $68,708 (Cdn$92,249) (2015 – $nil) to Dr. Nitan Arora, our Chief Financial Officer, which amounts are non-interest bearing, unsecured, and due on demand.

As at December 31, 2016, we owed $1,558 (2015 – $nil) to Dr. Barjinder Sohal of the Company which amount is non-interest bearing, unsecured, and due on demand.

As at December 31, 2016, we owed $6,704 (Cdn$9,000) (2015 – $nil) to Dr. Nitan Arora of the Company, which amount is non-interest bearing, unsecured, and due on demand.

As at December 31, 2016, we owed $5,800 (2015 - $nil) to the spouse Navjot Nanda of the Company which amount is non-interest bearing, unsecured, and due on demand.

As at December 31, 2016, we owed $2,980 (Cdn$4,000) (2015 - $5,780 (Cdn$8,000)) to the spouse of Navjot Nanda of which amount is non-interest bearing, unsecured, and due on demand.

Promoters and Certain Control Persons

Other than the directors and officers of our company, we have no promoters.

Corporate Governance

We currently act with three directors, consisting of Dr. Barjinder Sohal, Dr. Nitan Arora and Navjot Nanda.

We do not have a standing audit, compensation or nominating committee, but our entire board of directors acts in such capacities. We believe that our board of directors is capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. The board of directors of our company does not believe that it is necessary to have a standing audit, compensation or nominating committee because we believe that the functions of such committees can be adequately performed by the board of directors. Additionally, we believe that retaining an independent director who would qualify as an “audit committee financial expert” would be overly costly and burdensome and is not warranted in our circumstances given the early stages of our development.

Director Independence

We currently do not have any independent directors, as the term “independent” is defined by the rules of the NASDAQ Stock Market.

Item 14. Principal Accounting Fees and Services

The aggregate fees billed for the most recently completed fiscal years ended December 31, 2016 and 2015 for professional services rendered by the principal accountant for the audit of our annual financial statements and review of the financial statements included in our quarterly reports on Form 10-Q and services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for these fiscal periods were as follows:

	Year Ended
	December 31, 2016		December 31, 2015
	$		$
Audit Fees		23,937		23,937
Audit Related Fees		2,381		2,381
Tax Fees		Nil		Nil
All Other Fees		530		530
Total		26,848		26,848

Our board of directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by the board of directors either before or after the respective services were rendered.

Our board of directors has considered the nature and amount of fees billed by our independent auditors and believes that the provision of services for activities unrelated to the audit is compatible with maintaining our independent auditors’ independence.

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a) Financial Statements

(1)

Financial statements for our company are listed in the index under Item 8 of this document

(2)

All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

(b) Exhibits

Exhibit
Number		Exhibit Description
(3)		Articles of Incorporation; Bylaws
3.1		Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
3.2		Bylaws of DNA Testing Centers, Corp. (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
(10)		Material Contracts
10.1		Lease Agreement between Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.2		Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.3		Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A filed on October 24, 2014).
10.4		Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.5		Agreement between DNA Testing Centers Corp and DNA Testing Centers of Canada, Ltd. (incorporated by reference to our Registration Statement on Form S-1 filed on January 28, 2015).
10.6		Amending Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).

10.7		Amending Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
10.8		Amending Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
(31)		Rule 13a-14(a) / 15d-14(a) Certifications
31.1*		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1*		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.1*		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
101**		Interactive Data File (Form 10-K for the year ended December 31, 2015 furnished in XBRL).
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DNA TESTING CENTERS, CORP.
	(Registrant)
Dated: August 15, 2017	/s/Barjinder Sohal
	Dr. Barjinder Sohal
	President, Chief Executive Officer and Director (Principal Executive Officer)
Dated: August 15, 2017	/s/Nitan Arora
	Nitan Arora
	Chief Financial Officer, Vice President and Director (Principal Financial Officer, Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Dated: August 15, 2017	/s/Barjinder Sohal
	Dr. Barjinder Sohal
	President, Chief Executive Officer and Director (Principal Executive Officer)
Dated: August 15, 2017	/s/Navjot Nanda
	Navjot Nanda
	Treasurer, Secretary and Director
Dated: August 15, 2017	/s/Nitan Arora
	Nitan Arora
	Chief Financial Officer, Vice President and Director
	(Principal Financial Officer, Principal Accounting Officer)

Filing Compare · DNA Testing Centers Corp